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A series of conformationally constrained pseudopeptides derivative of the 
tripeptide pYVN were designed and synthesized.  The conformationally restricted 
compounds contained either trans- or cis-cyclopropanes as replacements to enforce 
locally extended and reverse turn peptide conformations, respectively.  In addition, the 
proper flexible control molecules were prepared.  All compounds were evaluated for the 
ability to bind to the Grb2-SH2 domain in order to determine the energetic consequences 
of introducing a conformational constraint into peptide ligands.  No difference in the 
∆Gbinding between the trans-cyclopropane and its control partner was observed.  
Surprisingly, there was an entropic disadvantage when comparing the binding energetics 
of the constrained and flexible pseudopeptides.  Therefore, the introduction of the 
cyclopropane constraint was associated with an entropic disadvantage in the system, 
which is the opposite of conventional wisdom.  An X-ray crystal structure of the trans-
cyclopropane containing ligand bound to the Grb2-SH2 domain was obtained and 
 viii
discussed.  On the other hand, cis-cyclopropane containing pseudopeptides do not seem 
to enforce the desired turn conformation of the ligand. 
A method to allow access to unsymmetrical C-aryl glycoside natural products was 
developed through employing a disposal tether to enforce the desired regioselectivity in a 
[4+2] cycloaddition between benzyne and glycosyl-substituted furan.  Application of this 
novel strategy toward the synthesis of kidamycin is discussed.  Additional synthetic 
routes, including utilizing Suzuki’s O → C glycoside rearrangement are also provided.  
Studies toward the synthesis of sugar ring E and F are illustrated.  
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Chapter 1. After 25 Years, Are Conformational Constraints Really 
Worth the Energy? 
1.1    INTRODUCTION 
A major goal in developing leads for drug candidates is to design and prepare 
molecules with enhanced binding affinities.  It is common practice in medicinal 
laboratories to incorporate conformational constraints into flexible ligands, typically by 
introducing a ring.1-6  However, the true energetic consequences of introducing a cyclic 
conformational constraint have not been rigorously evaluated.  This chapter will 
showcase and critically evaluate examples of conformational constraints found in the 
literature.   
1.1.1  Energetics of Binding 
When a protein (P) and ligand (L) interact under equilibrium conditions, the 
strength of the ligand-protein complex (PL) is expressed by an association constant Ka, 
Equation 1.1.   




[P] [L] (1.1) 
 
The Gibb’s free energy of binding (∆Gbinding) is obtained from the difference between 
the free energy of the ligand-protein complex relative to the combined free energies of 
the ligand and protein in solution.  The ∆Gbinding is related to Ka according to Equation 
1.2 where R is the gas constant and T is the temperature in Kelvin.   
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∆Gbinding = -RTlnKa       (1.2) 
The ∆Gbinding is composed of two thermodynamic components, the enthalpy of binding 
(∆Hbinding) and entropy of binding (∆Sbinding), Equation 1.3.   
 
    ∆Gbinding =∆ Ηbinding - T∆Sbinding         (1.3) 
 
The ∆Hbinding is the sum of the strength of all the non-covalent interactions between the 
protein and the ligand formed during binding, relative to the sum of the strength of all the 
interactions of the protein and the ligand with the solvent prior to complexation.  The 
entropic component takes into account the disorder (degrees of freedom) of ligand, 
protein and solvent during the complex formation.     
The enthalpic components of binding are determined by weak interactions, which 
are individually worth at least one order of magnitude less than the amount of energy 
required to break a covalent bond.7  There are many different types of weak interactions 
involved in the formation of ligand-protein complexes, which include electrostatic, 
hydrogen bond, and van der Waals interactions.  These interactions have been estimated 
for common functional groups found in biological systems (ie. hydrocarbons, 
ammonium, phosphate, hydroxyl, and carboxylate, etc.).8   
Electrostatic interactions, the Coulombic interaction between two opposing 
charges, are the strongest of the non-covalent interactions and are worth about 12 kcal 
mol-1.7  Such interactions include ionic bonds, salt linkages, salt bridges or ionic pairs, 
with the optimal distance between the two charges being 2.8 Å.9  The most common 
charged moieties found in biological systems are ammonium, carboxylate and phosphate 
groups.  Additionally, metal ions can be involved in electrostatic interactions; iron, 
calcium, and magnesium ions are most common.  In determining the electrostatic 
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contribution to binding, one must take into account the difference between the 
electrostatic interactions of the protein and ligand before and after complexation.   
A hydrogen bond between functional groups is not as strong as the electrostatic 
interaction and is worth about 2 – 11 kcal mol-1.7  This is dependent upon the direction 
and distance between the species as discussed below.  It is considered a dipole-dipole 
interaction involving the sharing of hydrogen atoms by two other atoms, the hydrogen 
donor and hydrogen acceptor.  In biological systems hydrogen bonds are usually 
encountered between nitrogen and oxygen heteroatoms.  The optimal distance between 
most hydrogen donors and acceptors is 2.7 – 3.1 Å.9  Before the ligand-protein complex 
is formed, the functional groups of the ligand and protein are involved in highly ordered 
hydrogen bonds with the surrounding water molecules of the solvent.  On complexation, 
these hydrogen bonds are disrupted, and are replaced by hydrogen bonds between the 
ligand and the protein.  The water molecules that were previously involved in interactions 
with the ligand and protein become involved in hydrogen bonds within the bulk solvent.  
The hydrogen bonding contribution to ∆Gbinding depends on the difference between the 
energies of these hydrogen bonds. 
Pauling first highlighted the importance of hydrogen bonding, and he reported 
that the values of hydrogen bond contributions vary.10  The strongest hydrogen bond is 
formed when the hydrogen acceptor and donor are co-linear within a range of 130 – 
180o.11  Fersht and Williams have reported that hydrogen bonding between neutral 
charge atoms contributes 0.5 – 1.5 kcal mol-1 to the ∆Gbinding, an amount that 
corresponds to a 2- to 15-fold increase in binding affinity.12,13  On the other hand, charge 
assisted hydrogen bonds may be worth as much as 2.4 – 4.7 kcal mol-1, and a 
corresponding 3000-fold increase in affinity.11,12  A charge assisted hydrogen bond is a 
hydrogen bond between a charged species (carboxylate or ammonium) and a hydrogen 
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atom.  The hydrogen bond between two amides is estimated to be worth 0.5 – 1.9 kcal 
mol-1.14,15   
On the other hand, van der Waals interactions between functional groups are 
much weaker than hydrogen bonds and are worth about 1 kcal mol-1.9  They are non-
specific attractive forces caused by the natural occurrence of the change of charge around 
an atom (induced dipole-induced dipole interactions) and are sometimes referred to as 
London dispersion forces.  The optimal range for a van der Waals interaction is 3 – 4 Å.9  
Kuntz has estimated that the maximal contribution of van der Waals interaction to 
∆Gbinding is1 kcal mol-1 per atom.16 
There are three main entropic components to the ∆Gbinding.  When the protein and 
ligand interact, there is a loss of overall rotational and translational entropy in forming 
the complex.  The rotational and translational entropy refer to the tumbling and 
translation of the molecules through space, respectively.  The energetic contributions of 
translational and rotational entropy to ∆Gbinding are unfavorable for the formation of the 
complex.  Both the ligand and protein have more translational and rotational freedom in 
solution than in the protein-ligand complex, with the overall loss in the energy estimated 
to be worth 14 kcal mol-1.8,17,18   
The conformational entropy refers to the internal motion, bond stretches and 
rotations of the protein, ligand, and complex.  It is commonly believed that both the 
ligand and protein lose conformational entropy upon forming the complex.17,19-21  The 
conformational entropy of protein side chain residues is known to be an important factor 
for estimating binding affinities.22  However, most research has been focused on the loss 
of conformational entropy for the ligand upon complexation.  It has been estimated that 
each rotatable bond that is rigidified upon binding of the protein and ligand has an 
associated ∆Gbinding penalty of 0.7 – 1.6 kcal mol-1 due to loss of conformational 
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entropy.8,13,23-25  For example, the conformational entropy lost upon binding is 
estimated to be worth 3.7 – 4.9 cal mol-1 per rotor lost for a hydrocarbon residue.17  The 
amount of conformational entropy lost by the ligand during binding is the basis for the 
theory that scientists site when introducing conformational constraints (see Section 
1.1.3). 
All three forms of entropy and enthalpy are involved in the hydrophobic effect 
which plays a critical role in ∆Gbinding.  This effect has both an enthalpic and entropic 
component; however, the contribution of the hydrophobic effect is mostly attributed to 
entropy.  Upon binding, the strength of the newly formed hydrogen bonds in the ligand-
protein complex and between water molecules of the solvent contributes to the enthalpic 
portion of the hydrophobic effect.  Water molecules form more hydrogen bonds with 
other water molecules in the bulk solvent than with the protein or ligand surfaces, as 
many as 3 – 4 hydrogen bonds per water molecule.11  Solvation of the protein and ligand 
rupture some of these water-water hydrogen bonds, which are recovered upon formation 
of the ligand-protein complex.  Reports in the literature for the enthalpic contribution of 
the hydrophobic effect vary, but it has been reported to be worth up to 0.5 kcal mol-1 Å-
2.11 
The entropic component of the hydrophobic effect stems from the entropy gained 
by releasing ordered water molecules from the protein and ligand surfaces into bulk 
solvent upon complexation.  The hydrogen bonding network in the bulk solvent is 
dynamic and thus bulk water is relatively disordered.  However, there is an unfavorable, 
highly static structure of water molecules surrounding the protein and ligand in solution, 
and this cage-like structure is entropically less favorable.7  During the binding of protein 
and ligand, entropy is gained as cage-like water molecules are released into the bulk 
solvent.   
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The energy of this hydration entropic term has two components.  The first of these 
is the amount of surface area that is in contact with the solvent, known as the solvent-
accessible surface area (SAS).  The unbound protein surface is surrounded by water 
molecules; however, upon binding of a ligand, the SAS of the protein exposed to solvent 
is minimized.  The SAS of a protein can be calculated using several methods.26-31  The 
∆SAS is calculated atom by atom as the difference in the SAS between the complex and 
the sum of the SAS of the protein and ligand and can be partitioned into polar and 
nonpolar components: O, N, and S atoms are defined as polar while all carbon atoms are 
defined as nonpolar.28  The total energy gained by ∆SASnon-polar during the binding 
event is estimated to be worth about 22 – 28 cal mol-1 Å-2.32,33 
The second term related to the entropy of hydration is the atomic solvation 
parameter (ASP) which defines the energy of transferring atomic surfaces to water and 
sometimes referred to as the energy of solvent transfer.7   The energy of solvent transfer 
for the ligand can be derived from the partition coefficient P of the small molecules, 
which is the equilibrium constant between the concentration of the molecule in water and 
in organic solvent and is related to the free energy of ASP (∆GASP), Equation 1.4 and 








∆GASP = -RTlnP     (1.5) 
 
The value P for many common functional groups has been calculated,34-36 and can be 
determined by octanol-water partition experiments.37  The solvation energies for many 
organic and biological molecules has also been predicted.30  The ASP values can also be 
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determined for surfaces of proteins.7  The total contribution of the hydrophobic effect to 
∆Gbinding, both enthalpic and entropic, has been estimated to be between 0 – 3 kcal mol-1 
Å-2, the strongest being for a completely buried heavy atom.11,13,16  
Enthalpy-entropy compensation has been widely reported in many biological 
systems and in molecular recognition events.33,38  It is observed as a linear relationship 
between the ∆Hbinding and ∆Sbinding, and its origin is currently debated in the literature.  
Some researchers report that it is an extra thermodynamic parameter involved in the 
protein and ligand binding, an unexpected linear correlation between ∆Hbinding and 
∆Sbinding values.39  For example, when interactions between a ligand and protein are 
strongest, the ∆Hbinding is negative, and the ligand is tightly held by the protein.  
However, this tight interaction is accompanied by higher order and hence a less favorable 
∆Sbinding.14,40  Williams attributes enthalpy-entropy compensation to cooperativity in 
binding where more positive cooperativity manifests itself in a more favorable enthalpy 
but a less favorable entropy.41  Some researchers associate the enthalpy-entropy 
compensation with weak intramolecular interactions.11,42  However, some believe that 
enthalpy-entropy compensation may be an artifact of experimental error, particularly 
when van’t Hoff plots (see Section 1.1.2 for definition) are used to determine ∆Hbinding 
and ∆Sbinding.33,38  Due to experimental limitations, K values measured using isothermal 
titration calorimetry (ITC, see Section 1.1.2 for definition) typically range between 102 to 
108 M-1 creating a ‘window’ in which interactions are confined.  Thus, the range of 
observable ∆Hbinding values is limited and may give rise to an observed linear 
relationship between the ∆Hbinding and ∆Sbinding.39  In fact, ∆Sbinding is usually obtained 
by measuring ∆Hbinding, so any error in the measurement of enthalpy will affect the value 
of entropy and may result in a linear relationship between the enthalpy and entropy.43  In 
order for the compensation to be considered a real phenomenon, the experimental 
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temperature must be outside of the confidence interval for the compensation temperature 
Tc, where Tc is the linear relationship between ∆Hbinding and ∆Sbinding (Equation 








The 95% confidence interval for Tc is Tc ± 2σ, where σ is the estimated standard error in 
Tc.  If the experimental temperature is within Tc ± 2σ, the enthalpy-entropy 
compensation may not be a real phenomenon and the linear correlation between 
∆Hbinding and ∆Sbinding is probably due to the experimental method. 
The change in heat capacity (∆Cp) upon binding is also an important 
thermodynamic parameter to consider where comparing protein and ligand interactions.  
Heat capacity is the amount of heat required to increase the temperature of a substance by 
1 degree Kelvin.  It is also the temperature dependence of the ∆Hbinding (Equation 1.7). 
 
∆Cp =
∆Hbinding (1.7)T  
 
There is a direct and experimentally useful correlation between the ∆Cp and the ∆SAS 
where measuring ∆Cp provides a useful method for probing the structural effects of the 
complex formation.46  A negative ∆Cp is attributed to the burial of nonpolar surfaces 
upon protein and ligand binding, whereas a positive ∆Cp is attributed to the burial of 
polar surfaces.47  Large ∆Cp effects are also associated with the hydrophobic effect.39  
Similar ∆Cps for different ligands binding to a protein suggest that there is no large 
structural perturbation between the respective binding events.48   
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1.1.2 Methods of Determining Binding Energetics 
Scientists use different methods to measure the binding interactions between 
proteins and ligands.  In some cases the dissociation constant Kd of binding is directly 
measured, where Kd is the reciprocal of Ka.  When measuring the ability of an inhibitor to 
bind to a protein, many researchers express the results in IC50, which is the inhibitor 
concentration required to cause 50% inhibition.  The inhibition constant Ki is related to 
both Kd and IC50 by the Cheng-Prusoff Equation where C is the concentration of the 
substrate that is inhibited (Equation 1.8).8  
 






When either the substrate concentration is small or Kd is large, Ki will be approximately 
equal to IC50. 
Researchers use isothermal titration calorimetry (ITC) to measure the energetics 
of binding at a constant temperature and determine each thermodynamic parameter of the 
binding event, including Ka, ∆Gbinding, ∆Hbinding, and ∆Sbinding.11,39,49-52  The heat 
released or absorbed during the binding event is monitored by the calorimeter.11,53,54  
The reference cell contains only buffer while the sample cell contains buffer plus protein.  
An injection system is filled with the ligand.  During an ITC experiment, the ligand is 
injected into the sample cell and the time dependence of the electric power (µcal sec-1) 
necessary to maintain constant temperature between the reference and sample cells after 
each injection of ligand is recorded by the instrument.  Peaks correspond to the heat 
released, or absorbed, during the binding event. 52  Negative peaks are associated with 
exothermic interactions while positive peaks are associated with endothermic 
interactions.  The heat released or absorbed after each injection is obtained by calculating 
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the area under each peak and provides a binding curve that furnishes the Ka, 
stoichiometry and ∆H of binding through nonlinear least squares analysis done by the 
Origin program.50,52  Simple calculations then afford ∆Gbinding and ∆Sbinding.  Each ITC 
experiment should be repeated at least three times and the values averaged.  In order to 
account for any heat of dilution during the experiment, a blank titration, ligand titrated 
into buffer solution, should also be obtained and the values subtracted from each ligand 
into protein titration.  
Van’t Hoff plots offer another method to measure the thermodynamic parameters 
of binding.  Binding affinities are measured at different temperatures from which 
∆Hbinding and ∆Sbinding values can be extracted from a linear plot of ln Ka verses 1/T 
where -∆Hbinding/R is the slope and ∆Sbinding/R is the intercept.55,56  However, in 
biological systems ∆Gbinding only exhibits a low temperature dependence, and a reliable 
determination of ∆Hbinding and ∆Sbinding may not be possible with van’t Hoff plots.  For 
example, where ITC shows a temperature dependence of ∆Hbinding and T∆Sbinding, van’t 
Hoff plots often show non-linear behavior for ∆Gbinding as a function of reciprocal 
temperature.11,38 
1.1.3 Theory Behind Conformational Constraints 
 There are a limited number of strategies medicinal chemist can used to strengthen 
the interactions between the protein and ligand and provide compounds with higher 
potency.  The enthalpic contribution to ∆Gbinding can be increased by strengthening the 
electrostatic, hydrogen bond and/or van der Waals interactions in the ligand-protein 
complex relative to those between the unbound ligand and protein with the solvent.  The 
entropic component of ∆Gbinding can be made less positive through increasing the 
hydrophobic effect upon binding, which can be accomplished by adding hydrocarbons to 
the ligand.  By adding more nonpolar surface to the ligand, interactions between the 
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ligand and the solvent become unfavorable which results in a greater entropic advantage 
for the binding event.  The translational and rotational entropic components of binding 
cannot be easily changed.  However, it is conventional wisdom that by synthetically pre-
organizing a ligand into the biologically active conformation, the impact of the 
conformational entropic penalty of ∆Gbinding will be minimized.  Everything else being 
equal, a conformationally constrained molecule should have a higher binding affinity 
because it is associated with a smaller conformational entropic cost upon binding.23  The 
idea of introducing conformational constraints in peptide ligands to rigidify them into 
their biologically active conformation was first hypothesized in 1979, and many 
medicinal chemists have used this hypothesis to assist in the development and design of 
molecules that bind more tightly to proteins.57 
In solution, peptides are highly flexible; the peptide bond can adopt either a trans- 
or cis- conformation, usually trans- due to sterics, and the amino acid side chain can 
orient itself in many directions.  The torsional angles associated with the amide nitrogen-
Cα bond and the Cα-carbonyl carbon bond are defined as φ and ψ, respectively.  The 
torsional angle associated with the Cα-Cβ bond is χ1.   
There are three different designs used to introduce conformational constraints into 
peptide ligands to rigidify or pre-organize them in their biologically active conformations 
(Figure 1.1).  The first of these is side chain to side chain constraint, in which two side 
chains are linked together to form a macrocycle.  Alternatively, a side chain can be 
connected to the backbone via a bridge, creating a side chain to backbone constraint.  A 
backbone to backbone macrocyclization can also be used to rigidify the ligand.   
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Figure 1.1:  Different designs used to introduce conformational constraints into peptides. 





































A:  side chain to side chain B:  backbone to side chain
C:  backbone to backbone  
 
There are many synthetic methods used to introduce cyclic conformational 
constraints into peptides.1  Backbone to backbone cyclization can be achieved by 
macrolactamization.  Side chain to side chain connections can be accomplished using 
disulfide bridges, ring closing metathesis and amide bonds.  Many different linkages are 
used in designing side chain to backbone cyclizations including ethers, amines and 
carbocycle moieties.  Ideally, the cyclization should not perturb any of the direct 
interactions between the ligand and protein or the solvent, otherwise the increased or 
decreased binding affinity of the cyclic molecule could be due to these interactions and 
not the pre-organization caused by the introduction of the conformational constraint.   
Fairlie has stated that “a central principle in medicinal chemistry is that 
molecules, which are conformationally pre-organized or fixed into a shape that is 
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recognized by a receptor, will have higher affinity for that receptor due to the reduced 
entropy penalty for adopting the receptor-binding shape.”2  Additionally, in the 
development of host-guest complexes, pre-organization is proposed to be a central 
determinant of the binding of metal ions to spherands, cryptands, corands, and podands.59  
According to this theory, the entropic penalty for binding of a cyclic compound should be 
dramatically less than that for an acyclic counterpart.  This penalty has been estimated to 
be 0.7 – 1.6 kcal mol-1 per rotor.8,13,23-25  However, the position on the ligand where the 
conformational constraint is introduced needs to be considered carefully.  The constraint 
should not perturb any of the protein-ligand interactions crucial for binding affinity.  In 
addition, Bartlett has stated that in some cases a highly flexible bridge might induce more 
conformational mobility, making the cycle more flexible than its non-restricted partner.60  
In addition, a poorly designed bridge may distort the binding region, which could impact 
the energetics of binding and make it difficult to determine the energetic effect of 
introducing a conformational constraint.61  Although no one has critically evaluated its 
usefulness, the implementation of conformational constraints is common practice in 
many medicinal chemistry laboratories and is still considered an important step in drug 
discovery.   
In addition to increasing affinity through reduction of the entropic penalty of 
binding, the introduction of a conformational constraint has many other advantages.  By 
adding unnatural constraints, proteases may not degrade the constrained molecule as 
quickly, and the ligand might be expected to survive longer in vivo.  Backbone to 
backbone cyclization may remove the ionized C- and N- termini of the peptide resulting 
in a more facile crossing of the ligand through membrane barriers.62  There are also 
reports that constrained molecules have better membrane permeation and oral 
bioavailability.63  The flexibility of native peptides renders them relatively nonselective 
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in binding, so, incorporation of conformational constraints into linear peptides may force 
their structure into the binding conformation of one particular receptor, thus making them 
more selective and eliminating undesired biological side effects.  In addition, introducing 
conformational constraints can provide important information about the structure of the 
bound ligand.  For example, one ligand with a particular restricted conformation may 
bind with higher affinity to the protein than a ligand with a different restricted 
conformation.  Therefore, the bioactive ligand conformation mostly likely resembles the 
conformation constrained in the higher affinity ligand.  On the other hand, by locking 
otherwise flexible amino acids into the protein binding conformation, independent 
structure-activity changes can be made elsewhere in the inhibitor without affecting the 
overall ligand conformation.  Constrained cyclic peptides have also been used as 
templates to reduce the effect of “induced fit,” which is associated with unpredictable 
changes in one region of a ligand that influence the ligand-protein interactions at a 
different region of the ligand.64  
In order to critically evaluate the energetic advantage gained by introducing a 
conformational constraint, one must have proper control molecules to evaluate the true 
effect of cyclization on binding and not the effect of the bridge itself.  In an ideal 
situation, the only difference between the rigid and flexible control molecules would be 
H2, the formal hydrogenolysis of one of a bond contained in the cycle (Figure 1.2).  
However, examples of such systems are difficult to find in the literature.  At any rate, 
there should be minimal structural changes between the constrained molecule and its 
flexible control.  For example, both ligands should contribute the same hydrogen bonds, 
hydrophobic effect, electrostatic and van der Waals interactions to complex formation.  
The molecules in each pair should also have similar molecular weights and the same 
number of heavy atoms (C, N, O, S, P, etc).  The molecules should also have the same 
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relative solvation energies, having the same polar and nonpolar solvent accessible surface 
areas.  For example, a lactam linkage in a macrocycle and an amine and carboxylate 
groups in an acyclic control may look very similar but they interact differently with a 
protein and the solvent.  The amide bond could have neutral charge hydrogen bond 
interaction with the protein and the solvent, whereas both the amine and carboxylate 
groups would have electrostatic and charge assisted hydrogen bond interactions with the 
protein and the solvent.  In addition, the amide, amine and carboxylate groups likely have 
different relative solvation energies.  These differences could be substantial and might 
affect the binding affinities for the cycle and control, which one cannot anticipate, 
making it difficult to determine the true impact of introducing a conformational constraint 
on the binding affinity in such systems. 
 
Figure 1.2:  Examples of constrained ligands and their ideal control partners where X = 
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One potential problem to consider when designing ideal control partners for 
cyclic conformational constraints was illustrated by Bartlett and co-workers who were 
interested in using macrocyclic conformational constraints to enhance binding to 
thermolysin.25  A linker was designed to connect the carbon α  to the phosphorus atom in 
1.001 with the C-terminal carboxylate to form a backbone to side chain bridge providing 
bicycle 1.002.  The conformational constraint was devised to enforce the biologically 
active orientation for thermolysin binding.   The acyclic analogue 1.003 was envisioned 
as the control and is related to 1.002 by cleavage of a carbon-carbon bond to the 
hydropyran ring.  Inhibition constants were determined, and 1.002 was found to be a 20 
times more potent nanomolar inhibitor of thermolysin than the acyclic molecule 1.003.  
X-ray crystal structure analysis of the bound conformations of 1.002 and 1.003 showed 
that the backbone and side-chain atoms of these molecules are virtually superimposable 
with each other.  However, the aromatic unit of the 1.003 is rotated 168o in comparison 
with 1.002, adopting a different position in the thermolysin active site.  The important 
structural data reveals that the difference in affinity between these two molecules is not 
simply the result of cyclization but also due to different interactions between the two 
ligands bound to thermolysin.  The only chemical difference between the control and 
macrocyclic ligands was the addition of two hydrogen atoms.  In order for the molecules 
to have the same bound conformation, the length of a carbon-carbon bond in the cycle 
must increase from the length of a carbon-carbon bond (1.5 Å) to the van der Waals 
contact distance of a CH group (about 3 - 4 Å).  However, in this example the enzyme 
binding site was not flexible enough to accommodate this substantial change without the 
“reorientation” of the aromatic unit.  Thus, researchers must carefully consider the design 































The above example illustrates that structural information of the binding mode of 
the constrained ligand is crucial for determining the benefit of introducing the 
conformational constraint.  The introduction of the conformational constraint must 
stabilize the biologically active conformation for the ligand binding to the protein.  
Otherwise, as shown, the enhanced binding affinity of the restricted ligand cannot be 
attributed to minimization of the conformational entropic penalty of binding.  When 
structural data is lacking from an example, it is difficult to interpret the experimental 
results. 
In addition, structural information is essential to verify that the constrained and 
flexible ligands have uniform binding modes.  Otherwise, any energetic advantage 
associated with the binding of the constrained molecule could be attributed to better 
binding interactions between the molecule and the protein and not the reduction of the 
entropic penalty of binding or vice versa.  Furthermore, ITC should be used to evaluate 
the binding affinities of the constrained and control ligands.  The ITC experiments can 
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evaluate the entropic contribution to the binding event and determine if the introduction 
of the conformational constraint has affected the conformational entropic penalty paid 
upon ligand binding to the protein.  
The experimental methods used to obtain the binding affinity data are also crucial 
to evaluating the effect of introducing a conformational constraint.  Using enzyme-based 
assays, where the binding affinities of ligands to proteins are directly measured, we can 
compare the values obtained for the constrained and flexible molecules in order to 
determine the effect of introducing the conformational constraint on affinity.  However, 
many times in the literature cell-based assays are employed to evaluate the pre-organized 
and control pair.  This method indirectly measures binding affinities as there are other 
factors including membrane binding, transport, and interactions with other cellular 
enzymes (including proteases) which may cloud the experimental results.  For example, 
in a cell-based assay a constrained ligand may appear to bind tighter to a protein than a 
flexible control, but it is possible that the constrained ligand is not degraded by cellular 
proteases present in the assay while the control partner is quickly destroyed.  Thus, it 
would appear that the control molecule did not bind to the protein as well as the 
constrained ligand, where in reality, the flexible molecule did not have the same access to 
the protein as the constrained ligand.  Therefore, one must rigorously evaluate the 
experimental methods used to compare the ligand partners before drawing any 
conclusions as to the effect of introducing a conformational constraint on the binding 
affinity of the ligands. 
In designing new ligands, many medicinal chemists have used the hypothesis that 
introducing a conformational constraint will reduce the entropic penalty of binding and 
create molecules with better binding affinity.2,23,65-69  Many times a cyclic peptide is 
prepared and evaluated but the proper control molecules are never considered and 
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whether or not conformational constraints actually enhanced binding affinity is rarely 
addressed in the literature.  In addition, sometimes scientists don’t explicitly describe the 
results in a manner that makes it obvious that a conformational constraint was used.  
Thus, it is difficult to find examples where the validity of the pre-organization theory has 
been evaluated.  Presented here is an overview of the field of conformational constraints.  
Bear in mind that many of the examples presented here do not fit the criteria that allow 
for the evaluation of the validity of the conformational constraint theory. 
1.2  EXAMPLES OF SIMPLE CONFORMATIONAL CONSTRAINTS 
Researchers have introduced conformational constraints into ligands to enhance 
binding potency.  The simplest way to introduce a conformational constraint is through 
unsaturation.  For example, a double bond was introduced into dehydroquinate synthases 
inhibitor 1.006 providing the Z- and E-vinyl homophosphonates 1.004 and 1.005, 
respectively.70  The Z-analogue 1.005 bound weakly to dehydroquinate synthases, 
whereas 1.004 and 1.006 both exhibited micromolar activity with constrained 1.004 being 
ten-fold more active than flexible 1.006.  In this example, there is no substantial 
difference in the interactions between the restricted and control ligands with the solvent 
or the protein.  Thus, it seems that by introducing a double bond conformational 






























In order to assess the energetic contribution to binding from restricting rotors 
through introducing a double bond conformational constraint, compounds 1.007 and 
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1.008 were prepared as analogues of N-acetyl-D-alanyl-D-alanine (1.009).71  The binding 
of these ligands to ristocetin A, a member of the vancomycin group of antibiotics, was 
measured.  Both had millimolar activity with rigid 1.007 being nine times more potent 
than flexible 1.008.  Once again there is no substantial difference between the two 
molecules expect for the rigidification from the carbon-carbon double bond, so the 
difference in binding affinities may be attributed to the number of rotors restricted in 
1.007.  The authors speculate that the introduction of the double bond likely increased the 
barrier of rotation for each single carbon-carbon bond on either side of the double bond 
restriction.  The authors estimate that 1.5 rotors are restricted by introducing the double 
bond into 1.007 and the free energy per rotor restricted was calculated to be 0.9 kcal mol-
1, which is well within the range predicted in the literature for the entropy penalty of 
binding minimized through the introduction of a conformational constraint (see Section 
1.1.3).  Thus, once again the introduction of a double bond conformational constraint 
enhanced binding affinity. 


















In addition to double bonds, simple carbocycles have been used to install 
conformational constraints into peptide ligands.  For example, cyclopropane containing 
rigid glutamate analogues have been prepared and analyzed for their affinity to various 
glutamate receptor subtypes in brain membranes.72  The cyclopropane-containing 1.010 
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and 1.011 analogues of glutamate and linear 1.012 were evaluated as inhibitors for N-
methyl-D-aspartate receptors.  The cyclopropane 1.010 was not active, whereas the linear 
1.012 exhibited nanomolar potency, and the cyclopropane 1.011 was 17 times more 
active than flexible 1.012.  There is an additional methylene unit present in the rigid 
compounds but not found in the linear control.  How this additional residue effects 
interactions with the protein or solvent is unknown.  Even so, it appears from the data 
presented here that the introduction of the cyclopropane constraint did increase potency.  
Unfortunately, however, a cocktail of enzymes was present in the binding assay and thus 










1.010 1.011 1.012  
 
In another example, cyclopropane 1.010 and control 1.012 were also evaluated as 
ligands for the metabotropic glutamate (mGlu) receptors.73  The cyclopropane 1.013 and 
its control 1.014 were also examined.  All compounds exhibited micromolar potency and 
the linear controls 1.012 and 1.014 were as much as 10-fold less potent than the cycles 
1.010 and 1.013.  In this example, only cell-based assays were employed which are, 
unfortunately, inadequate for evaluating the consequences of introducing a cyclopropane 








1.013 1.014  
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Monn and co-workers also synthesized conformationally constrained glutamic 
acid analogues as highly potent and selective neurotransmitters for group 2 mGlu 
receptors.74  The glutamic acid skeleton was incorporated into a fused 
bicyclo[3.1.0]hexane nucleus in 1.015 in order to constrain the glutamate into the 
conformation required for optimal binding.  The cyclopropane-containing glutamic acid 
1.010 was used as the flexible control.  Modeling suggested that the bicycle closely 
mimicked the proposed bioactive conformation required to interact with the 2 mGlu 
receptor.  The constrained molecule contains two additional carbon units which are not 
found in the control and the impact these residues have on protein or solvent interactions 
is unknown at this time.  The bicyclo 1.015 was slightly more active, with nanomolar 
potency, than the control ligand 1.010.  Again, multiple enzymes were present in the 
binding assay, which make it difficult to determine the true impact on binding affinity 








1.015 1.010  
 
Another example of utilizing a simple carbocycle as a conformational constraint 
can be found in one of the earliest examples of introducing a conformational constraint 
into a peptide.  A lactam moiety was introduced into the luteinizing hormone-releasing 
hormone pyroGlu-His-trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 (1.016) to provide ligand 
1.017.65  Modeling suggested the close proximity of the pro-S hydrogen of Gly6 to N-H 
of Leu7 in 1.016 suggesting that these positions were ideally suited for the introduction of 
the conformational constraint.  The five-membered lactam was designed by replacing the 
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Gly6 pro-S hydrogen with a methylene group and connecting it to the N of Leu7.  The 
lactam ring was proposed to stabilize a β-turn conformation by restricting rotation and 
forcing the Gly-Leu peptide bond to remain in the required trans-conformation.  Lactam 
1.017 was found to be two to eight times more potent than the acyclic control 1.016 for 
inducing release of luteinizing hormone in vivo and in vitro.  The structural difference 
between control 1.016 and 1.017 is two hydrocarbon residues and N-H moiety and the 
consequence of the interactions with these groups and the protein and solvent is difficult 
to estimate.  In addition, the only assays employed in this study where cell-based thus 
making it difficult to evaluate the true impact of the conformational constraint on binding 
affinity.  Although it appears from the data that introducing a conformational constraint 
enhanced binding affinity, issues make it difficult to validate this conclusion. 



















Another example of the introduction of a simple carbocycle conformational 
constraint involved using a proline ring as a scaffold to design analogues of adda (1.018), 
which is a potent inhibitor of protein phosphatase 1 and 2A (PP1 and PP2A).75  
Compounds 1.019a, 1.019b, and the flexible control 1.020 were prepared and the cis-
1.019a was four-fold more active than trans-1.019b with both exhibiting micromolar 
activity.  However, the acyclic control 1.020 relative to 1.018 was inactive (IC50 > 100 
µM).  Since the acycle 1.020 was inactive, the authors speculated that the pyrrolidine 
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heterocycle plays a role in the enhanced potency, perhaps by pre-organizing the active 
conformation for the two carboxyl groups.  Even though it seems that pre-organization 
enhanced potency in this system, there are two carbon residues different between the 
control and rigid molecules.  The impact of this difference to the binding affinity has not 
been examined and thus, it is difficult to evaluate the introduction of the conformational 












1.019a, R1 = CO2H, R2 = H










A larger carbocycle, a azepanone ring, was used by Marquis and co-workers to 
introduce a conformational constraint in inhibitors of cysteine protease cathepsin K 
providing 1.021.76  Compound 1.022, which contains the same hydrogen bond 
donor/acceptor count as 1.021 but has one less methylene unit, was examined as the 
control.  The incorporation of the conformational constraint into 1.022 increased the 
inhibitor potency by 1000-fold to subnanomolar potency in the in vitro cell-based assay, 
and gave a compound having good oral bioavailability.  The authors provide important 
structural evidence that the cycle 1.021 binds in the biologically active conformation to 
the protease and the methylene groups of the azepanone ring make no contacts with the 
protein. This example clearly demonstrates that an enhanced activity is observed on the 
introduction of a conformational constraint.  Unfortunately, only a cell-based assay was 
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employed in this example which, as previously discussed, is inadequate for determining 

























1.021 1.022  
 
In 2003, Burke and co-workers introduced a carbocyclic conformational 
constraint into the pY residue of Src homology 2 domain of the growth factor receptor 
binding protein 2 (Grb2-SH2 domain) binding ligands in order to stabilize the bound 
conformation.77  The installation of the carbocycle in 1.023 constrained the three torsion 
angles (χ1,  χ2 and φ ) of the ligand’s pY residue to values similar to those observed for 
its biologically active conformation.  An X-ray crystal structure of unbound 1.023 
showed that this analogue is stabilized into the orientation required for Grb2-SH2 domain 
binding.  The unconstrained phosphorylated N-acetyltyrosine methyl ester 1.024 was 
examined as a control which contained extra methylene residues not present in the 
constrained system.  Comparison of the binding affinity of 1.023 with the 
conformationally more flexible phosphotyrosine 1.024 revealed no apparent increase in 
affinity, both compounds were approximately equipotent within experimental error (with 
low millimolar potency).  Unlike the previous examples, the authors claim that a 
























1.3  EXAMPLES OF SIDE CHAIN TO SIDE CHAIN CONFORMATIONAL 
CONSTRAINTS 
Research groups are also interested in introducing conformational constraints by 
linking peptide side chain residues.  For example, Bartlett and co-workers used a 
methylene moiety to link two amino acid side chains and form a macrocyclic inhibitor of 
the aspartic protease penicillopepsin providing 1.025.78-80  Two different acyclic controls 
were prepared for the macrocycle.  Due to the problems encountered in the thermolysin 
system previously described (see Section 1.1.3), the linear compounds 1.026 and 1.027 
were derived by replacing the methylene units on either side of the phenyl ring of 1.025 
with hydrogens in order to enable the controls to adopt the same bound conformation as 
the macrocycle.  The authors speculate that conformational formed with an extra 
methylene unit in each of the control ligands would not fit into the penicillopepsin active 
site.  The cyclic molecule 1.025 had higher binding affinity than either of the control 
partners (1.025: Ki = 0.1 nM, 1.026: Ki = 42 nM, 1.027: Ki = 1300 nM,).  However, since 
the controls had substantially different potencies, this example illustrates the importance 
of selecting the proper control molecules when determining the effect of introducing a 

































The authors estimated the energetic effect on binding caused by introducing the 
conformational constraint by comparing the number of independent rotations restricted in 
each ligand ant the ligand binding affinities.  An average value of 0.9 kcal mol-1 per rotor 
was calculated.  This is within the range estimated for the conformational entropy penalty 
of binding reduced by pre-organizing a ligand into its biologically active conformation 
(see Section 1.1.3).  In addition, the 3.6 kcal mol-1 binding energy difference between 
macrocycle 1.025 and control 1.026 is among the highest value reported for the 
enhancement in binding potency due to the introduction of a conformational constraint.  
However, 1.026 contains an extra N-H moiety that could provide additional interactions 
compared with 1.025 and 1.027 and compound 1.025 also contains an additional 
methylene group compared with the controls 1.026 and 1.027.  These moieties could 
provide additional energetic interactions in the ligand-protein complex.  On the other 
hand, X-ray structures of 1.025 and 1.026 bound to the protease were solved and the 
position and conformation of the ligands in the complexes are virtually identical with the 
most pronounced conformation difference between the two ligands being the χ2-angle at 
the Phe residue.24  In addition, the conformation of the bound cycle closely resembles the 
solution structure obtained from NMR data.  It seems that in solution 1.025 is pre-
organized into its bound conformation.  Thus, it appears that in the example, the 
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introduction of a side chain to side chain conformational constraint did enhance binding 
potency. 
Research groups have also utilized ether linkages to introduce side chain to side 
chain conformational constraints.  For example, in 1994 a series of nanomolar 
macrocyclic inhibitors of HIV-1 protease were prepared.81  Cycle 1.028 was the most 
active constrained analogue in the series being six times more potent than the control 
molecule 1.029 in an enzyme-based assay.  However, the ether linkage present in cycle 
1.028 was not present in the control 1.029 making it difficult to evaluate the effect of 
introducing a conformational constraint because it is not known how this difference could 






















1.028, n = 2
1.029  
 
Fairlie and co-workers have also designed numerous cyclic peptide inhibitors of 
HIV-1 protease using ether side chain to side chain linkages.82,83  Macrocyclic 
compound 1.030 was compared to the Boc-carbamate acycle 1.031.84  The acyclic 
compound 1.031 was 37 times less active than the cyclic derivative 1.030, and the 
authors suggested that the enhanced potency was likely to be an underestimate of the 
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advantage from introducing the conformational constraint, since the linear compound can 
potentially make additional interactions with the enzyme via hydrogen bonding of its 
ester group and hydrophobic effect with the tBu moiety.  These statements may be valid; 
however, in this example the estimation of the impact of introducing the conformational 


























1.030 1.031  
 
In another example, 15-membered restricted macrocyclic derivatives of Leu-Asn-
Phe and Phe-Ile-Val tripeptides 1.032 and 1.034 were also designed as HIV-1 protease 
inhibitors using ether linkages.  The acyclic controls 1.033 and 1.035 were the peptide 
equivalents of 1.032 and 1.034 minus the ether bridge.  Modeling studies suggested that 
the cyclic and acyclic inhibitors had similar conformations and formed similar contacts 
with the enzyme.  Constrained compound 1.034 was two times more potent than the 
linear 1.035 in an enzyme-based assay, whereas the macrocycle 1.032 was more active 
than control 1.033 by 72-fold.  It may appear from this example that the introduction of a 
side chain to side chain conformational constraint enhanced binding affinity; however, 
since the cycles and controls could have different interactions with the protein and 






























































Next the research group designed the conformationally constrained bicyclic HIV-
1 protease inhibitor 1.036 containing both macrocyclic components of 1.032 and 1.034 
pre-organized in the desired conformations for enzyme binding.85  The linear derivative 
1.035 was again used as a control, although it lacked the ether linkages present in each of 
the macrocyclic rings in 1.036.  Molecular modeling and 1H NMR studies indicated that 
each ring in 1.036 was constrained in a conformation that superimposed well with the 
bound conformation of acyclic peptide 1.035.  By constraining the two otherwise flexible 
tripeptide components in 1.035 to the conformations required for binding, the authors 
expected a significant entropic and thus energetic advantage for the binding of 1.036 over 
the acyclic inhibitor 1.035.  However in the biological assay, compounds 1.035 and 1.036 
were found to be equipotent having nanomolar potency.  Very important X-ray structures 
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revealed that the cycle 1.036 and the control 1.035 might have different hydrogen bond 
interactions with the protease.  Even so, it appears that an ether linkage conformational 
































As another example of introducing a conformational restriction containing an 
ether linkage, rigid 1.037 was derived through the installation of a carbon-carbon bond in 
1.038.  The compounds were prepared as small-molecule inhibitors of histones 
deacetylases (HDAC) because inhibition of HDAC is a potential strategy for the 
development of small molecule anticancer agents.86  The control and constrained 
molecules only differ in the number of carbon-carbon bonds.  Due to the similar make up 
of the molecules, the cycle and control should have the same interactions with HDAC 
and the solvent.  Any difference in the binding affinities could then be associated with the 
introduction of the conformational constraint.  Nanomolar inhibitors 1.037 and 1.038 had 
equal activity against HDAC.  Although no structural information was provided to 
determine if 1.037 and 1.038 bind in similar modes to the protein, it seems that once 





















1.037 1.038  
 
In another example where side chain to side chain linkage did not enhance 
binding affinity, the 14-membered macrocyclic hydroxamic acid 1.039 that inhibits tumor 
necrosis factor α (TNF-α) release was designed as a cyclic analogue of 1.040.  Two 
methylene residues were used to link the methyl and methoxy moieties in 1.040 to afford 
1.039.87  An X-ray structure of an inhibitor-enzyme complex was inspiration for this 
macrocycle because it revealed the close proximity of the methyl and methoxy ligand 
groups.  The control 1.040 was found to be equipotent as the cyclophane 1.039 in 
micromolar inhibition of TNF-α release.  The important X-ray crystal structure of 1.039 
bound to MMP-3 reveals that the 14-membered ring holds all the structural elements in 
positions analogous to those of 1.040 bound to the protein.  Hence, the introduction of a 
conformational constraint did not change the mode of binding in this system.  Since the 
constrained and control molecules are equipotent and bind to the protein in the same 
manner, one might assume that there was no impact on binding energetics by introducing 



















Lactam bridges have also be utilized to introduce side chain to side chain 
conformational constraints.  For many years, Aldrich and co-workers have been 
interested in synthesizing rigid dynorphin A (Dyn A) analogues as selective κ opioid 
receptor agonists.88  Dyn A-(1-13)NH2 is a highly flexible peptide with the following 
amino acid sequence:  Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-OH.  
The low selectivity for the κ opioid receptor is partially attributed to the conformational 
flexibility of the ligand.  The N-terminus of Dyn A has been estimated to adopt a helical 
structure from Tyr1 through Arg9 when interacting with κ receptors.89  The side chain to 
side chain cyclic constraints were installed in order to stabilize this structure and the 
amino acid residues involved in the constraint were carefully selected such they were not 
critical residues for receptor recognition.  Cycle 1.041 was the most potent nanomolar 
inhibitor for the κ opioid receptor and was six times more active than its linear control 
partner 1.042 in the cell-based assay.  Futhermore, the linear control 1.042 contains a free 
amine that is not present in the cycle and this moiety could also be positively charged at 
physiological pH.  The impact of interactions between this amine residue and the solvent 
and protein are unknown.  Thus, it is difficult to determine the effect of introducing a 




































1.4  EXAMPLES OF BACKBONE TO BACKBONE CONFORMATIONAL CONSTRAINTS 
Research groups have also been interested in installing backbone to backbone 
linkages in order to design conformational constraints into peptide ligands.  Carbon 
chains and ester or amide bonds have been used as the bridging units in many constrained 
molecules.  For example, a macrocyclic nanomolar inhibitor of NS3 protease, a potential 
therapeutic target of hepatitis C virus infection, was synthesized with the hope that 15-
membered macrocycle containing a Z-double bond would enforce the conformation 
required to bind to NS3.90  The macrocyclic constraint was designed by installing an 
alkyl chain between backbone atoms. The only difference between 1.043 and its ideal 
control 1.044 was the breaking of a carbon-carbon bond in the alkyl backbone bridge.  In 
vitro IC50 values were determined and constrained 1.043 had 36-fold increased potency 
over flexible 1.044.  An important X-ray structure of 1.043 bound to the protease was 
solved and confirmed that 1.043 had a similar bound conformation as other inhibitors 
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previously reported.  In this example, it is clear that the introduction of a conformational 






















1.043 1.044  
 
Burke and co-workers also designed a carbon bridge that linked the backbone 
atoms of a peptide in order to introduce a conformational constraint.  Ligands 1.045 and 
open-chained analogue 1.046 were evaluated for their ability to bind to the Grb2-SH2 
domain.91   All compounds had nanomolar potency with the macrocycle 1.045 having 
seven-fold higher binding affinity than its acyclic partner.  However, the oxalyl group in 
1.046 might interact differently with the domain or solvent than the carboxylate group 
found in 1.045.  In addition, the hydrocarbon bridge in the macrocycle 1.045 could also 
provide additional contacts with the protein or solvent.  Thus, it is difficult to judge the 





























Also using carbon backbone to backbone linkage, Ettmayer made a number of 
cyclic phospholactams as Grb2-SH2 domain binding antagonists.92  In competitive 
ELISA assays, the macrocycle 1.047 was found to be 2.6-fold more active, with 
submicromolar potency, than its control 1.048.    Two dimensional NMR studies of the 
ligands in aqueous solution suggested that the pTyr-Val-Asn motif of 1.047 is stablized in 
the β-turn that is required for interaction with Grb2-SH2 domain, whereas in solution the 
structure of 1.048 is a random coil.  There are no major discrepancies between the 
constrained and control molecules, they both should have the same interactions will the 
protein and the solvent, and thus, the introduction of a conformational restriction seemed 

































1.047 1.048  
Greco and co-workers also designed backbone to backbone macrocyclic serine 
protease inhibitors using methylene residues as the bridging atoms with the intent of 
evaluating the effects of ring size on binding activity.93  Cycle 1.049 was the most active 
rigid compound with nanomolar potency and the acycle 1.050 served as the linear 
control; the compounds displayed similar inhibition activity, with only a two-fold 
difference in potency.  However, the control has an amine residue that is not present in 
the cycle.  Based on the X-ray structure of a similar cyclic inhibitor bound to the 
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protease, this amine in the flexible control 1.050 seems close enough to interact with 
protein residues potentially giving the control ligand additional interactions with the 
protease relative to the cyclic derivatives, which were not discussed in this study.  It is 
therefore difficult to estimate the effect of introducing a backbone to backbone 
























1.049, n = 5 1.050  
 
Liskamp also introduced a carbon chain to design a backbone to backbone 
constraint in 1.053 forming the macrocycles 1.051 and 1.052 in order to enhance Grb2-
SH2 domain binding.94  The control 1.053, which was the synthetic precursor for 1.051 
and 1.052, differs from the cyclic compounds by two methylene units.  The double bond 
in 1.051 introduces an additional constraint relative to 1.052.  The binding affinities for 
1.051, 1.052 and 1.053 were measured, and the unsaturated cyclic peptide 1.051 was 
slightly less active than the linear peptide 1.053, whereas the reduced cyclic peptide 
1.052 was approximately equipotent as the linear peptide 1.053 both exhibiting 
nanomolar potency.  It should be noted, however, that these energetic differences are 
relatively small.  This example, once again, illustrates that conformational constraints do 
not always enhance binding affinity to SH2 domains.  The authors suggest that enthalpy-
entropy compensation may be responsible for counteracting any entropy gained through 
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In addition to carbon units, amide bonds have also been used to link the backbone 
residues of peptides together in order to introduce conformational constraints.  In one 
such example, the bioactive properties of a series of cyclic peptides were determined in a 
lettuce seeding assay to measure chlorosis induction, a disease condition in plants that is 
characterized by yellowing.95  Tentoxin (1.054), which causes chlorosis, is the backbone 
to backbone macrolactam of the flexible peptide 1.055.  The rigid 1.054 was four-fold 
more active than the linear control 1.054.  Therefore, the introduction of a conformational 
constraint seemed to enhance binding potency of the linear peptide.  However, there are 
potentially different interactions between the functional groups of the ligands with the 
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solvent and/or protein.  The cycle 1.054 contains an amide group while the linear 1.055 
has carboxylate and amine moieties.  The effect each of these groups will have on the 
binding event makes the evaluation of the backbone to backbone conformational 






















Macrolactonization can also be used to introduce a backbone to backbone 
conformational constraint.  For example, Bartlett and co-workers synthesized the novel 
macrocyclic peptidase inhibitors 1.056 (both R- and S- enantiomers were prepared) by 
introducing a conformational constraint into 1.057.60,61  The lactone linkage in 1.056 
was cleaved with base to provide the hydroxy acid 1.057, which was used as a control to 
determine the energetic effect of macrolactonization on binding.  However, the basic 
conditions caused epimerization giving a 60/40 mixture of diastereomers of 1.057.  The 
compounds were tested for their ability to inhibit α-chymotrypsin.  The diastereomeric 
mixture 1.057 had a Ki of 1500 µM, whereas the S-lactone 1.056 had a Ki of 220 µM, and 
the R-lactone 1.056 had a Ki of 1700 µM.  Comparison of the acyclic hydroxy acid 1.057 
with the lactone 1.056 indicated that the macrolactonization enhanced the affinity by 
about a factor of four, assuming that the inhibition observed for the acycle emanates from 
only one of two epimers present in the mixture.  However, one needs to consider that the 
lactone in 1.056 and the carboxylate and alcohol moieties in 1.057 could interact 
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differently with protein and solvent, and the true energetic consequences of introducing 
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1.5  EXAMPLES OF CONFORMATIONAL CONSTRAINTS WHERE THE 
THERMODYNAMIC PARAMETERS OF BINDING WERE MEASURED 
Many of the preceding examples suggest that the introduction of a conformational 
constraint could enhance the binding affinity of a flexible ligand as stated in the theory of 
pre-organization.  However, evidence that this increase affinity is caused by the reduction 
of the entropic penalty of binding has not been conclusively provided in the literature.  In 
order to determine the true entropic advantage that should accompany the introduction of 
the conformational constraint, the thermodynamic parameters of the binding of the 
constrained and control molecules need to be evaluated.  There are only a few examples 
of this in the literature.  For example, the effect of introducing a conformational 
constraints in pp60c-src SH2-domain binding ligands was evaluated using ITC.96  The C-
terminal portion of the native tetrapeptide ligand (N-Ac-pY-EEI-OH) was rigidified using 
a piperidine ring in order to define the structural requirement for the hydrophobic pY+3 
binding site of the SH2 domain.  The flexible analogue 1.059 was prepared as a control, 
although it contained two additional methylene groups.  Binding of the rigid 1.058 was 
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found to be more enthalpically favorable than the binding of the flexible 1.059 with the 
∆∆H being -1.1 kcal mol-1 (Table 1.01).  An unanticipated entropic disadvantage from 
pre-organization was also observed and therefore, this example suggests that the 
introduction of a conformational constraint may not reduce the entropic penalty of 
binding.  However, the overall binding difference between the pair was almost equal 
(∆∆G = 0.5 kcal mol-1) suggesting that enthalpy-entropy compensation (see Section 
1.1.1) is an important factor and may result in the introduction of a conformational 
constraint having no effect on binding affinity.  In addition, no structural data was 



























Table 1.01:  ITC data for binding to SH2 domain.96 
compounds K d (µM) ∆G (kcal mol-1) ∆H (kcal mol-1) ∆S (cal mol-1 K-1)
1.058 1.0 ± 0.5 -8.4 -5.4 ± 0.1 10
1.059 0.4 ± 0.1 -8.9 -4.3 ± 0.9 15.3
 
In another example, Spaller and co-workers designed and studied 
conformationally constrained ligands for the third PDZ (PDZ3) domain of the 
postsynaptic density-95 kDa protein, which mediates a variety of protein-protein 
interactions in eukaryotic cells.97  A group of macrocycles was prepared utilizing side 
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chain to side chain lactam linkages and evaluated using ITC (Table 1.02).  The ligands 
were designed based on the native peptide NH2-Try-Lys-Gln-Thr-Ser-Val-OH (1.060).  
The Gln residue at P-3 positions was converted to an amine-bearing side chain X and Ser 
at position P-1 was changed to a carboxylate-bearing side chain Y.  Coupling the X and Y 
side chains formed a lactam bridges providing cyclic compounds where the key binding 

























































































Table 1.02:  Binding profile for macrocycles and controls of PDZ3.97 
 
compounds K d (µM) ∆G (kcal mol-1) ∆H (kcal mol-1) T∆S (kcal mol-1)
1.061 4.47 ± 0.26 -7.29 ± 0.03 -2.29 ± 0.01 5.01 ± 0.03
1.062 5.54 ± 0.18 -7.17 ± 0.02 -4.77 ± 0.35 2.4 ± 0.3
1.063 18.5 ± 3.5 -6.45 ± 0.1 -2.47 ± 0.09 4.00 ± 0.01
1.064 5.03 ± 0.18 -7.22 ± 0.02 -3.08 ± 0.09 4.15 ± 0.07   
Many cyclic and acyclic pairs in this study showed very similar entropy of 
binding.  However, there was a large, favorable increase in entropy, T∆∆S = 2.6 kcal 
mol-1 for the cyclic derivative 1.061 relative to its acyclic control 1.062.  The authors 
speculate that this increase in entropy might be attributed to a decreased entropic penalty 
of binding (through rotor restriction).  However, in addition to the entropic gain 
associated with the introduction of the conformational constraint in the 1.061/1.062 pair, 
there was also an enthalpic loss resulting in a small difference in the overall ∆G.  This 
enthalpy-entropy compensation appears ubiquitous in biological systems and is once 
again a factor in ligand pre-organization.  It should be noted that the control 1.062 is 
“unavoidably imperfect”, because it contains amine and carboxylate groups, which may 
participate in dramatically different interactions with the protein and solvent than the 
amide present in the cyclic partner.  Nevertheless, it seems that the conformational 
constraint might have reduced the entropic penalty of binding but did not enhance the 
overall binding affinity.  
On the other hand, 1.064 was the almost ideal flexible control for macrocycle 
1.063 as the only difference between 1.063 and 1.064 was a formal hydrogenolysis of a 
carbon-nitrogen bond in the macrocyclic ring.  There is, however, an extra amide N-H 
group in the control 1.064 that could participate in interactions with solvent or protein..  
Interestingly, control 1.064 had a slightly higher affinity than cycle 1.063, mostly through 
an enthalpic gain (∆∆H = 0.61 kcal mol-1).  It appears that in this pair the pre-
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organization did not reduce the entropic penalty or increase potency.  This research 
illustrates that the choice of control molecule is crucial to evaluating the energetics of 
introducing a conformational constraint.  However, once again, the researchers did not 
provide any of the important structural information needed to further evaluate the 
conformational constraint theory. 
Disulfide bonds are naturally used to control the conformation of peptides and 
proteins, and forming disulfide bonds between proximal cysteine or related residues have 
been used as a tactic to introduce constraints in peptide ligands.  For example, Hruby 
designed conformationally restricted derivatives of enkephalin by installing disulfide 
linkages into the flexible dithiols in order to stabilize the β-turn required for activity.98-
101  ITC was used to examine the interaction between the lipid membrane and the cyclic 
and acyclic peptides 1.065 and 1.066 (Table 1.03).102  The control 1.066 had more 
favorable enthalpy of binding to the cell membrane while 1.065 had more favorable 
entropy of binding.  Enthalpy-entropy compensation was once again observed for the pair 
with the free energy of binding to the cell membrane being very similar for each 
compound.  Although the only difference between the molecules in the pair is the 
disulfide bridge which is replaced by two hydrogen atoms, the compounds could 
potentially interact differently with the protein and solvent.  In addition, one most 
consider the stability of the acyclic control, which could be easily oxidized to the 
corresponding cyclic compound.  Despite the fact that no structural data was provided, it 
seems that in this case the pre-organized compound had an entropic advantage over its 
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Table 1.03: Thermodynamic parameters for binding cyclic and acyclic enkephalin 
analogues to POPC/cholesterol. 
 
compounds K  (M-1) ∆G (kcal mol-1) ∆H (kcal mol-1) ∆S (cal mol-1)
1.065 385 -5.9 -4.4 5.1
1.066 890 -6.4 -13 -23  
 
1.6 THE INTRODUCTION OF CYCLOPROPANES AS CONFORMATIONAL 
CONSTRAINTS 
Although there are examples in the literature where the introduction of a 
conformational constraint has increased binding affinity, but there are also examples 
where pre-organization does not seem to affect binding potency.  In addition, there is 
little clear cut evidence that a conformational constraint reduces the entropic penalty of 
binding.  Thus, it seems that the two fundamental elements of the conformational 
constraint theory, namely enhanced binding affinity and minimized entropic penalty, 
have not been fully examined and may not, in fact, be true.  Even so, medicinal chemists 
still use this unproven theory to design and develop new molecules and drugs.  The 
Martin group has begun to investigate their cyclopropane conformational constraints in 
order to address these issues more thoroughly.  The Martin has explored the use of 
cyclopropanes to introduce conformational constraints into peptides since the early 
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1990s.  In some but not all cases, the proper control molecules were prepared to evaluate 
explicitly the effect of introducing a constraint.  We have also used thermodynamic and 
structural data to examine the conformational constraint theory.  This section summarizes 
the results to date.   
1.6.1  Introduction: Cyclopropanes Restrict Both Peptide Backbone and Side 
Chain Orientation 
In order to lock both the backbone and side chain of a peptide into the 
biologically active conformation, the Martin group designed 1,2,3-trisubstituted 
cyclopropanes as conformationally restricted mimics of peptide 1.067.  Many of the 
conformational constraints that have been reported in the literature restrict only the 
backbone or side chain moiety of the parent peptide.  Using cyclopropanes it is possible 
to constrain both the peptide backbone and side chain into specific orientations at the 
same time.  In addition, it is straight forward to design and prepare the ideal control 
partners for these constrained pseudopeptides.  The cyclopropane replacements 1.068 and 
1.070 were developed by mutating the nitrogen atom of the amide bond in the native 
peptide 1.067 to carbon and covalently connecting it to C(β) on the side chain (mode a).  
These cyclopropanes are designed to restrict the φ and χ1  torsional angles of the peptide.  
Replacements 1.069 and 1.071 were derived from the native peptide 1.067 by replacing 
the amide carbonyl carbon with a sp3-carbon and connecting it to the C(β) on the side 



























































The stereochemistry around the cyclopropane ring plays an important role in 
determining the conformation of the native peptide that is mimicked.  For example, when 
the backbone atoms on the ring are in a trans-orientation as in 1.068 and 1.069 the 
peptide backbone is locally rigidified in an extended (β-strand) conformation by locking 
the φ or ψ angle at about -132o and 143o, respectively, as evident by X-ray crystal 
structures.103-105  Ideally, the torsional angles for a peptide β-strand of φ = -139o and ψ = 
135o.2  On the other hand, when the backbone substituents on the cyclopropane 1.070 or 
1.071 are cis, it has been hypothesized that a β−turn conformation would be stabilized 
(Figure 1.3).   
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The stereochemistry at the carbon atom bearing R2 on the cyclopropane ring 
determines which direction the side chain will be locked in space.  In 1.068a the 
conformation of the native peptide that is mimicked by the cyclopropane constraint is 
gauche (-), which can be seen by looking at the two dimensional, pseudo Fischer 
projection, representation (Figure 1.4).  In the gauche (-) conformation the χ1 torsional 
angle is approximately -60o.  In a similar fashion, cyclopropanes 1.068b and 1.069b 
mimic a gauche (+) conformation where the χ1 torsional angle is roughly +60o.  
However, in 1.069a, an anti conformation is mimicked where the χ1 torsional angle is 
180o.   
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Molecular modeling suggests that all these conformations are stabilized by the 
cyclopropanes.  The geometric properties of replacements can be best illustrated by 
examining the superimposition of the –Phe[COcpCO]Phe- replacements in Figures 1.5 
and 1.6. The N-terminal Phe of 1.072 was anchored in the gauche (-) conformation, and 
the superimposition of 1.072 with the corresponding Phe-Phe dipeptide 1.074 in which 
the backbone is in an idealized β-strand and both phenyl groups are fixed in gauche (-) 
orientations.  The root-mean-square fit for this rigid superimposition is approximately 
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0.35Å.104 The anti-conformation is shown in Figure 1.6 where 1.073 is overlayed with 





































Figure 1.5:  The overlay cyclopropane 1.072 with Phe-Phe dipeptide 1.074.58 
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The cyclopropane in 1.068-1.071 was anticipated to restrict two torsional angles 
of either φ and χ1 in 1.068 and 1.070 or ψ and χ1 in 1.069 and 1.071.  In addition, the 
dicarbonyl pseudopeptides based on 1.068 would have additional restriction of the φ2 and 
ψ torsional angles due to interactions of the carbonyl π orbitals with the carbon-carbon σ 
bond of the cyclopropane ring as illustrated in Figure 1.7 and 1.8.106,107  This orientation 
has been seen in X-ray crystal structures of the cyclopropane-containing molecule alone 
and complexed with proteins.103-105  The χ2-angle is also restricted due to sterics; 
however, the φ2-angle is a more flexible than the same torsional angle in the peptide 
because the amide was changed to a ketone.  It is anticipated that two to three rotors are 
restricted on the native peptide by introducing the cyclopropane constraint.  The total 
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energetic advantage that arises from restricting the rotors should be about 1.4 kcal mol-
1(see Section 1.1.3). 
 
Figure 1.7:  The preferred conformation of a carbonyl on a cyclopropane ring where the 






Figure 1.8:  The preferred conformation of a carbonyl on a cyclopropane ring where the 
C-terminus carbonyl distorted bisection of the cyclopropane in a compound 





Although some hydrogen-bond accepting capability of an amide carbonyl group 
in mimics 1.068 and 1.070 is maintained by the keto functions, omission of a backbone 
N-H in these surrogates eliminates possible hydrogen bond donor and acceptor 
interactions.  However, this amide functionality can be maintained by moving the amide 
nitrogen over two carbons as in 1.075 and 1.076, thereby converting the keto 
functionality of the cyclopropanes 1.068 and 1.070 into a retro amide and helping to 




































The installation of cyclopropane in 1.067 producing 1.069 and 1.071 requires an 
amide bond in 1.067 replacing an amino residue.  Most of the time neither the carbonyl 
oxygen nor the N-H of this mutated amide bond in 1.067 interacted directly with the 
proteins systems evaluated.  It seemed reasonable to assess the impact of this aminoethyl 
substitution.  If the newly installed amino group were highly detrimental to binding, 
second generation ligands could be designed in which an ether could link the residues.  
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1.6.2  Introduction of Cyclopropane Conformational Constraints into Peptide 
Ligands 
Cyclopropanes have been installed in many different peptide ligands (types 1.068 
– 1.071) with the purpose to obtain ligands with greater binding affinities.104,105,108-115  
In general the cyclopropane-containing molecules were equipotent but rarely better than 
their control counterpart. 
A cyclopropane was first incorporated at the P3 position of renin inhibitors.113  
Cyclopropanes 1.077a-d and their proper control molecules 1.078 and 1.079 were 
prepared and evaluated.  Cyclopropane 1.077c and 1.077d were equipotent and had 
similar binding affinities as the control 1.079 but these ligands were the least active of all 
the compounds in question suggesting that the conformations stablized in these ligands 
were not appropriate for binding.  On the other hand, cyclopropane 1.077a was 200-fold 
more active than cyclopropane 1.077b and thus the conformation stabilized by 
cyclopropane 1.077a most resembles the biologically active conformation.  However, 
1.077a was found to be about two-fold less active than control 1.078.  Thus, in this case 
pre-organization provided some insight into the bound ligand conformation but did not 
increase binding potency compared with the proper control.  However, no structural 























































































Next a system where the important structural data could be obtained was 
explored.  HIV-1 protease inhibitors were used as a platform to examine the effects of 
introducing cyclopropanes into peptide ligands.104  Compounds 1.080, 1.081 and 1.083 
contained two N-terminal truncated cyclopropane replacements incorporated at the P2 
and P2’ subsites of the native ligand that appeared to match the extended conformation 
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adopted by the peptide upon binding to the protease as shown by X-ray structures of 
enzyme complexed with inhibitors.116,117  The cyclopropanes 1.080 and 1.081 were 
nearly equipotent to the subnanomolar flexible inhibitor 1.082, whereas the N-methyl 
cyclopropane ligand 1.083 was a significantly weaker inhibitor than its flexible analogue 
1.084.  Two dimensional 1H NMR studies indicated that 1.080 adopted a well-defined, 
preferred conformation in solution (DMSO-d6) in which the peptide backbone was in an 
extended conformation.  This suggests that in solution the cyclopropanes stabilize the 
biologically active, extended, conformation of the ligand.  A three-dimensional X-ray 
structure of 1.081 complexed with HIV-1 protease was also obtained, and the structure 
superimposed well onto the bound conformation of a related linear inhibitor 1.084, 
particularly in the P2-P2’ regions (Figure 1.9).  The similar conformations of the bound 
and solution structure of the cyclopropanes can be seen in Figure 1.10.  It seems that the 
pre-organized conformation of the ligands in solution mimics their biologically active 
structure.  However, the assay data reveals that the incorporation of the cyclopropanes 





















































































1.080, R = Me





Figure 1.9:  Overlay of inhibitors complexed 1.081 (orange) and 1.084 (white) with HIV-




Figure 1.10:  Comparison of the X-ray structure of 1.081 complexed with HIV-1 
protease and the structure of compound 1.080 in solution determined by 




We, like many others, had made the assumption that there should be energetic 
benefits associated with pre-organizing a ligand into its biologically active conformation, 
namely, a reduction in conformational entropy paid upon complexation.  Favorable 
entropy of binding was predicted to elicit enhanced binding, provided there were no 
enthalpic penalties arising from a loss of attractive interactions or the introduction of 
unfavorable steric interactions in the protein-ligand complex.  However, in most of our 
experiments, the conformationally constrained cyclopropane ligands were at best equal 
to their flexible peptide counterparts.  Hence, the primary goal of preparing tighter 
binding pseudopeptides through introduction of conformational constraints was not 
achieved.  The next question we asked was “Why?”  
Because there had been no studies that had directly measured the thermodynamic 
parameters (Ka, ∆G, ∆H and ∆S) for binding of constrained cyclopropane-containing 
ligands; a set of experiments were designed to evaluate the energetic consequences by 
introducing a cyclopropane constraint into peptide ligands using a biological system that 
could provide useful structural and thermodynamic data. Attention was turned to the Src-
SH2 domain system to correlate the structure and energetics of binding.  Many X-ray 
structures of the domain had been solved, and calorimetry measurements had been 
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performed.118-120  This domain preferentially binds the phosphotyrosine-containing 
tetrapeptide Ac-pTyr-Glu-Glu-Ile-OH (1.085) in an extended conformation, and the N-
terminal amide N-H is not involved in binding with the protein; therefore, incorporating a 
cyclopropane at this residue should have no detrimental effect to the binding affinity.118  
The cyclopropane mimics 1.086 and 1.088 were designed to mimic this conformation, 
while the flexible ligands 1.087 and 1.089 would serve as the controls.109  The energetics 
of binding of these compounds were determined by ITC (Table 1.04).105  The 
cyclopropane ligands 1.086 and 1.088 bound with approximately equal affinity relative to 
their corresponding flexible analogues 1.087 and 1.089.  Both cyclopropanes exhibited a 
significant entropic advantage (∆∆S = 5 – 9 cal mol-1 K-1) of binding over their flexible 
controls.  This favorable entropy corresponds approximately to that predicted for 
restricting two to three rotors and supports the hypothesis that pre-organization of a 
ligand in its active conformation does result in a favorable entropic contribution to 
binding (see Section 1.2).  Nevertheless, both cyclopropanes bound to the SH2 domain 
with significantly less favorable enthalpies (∆∆H = 1.4 – 1.9 kcal mol-1) relative to their 
flexible controls, resulting in approximately equal potency for the pairs.  This enthalpy-
entropy compensation has been seen in numerous examples throughout this review (see 
Section 1.1).  In addition, the data obtained for mimics 1.088 and 1.089 suggests that 
elimination of the amide nitrogen when introducing cyclopropanes like 1.068 into native 








































































































Table 1.04:  Thermodynamic profile for the binding of ligands to Src-SH2.105,121 
compounds Ka (M
-1) ∆G (kcal mol-1) ∆H (kcal mol-1) ∆S (cal mol-1)
1.085 4.1 (± 0.1) x 106 -9.01 ± 0.01 -6.06 ± 0.05 -9.9 ± 0.2
1.086 9.7 (± 1.5) x 106 -9.52 ± 0.09 -4.6 ± 0.2 17 ± 1
1.087 1.7 (± 0.6) x 107 -9.8 ± 0.2 -7.33 ± 0.2 8.3 ± 0.5
1.088 6.3 (± 0.6) x 106 -9.26 ± 0.06 -5.01 ± 0.05 14.3 ± 0.4
1.089 1.4 (± 0.1) x 107 -9.72 ± 0.06 -6.92 ± 0.09 9.4 ± 0.4
 
In order to probe the contribution of introducing the cyclopropane conformational 
constraints on surfaces of the SH2 domain during binding, the ∆Cp values for compounds 
1.086 and 1.087 were determined and were found to be identical within experimental 
error.  This suggests that in the binding of 1.086 and 1.087 to the domain, the same 
protein surfaces become buried and that 1.086 and 1.087 may bind to the Src-SH2 
domain in similar modes (see Section 1.1).  A crystal structure of the cyclopropane 1.086 
complexed with the SH2 domain shows that the compound binds in a similar manner to 
the native peptide, and that the biologically active conformation of the native ligand is 
mimicked by incorporation of a cyclopropane (Figure 1.10).  This experiment 
demonstrated that the incorporation of a cyclopropane did provide an entropic advantage 
in protein binding, but did not enhance the overall binding affinity, which may be 
explained by the observed enthalpy-entropy compensation. 
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Figure 1.10:  Overlay of cyclopropane 1.086 shown in green with the native ligand 




 To further explore the phenomenon of enthalpy-entropy compensation in this 
system, several mutants of 1.086 and 1.087 were prepared that contained different 
residues at the pY+1, pY+2, and pY+3 positions giving compounds 1.090-1.101.121  The 
thermodynamic data from these ligands revealed no significant differences in ∆G when 
compared to the ligands (Table 1.05).  There were, however, significant variations in the 
magnitudes of ∆∆H and ∆∆S between each pair with all the cyclopropane-derived 
molecules showing an entropic advantage.  For example, the ∆∆S for the pY+1 Ala 
variants 1.100 and 1.101 was calculated to be 12.4 cal mol-1 while the ∆∆S is only 2.9 cal 
mol-1 when comparing the cyclic and flexible pY+1 Asp variants 1.094 and 1.095.  There 
is no structural data for these compounds bound to the SH2 domain.  Thus far we cannot 
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1.091, R = H
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Table 1.05: Thermodynamic binding parameter for Src-SH2 mutant ligands.121 
 
compounds K a (M
-1) ∆G (kcal mol-1) ∆H (kcal mol-1) ∆S (cal mol-1)
1.090 3.7 (± 0.3) x 106 -9.95 ± 0.05 -3.47 ± 0.01 18.4 ± 0.2
1.091 7.7 (± 1.6) x 106 -9.4 ± 0.1 -6.1 ± 0.10 11.0 ± 0.6
1.092 5.5 (± 0.8) x 106 -7.8 ± 0.1 -1.10 ± 0.05 22.5 ± 0.5
1.093 5.7 (± 1.2) x 106 -9.1 ± 0.1 -4.79 ± 0.04 14.8 ± 0.6
1.094 3.0 (±0.1) x 106 -8.82 ± 0.02 -4.69 ± 0.04 13.9 ± 0.2
1.095 4.7 (±0.1) x 106 -9.09 ± 0.01 -5.81 ± 0.05 11.0 ± 0.2
1.096 5.0 (±0.1) x 106 -9.13 ± 0.04 -6.09 ± 0.03 10.2 ± 0.1
1.097 4.8 (±0.2) x 106 -9.09 ± 0.02 -7.36 ± 0.06 5.9 ± 0.2
1.098 3.8 (±0.3) x 106 -8.96 ± 0.05 -3.75 ± 0.04 17.5 ±0.3
1.099 6.2 (±0.2) x 106 -9.26 ± 0.02 -7.02 ± 0.03 7.5 ± 0.2
1.100 4.1 (±0.1) x 106 -9.01 ± 0.01 -3.05 ± 0.01 20.0 ± 0.1
1.101 4.6 (±0.1) x 106 -9.08 ± 0.02 -6.83 ± 0.08 7.6 ± 0.3  
 
1.7 CONCLUSIONS 
The conformational constraint hypothesis, which states that pre-organization of a 
flexible ligand will enhance binding affinity through reduction of the entropic penalty of 
binding, is often used in the design of novel ligands.  Conformational constraints clearly 
have their place in drug discovery, as they can increase cell permeability,63 increase 
selectivity.122-125 and increase stability.  Furthermore, constraints can be used to 
determine the biologically active conformation of the ligand; however, in the case of 
HIV-1 protease inhibitors, flexible inhibitors are sometimes more accommodating to 
mutations of the protease.23  The validity of the hypothesis is in question.  Proper design 
of the constrained and control molecules is very important.  Although not interested in 
testing the validity of this hypothesis, many research groups have neglected to make the 
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ideal control molecules to compare explicitly what effect introducing a constraint has on 
the system.  Without the proper control molecules it is very difficult to assess the 
energetic advantage or disadvantage associated with conformational constraint 
introduction.  In the few cases where such ideal controls are present, the enthalpy and 
entropy of binding are rarely measured, which makes evaluating the entropic effect of 
restricting ligand conformation impossible to determine.  Any increase in binding cannot 
be arbitrarily attributed to a more favorable entropy of binding alone.  In the few 
examples where the thermodynamic parameters of binding were determined, there is a 
balancing act between the entropic and enthalpic terms; any entropy gain is accompanied 
by an enthalpic penalty, resulting in ligand pairs that are equipotent (i.e. enthalpy-entropy 
compensation).  In many examples, the binding energy difference between the ligand 
pairs is too small (< 5-fold or < 0.7 kcal mol-1) to account for the 0.7 – 1.6 kcal mol-1 
stabilization per restricted rotor predicted by the theory for the introduction of a 
conformational constraint (see Section 1.1.3).  In addition, it is not clear how many times 
the hypothesis has failed because examples that do not increase binding affinity remain 
unpublished.   
Structure-based approaches have generally pursued a “lock and key” model to 
understand protein/receptor and ligand interactions; however, it is now know that the 
ligand and the receptor are not rigid when complexed.32  Residual thermal motions in the 
complex tend to reduce the enthalpy of binding as the atoms move away from their 
equilibrium positions, while the entropy associated with this residual motion is favorable.  
Thus, optimizing the design of a conformationally constrained ligand presents a 
dilemma.25  Should this residual motion be taken advantage of by pre-organizing the 
ligand only enough to allow for this motion?  Or should it be made as inflexible as 
possible, in order to optimize the enthalpic interactions with the binding site?  The 
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importance of dynamics to binding affinity between a ligand and a protein has never been 
addressed.   
Twenty five years after is introduction into the literature, the legitimacy of 
conformational constraint theory is under question.  Applications of the pre-organization 
theory could be based solely on chance.  In some studies affinity is enhanced with the 
introduction of a conformational constraint, while in other cases affinity is not changed.  
Addittionally, sometimes entropic advantage is associated with the pre-organization and 
other times there is not.  Scientists should demand and strive to understand what is really 
occuring rather than relying on luck.  The proper experiments required to fully examine 
and truly validate or invalidate this pre-organization theory need to be designed and 
implemented.   
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Chapter 2. Cyclopropane-Derived Pseudopeptides for the Grb2-SH2 
Domain 
2.1 INTRODUCTION 
Previous work in the Martin group has established that ligand preorganization 
does not necessarily lead to higher affinity binding, even though ∆Sbinding is more 
favorable.  In order to further probe the entropic impact of ligand rigidification, we set 
out to evaluate a different biological system.  It was important to identify a system that 
was structurally well characterized.  Furthermore, it was essential that replacement of an 
amino acid residue with a cyclopropane would not eliminate or modify interactions with 
the target protein.  We also wanted a system where no conformational change of the 
protein occurred upon ligand complexation, since this type of change might complicate 
interpretation of the ITC measurements.  In addition, a protein that could be used to 
evaluate the ability of cis-cyclopropanes to stabilize a β-turn was of interest.  We thus 
identified the SH2 domain of Grb2 (Grb2-SH2) as a perfect system to continue our 
evaluation of the energetic and structural consequences of introducing a cyclopropane 
conformational constraint into a peptide ligand.   
2.1.1 The Grb2-SH2 Domain  
The growth factor receptor binding protein 2 (Grb2) is an essential intracellular 
adaptor protein involved in signal transduction cascades inside mammalian cells.  The 
protein itself is devoid of intrinsic enzyme activity.126  Grb2 contains a Src homology 
region 2 (SH2 domain), that is flanked by two Src homology region 3 (SH3) domains on 
each side.  SH2 domains are conserved sequences of approximately 100 amino acids 
found in various signaling molecules.  In unstimulated cells, Grb2 is located in the 
cytosol complexed with Son of sevenless (Sos) protein through Grb2-SH3 domains that 
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bind to proline-rich sequences in Sos.  When growth factors bind (e.g. epidermal growth 
factor a 6-kD polypeptide that stimulates the growth of epidermal and epithelial cells127) 
to the extracellular domain of receptor tyrosine kinases, the kinases become activated 
resulting in autophosphorylation of specific tyrosine residues in the intracellular domain 
(Figure 2.1).128  Grb2 then interacts through its SH2 domain with the phosphorylated 
residue by recognizing the sequence pTyr-X-Asn-X, wherein X can be almost any 
residue.  The interaction between the Grb2-SH2 domain and a phosphorylated receptor 
sequence leads to the translocation of the cytoplasmic Grb2-Sos complex to the cell 
membrane, thus bringing Sos into the vicinity of membrane anchored Ras, a nucleotide 
exchange factor.  Sos can promote the activation of Ras by exchanging Ras bound GDP 
for GTP.  This activation enables a cascade of further signals to the cell nucleus through a 
series of kinases, eventually resulting in gene expression that governs cell proliferation 






























Many X-ray crystal structures of the Grb2-SH2 domain in both bound and 
unbound forms have been reported.129-134  There are also a number of NMR solution 
structures of complexes of Grb2-SH2 with peptide ligands.135-138  The crystal structure 
of the Grb2-SH2 domain complexed with the heptapeptide H2N-Lys-Pro-Phe-pTyr-Val-
Asn-Val-NH2 was solved in 1996 at 2.1 Å resolution.130  The positions of the ligand are 
labeled relative to the pTyr residue with the Val residue being the pY+1 position and Asn 
being the pY+2 position.  The Grb2-SH2 domain is unique relative to all other SH2 
domains because the SH2 domain of Grb2 contains a tryptophan residue (Trp121) that 
closes the pY+3 (three amino acid residues down from the pTyr residue on the peptide 
ligand) specificity pocket that is available in other SH2 domains such as Lck and Src.130 
By blocking this pocket, the backbone of the ligand is forced to change direction after 
residue pY+1 (one amino acid residue down from the pTyr residue of the peptide ligand), 
thus adopting a β-turn centered on this residue.  Interestingly, the T215W mutant of the 
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Src-SH2 domain has been crystallized in complex with a dodecapeptide in which the 
ligand adopts a β-turn binding very similar to that required for a peptide ligand to bind to 
the Grb2-SH2.139 
 The Grb2-SH2 domain can exist as a domain swapped dimer with the point of 
rotation at Trp121.131,134  A domain swapped dimer is formed when a globular domain 
of one protein molecule is intertwined with an identical protein chain of another 
molecule.  The swapped domain protein environment is essentially identical to that of the 
same domain in the protein monomer (Figure 2.2).140  For the Grb2-SH2 domain the 
swapping takes place at residues 121-123, with Trp121 located on the N-terminus of the 
hinge loop.131  Domain swapping is commonly found in the literature, and x-ray 
structures of dimers and monomers both complexed with and without ligand have been 
solved for the Grb2-SH2 domain.131,134 
Pure dimer and monomer of Grb2-SH2 can be isolated using gel filtration, and the 
dimer can be converted to monomer by heating, adding organic solvents, or by lowering 
the pH of the buffer.131  However, incubation of purified monomer or dimer 
(concentration <10 mg/mL, pH 7.0 and 4, 25 and 37 oC) did not result in interconversion 
of the two forms.  Thus, the energy barrier for dimer-monomer conversion is rather high, 
and the monomer or dimer is stable under mild conditions.  Importantly, ITC 
measurements using the monomer and dimer Grb2-SH2 resulted in equivalent binding 
measurements.131  Glutathion transferase (GST) fusion proteins are commonly employed 
to purify the Grb2-SH2 domain, and GST has a tendency to induce dimerization of the 
protein partner.134  Hence, we will avoid using GST fusion proteins in our expression 
and purification of Grb2-SH2. 
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Figure 2.2:  Cartoon of domain swapping. 
 
Closed monomers Domain swapped dimer
 
 
2.1.2 Ligands for the Grb2-SH2 Domain 
Several research groups have reported the synthesis of ligands for the Grb2-SH2 
domain.128  Their work suggests that there is considerable flexibility in the structure of 
the group at the pY+1 position.  For example α,α-disubstituted cyclic α-amino acids 
were used to stabilize the β-turn conformation at pY+1, and the most potent ligand 2.001 
had a cyclohexyl group at this site and exhibited an IC50 of 0.21 µM (Figure 2.3).141  
Many macrocycles have also been designed to stabilize the β-turn found in the ligand 
(see chapter 1).  For example, in 2.002 a backbone to backbone macrocycle was prepared 
as a ligand for Grb2-SH2 domain with an IC50 of 0.11 µM.129  The crystal structure of 
the macrocycle bound to the Grb2-SH2 domain clearly showed the β-turn conformation 
at the pY+1 position in the ligand and the binding interaction for the pTyr-Val-Asn 
sequence was identical to that observed in the corresponding linear peptide (NH2-Lys-
Pro-Phe-pTyr-Val-Asn-Val-Glu-Phe).  One of the most potent Grb2-SH2 antagonists 
1.045 also contains a macrocycle.  Some of the more potent Grb2-SH2 antagonists along 
with their biological data are shown in Figure 2.3. 
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2.002 IC50 = 0.11 µM
 
 
In most studies on binding affinity of ligands to the Grb2-SH2 domain only IC50 
values are reported.  However, ITC can provide the complete thermodynamic profile, 
including entropy, for ligand and protein binding interactions.  ITC has been used 
previously to determine the thermodynamic parameters for the binding of different Ala 
containing peptides to the Grb2-SH2.53   
2.2 DESIGN OF CYCLOPROPANE-CONTAINING LIGANDS FOR GRB2-SH2 DOMAIN 
The Martin group has recently determined the energetic parameters for the 
binding of ligands with trans-cyclopropane phosphotyrosine replacements 1.086 and 
1.088 binding to the Src-SH2 domain (see chapter 1).  The flexible analogues 1.087 and 
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1.089 served as controls in order to determine the effect of introducing conformational 
constraints upon the binding energetics.  The enthalpic and entropic consequences of 
using cyclopropane replacements at the pTyr residue of pTyr-Glu-Glu-Ile were evaluated 
employing ITC.  In comparing the constrained cyclopropanes to the flexible control, there 
was an entropic advantage associated with introducing the cyclopropane but this entropic 
gain was accompanied by a loss in enthalpy resulting from enthalpy-entropy 
compensation.  There was no net difference in the overall binding energy (∆∆Gbinding) 
between the cyclopropane and control ligands.  Further discussion about enthalpy-
entropy compensation can be found in Section 1.1.  Structural studies once again showed 
the ability of the trans-cyclopropane replacement to stabilize the extended backbone 
conformation.105 
While the data obtained in these studies supports the notion that incorporating a 
conformational constraint in a ligand can lead to an entropic advantage to the binding, 
whether or not this is a general phenomenon is still undetermined.  In addition, the use of 
cis-cyclopropane replacements has not yet been established to stabilize a β-turn.  We 
hypothesized that cis-cyclopropane replacements would conformationally stabilize 
reverse turns in pseudopeptides.  We hoped to demonstrate a cis-cyclopropane’s ability to 
stabilize a β-turn and use ITC to determining the thermodynamic parameters of binding 
(∆H, ∆S, ∆G and Ka).   
A crystal structure of Grb2-SH2 complexed with a ligand was recently solved that 
clearly shows the unique reverse turn at the pY+1 ligand H2N-Lys-Pro-Phe-pTyr-Val-
Asn-Val-NH2 (Figure 2.4).130  In the Grb2-SH2 domain, the extended conformation is 
sterically blocked by the Trp 121 side chain.  In order to evaluate the viability of cis-
cyclopropane replacements, Grb2-SH2 was chosen as a testing ground.  Based on 
evaluating the crystal structure of ligands bound to both the Src-SH2 domain and the 
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Grb2-SH2 domain, the binding pocket for pTyr residue in the Grb-SH2 domain is 
virtually identical to the binding pocket in the Src-SH2 domain allowing us to use the 
same cyclopropane and flexible pTyr replacements that were used previously for the Src-
SH2 domain.130  Since we wanted to evaluate the pTyr cyclopropane replacements in a 
different system, we designed cyclopropane-containing pseudopeptide ligands for the 
Grb2-SH2 domain. 
 
Figure 2.4:  X-ray structure of peptide ligand H2N-Lys-Pro-Phe-pTyr-Val-Asn-Val-NH2 





Compounds 2.004, 2.005, 2.006, 2.007, 2.008 and 2.009 were designed to enforce 
the structural features of the ligand 2.003 in the protein-ligand complex (Figure 2.5).  The 
trans-cyclopropane in pseudopeptide 2.004 was derived from the native tripeptide 2.003 
by replacing the nitrogen atom of the tyrosine residue in the native tripeptide with a 
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carbon atom and connecting this atom to the benzylic carbon of the Tyr side chain (mode 
a).  The carbonyl carbon atom of the Val was similarly replaced giving cis-cyclopropane 
peptide mimics 2.006 and 2.008 (mode b).  Flexible peptide replacements 2.005, 2.007 
and 2.009 containing the same number and type of heavy atoms (C, N, O and P) as their 
constrained counterparts, were synthesized as control molecules.  Accordingly, these 
flexible replacements are excellent controls because they only differ from their cyclic 
analogues by an equivalent of H2.   
 












































































2.006: R = Me















2.007: R = Me





The tyrosine N-H that is removed in order to form 2.004 and 2.005 should not 
affect binding as the crystal structure of the Grb2-SH2 domain complexed with ligands 
reveals that there are no hydrogen bonds between the domain and this N-H of the ligand.  
Even so, the amide functionality can be maintained by moving the amide nitrogen over 
two carbons creating a reverse amide and helping to maintain any hydrogen bonds at this 
position.  The tyrosine carbonyl carbon is within 3 Å of the side chain of Arg67 and is 
likely involved in a hydrogen bond interaction.  In the mimics 2.006 and 2.008, a basic 
amino residue replaces the amide bond at pY+1.  The spatial geometry of the amino 
residue in the mimics is different that the geometry of the amide bond in the native 
peptide.  Also, if protonated the amine replacement will have a different charge than the 
amide.  Because neither the carbonyl oxygen nor the N-H of this mutated amide bond 
interact directly with the Grb2-SH2 domain, it seemed reasonable to assess the impact of 
an aminoethyl substitution in these systems, even though there was no literature 
precedent for an amino functional group at this residue of the ligand.  
Modeling studies suggested that the cyclopropane ring in the pseudopeptides 
related to 2.004 and 2.006 can locally stabilize the extended and β-turn conformations, 
respectively.  Energy minimization calculations of the cyclopropane-containing ligands 
were estimated using the Tripos Force field supplied by Sybyl 6.4 and overlaid with the 
crystal structure of 2.003 bound to the Grb2-SH2 domain (Figure 2.6).130  In Figure 
2.6A, 2.004 (shown in red) overlays nicely with the ligand bound to the SH2 domain 
(shown in blue).  Examination of Figure 2.5B shows that the cyclopropane-containing 
mimic (shown in red) overlays well with the ligand bound to the protein (shown in blue).  
The trans-cyclopropane replacement 2.004 fixes an extended backbone conformation for 
the tyrosine residue similar to previous cyclopropane-containing ligands as shown in 
crystal structures of HIV-1 protease and Src-SH2 domain complexed with cyclopropane 
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derived pseudopeptides (see Chapter 1).104,105   We hypothesized that  cis-cyclopropane 
replacement 2.006 would constrain the backbone in the desired β-turn conformation.   
 
Figure 2.6:  A: Overlay of mimics 2.004 (red) and 2.003 (blue)     B: Overlay of mimics 




    
 
2.3 SYNTHESIS OF PY CYCLOPROPANE AND CONTROL LIGANDS 
We envisioned that the pYVN mimics 2.004 and 2.005 could be readily prepared 
from coupling the tyrosine mimics 2.010 and 2.011 with the dipeptide 2.012 (Schemes 
2.1 and 2.2), which had been previously synthesized in our laboratories.105,109,121  Since 

















































































The synthesis of the cyclopropane carboxylic acid 2.010 began with the 
conversion of 1,4-dibromobenzene 2.013 into diazoester 2.014 in four steps using a 
previously described procedure (Scheme 2.3).109  Asymmetric intramolecular 
cyclopropanation of the diazoester 2.014 using Rh2[(5S)-MEPY]4 as a catalyst gave the 
lactone 2.015 in 75% yield and 90% enantiomeric excess (ee).  The lactone 2.015 was 
opened under Weinreb amidation conditions to provide the alcohol 2.016.  The alcohol 
2.016 was then oxidized (TPAP, NMO), the resultant aldehyde was epimerized with 
Et3N, and the trans-cyclopropane 2.017 was then oxidized to the acid.  Acid catalyzed 
cleavage of the tert-butyl and dimethoxy benzyl protecting groups cleanly provided 
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2.018.  Phosphorylation of 2.018 under standard conditions then gave the protected 




























1) Et3N, MeOH, reflux, 
     then Jones reagent, 































































The synthesis of the phosphotyrosine flexible mimic acid 2.011 commenced with 
the conversion of 1,4-dibromobenzene (2.013) into the Grignard reagent and subsequent 
reaction with tert-butyl peroxybenzoic acid to give 4-tert-butoxybromobenzoate 2.018 in 
61% overall yield (Scheme 2.4).  Heck coupling of acrylic acid with 2.019 provided an 
α,β unsaturated acid that was reduced to give the propionic acid 2.020 in 83% yield over 
the two steps.144  We experience problems reproducing this procedure.  It was important 
to use pure H2O for the Heck reaction, since using deionized H2O from the tap resulted 
in poor yield, possibly due to some contamination in the deionized H2O.  The addition of 
the phase transfer catalyst Bu4NBr improved both the yields and reaction times for this 





















Bromoacetamide 2.022 was synthesized in 62% overall yield by reductive 
amination of 2,4-dimethoxybenzaldehyde 2.021 with methyl amine followed by 















3)Et3N, CHCl3, Br Br
O
62%2.021 2.022  
 
The oxazolidinone imide 2.023 was formed via the mixed anhydride of 2.020 
(Scheme 2.6).145  Deprotonation of 2.023 followed by treatment of the corresponding 
enolate with the bromoacetamide 2.022 gave 2.024 in 70% yield as a single 
enantiomer.121  When 2.024 was treated with the anion of benzyl alcohol, the benzyl 
ester 2.025 was isolated in 90% yield.  Deprotection of 2.025 with TFA and 
hydrogenolysis produced 2.030 in 77% yield over the two steps.  Finally, 2.030 was 
phosphorylated to provide the protected flexible phosphotyrosine mimic 2.011 (70% 







































































With 2.010 and 2.011 in hand, attention was turned towards synthesizing the L-
valinyl-L-asparaginyl-amide 2.012.  A number of amino acid coupling agents were 
examined to couple Boc-Val-OH 2.027 with Asn-NH2 2.028 (Scheme 2.7).  The amine 
moieties in amino acids Ile and Val are somewhat hindered and thus racemization can be 
a side reaction from the coupling of these amines to activated carboxylic acids.  When 
EDCI and HOBT were used to couple 2.027 and 2.028 the dipeptide 2.029 was obtained 
in 72% yield.  Although use of HATU gave the best yield (82%) of 2.029, its cost made 
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its use impractical.  The Boc protecting group was removed in quantitative yield with 


































The peptide 2.003 was synthesized via coupling of N-Ac-pTyr*-OH ( with the * 
indicating the phosphobenzylester protecting groups) 2.030143 with dipeptide 2.012.  
When HATU was used as the coupling reagent, clean product was obtained in 40% yield.  
A 6% yield of a mixture of two compounds 2.031 and 2.032 was also isolated and 
separated by flash column chromatography.  The 1H NMR and low resolution mass 
spectra indicated that the mixture consisted of two diastereomers.  Data indicates that the 
N-Ac-pTyr residue epimerized during the coupling (1H NMR peaks δ 1.68 (S-H), 1.66 
(R-H) and 0.82 (S-H), 0.71 (R-H) ppm).146  The coupling reaction was also preformed 
using EDCI and HOBt, and clean material was obtained in 14% yield together with a 
substantial amount (33% yield) of a mixture of two diastereomers 2.031 and 2.032.  Thus, 
use of HATU increased the yield for this coupling reaction and also decreased the 
epimerization.  HATU is presumably more effective because it brings the coupling 
partners closer together through intermolecular hydrogen bonding thus increasing the rate 
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of the reaction (Figure 2.7).147,148  The clean protected tripeptide underwent 
hydrogenolysis in EtOH:H2O (1:1) to give the native tripeptide 2.003 in 89% yield 




2.012, HATU, 2,6-Lutidine, 










H2, Pd/C, EtOH, H2O (1:1)
































































































 The pseudopeptides 2.004 and 2.005 were synthesized in good yields via coupling 
the flexible and constrained phosphotyrosine acid mimics 2.010 and 2.011 with the 
dipeptide 2.012 to provide the benzyl ester protected tripeptides 2.033 and 2.034 with no 
detectable epimerization (Scheme 2.9 and 2.10).  The coupling reagent HATU was 
chosen over EDCI/HOBt because it worked well in the synthesis of the tripeptide 2.003.    
Hydrogenolysis of the benzyl esters in 2.033 and 2.034 was plagued with problems due to 
their limited solubilities.  Although the benzyl esters 2.033 and 2.034 were completely 
soluble in DMSO, the hydrogenolysis did not proceed in this solvent and starting material 
was recovered.  The protected tripeptides 2.033 and 2.034 were partially soluble in 
acetonitrile:H2O (1:1), but again the hydrogenolysis was not successful.  Despite the 
limited solubility’s of the protected tripeptides 2.033 and 2.034 in EtOH:H2O (1:1), the 
hydrogenolysis proceeded in quantitative yield to give the desired tripeptides 2.004 and 





 2.012, HATU, 2,6-Lutidine,
 
















































2.012, HATU, 2,6-Lutidine, 





































H2, Pd/C, EtOH, H2O (1:1)
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2.4 SYNTHESIS OF PY+1 CYCLOPROPANE AND CONTROL LIGANDS 
With the pYVN-derived pseudopeptides 2.004 and 2.005 in hand, attention was 
turned toward the synthesis of 2.006 and 2.007, which contain cyclopropane 
replacements at the pY+1 position.   
2.4.1 First Generation Synthesis of 2.006 
We envisioned the pseudopeptides 2.006 and 2.007 would arise from coupling 
2.030 with the VN replacements 2.035 and 2.036 (Scheme 2.11 and 2.12).  Conversion of 
the methyl ester functionalities to amides followed by hydrogenolysis would furnish the 
desired peptides 2.006 and 2.007.  Due to the limited solubilities of 2.033 and 2.034, we 
decided to install the amide functionalities in 2.006 and 2.007 at a late stage in the 
























































We envisioned that the amine 2.035 could be obtained through an oxidation of the 
alcohol moiety in 2.037 and subsequent Curtius rearrangement (Scheme 2.13).  N-
Alkylation of the amino alcohol 2.038, which would arise from the cyclic urethane 2.039, 
could provide 2.037.149,150  Urethane 2.039 could come from the lactone 2.040 through a 
Curtius rearrangement following previous work done in our laboratories for the synthesis 
of MMP containing inhibitors.150  The lactone 2.040 could be obtained through 































The synthesis of the constrained VN replacement 2.035 began with the Rh2[(5S)-
MEPY]4-catalyzed cyclopropanation of the diazoester 2.042 which was obtained in 85% 
yield from 2.041 in 85% yield, (Scheme 2.14). 151,152 The asymmetric cyclopropanation 
proceeded in 81% yield to give the lactone 2.040 with 98% ee (determined by using 1H 


















The lactone 2.040 was then opened using hydrazine to give the hydrazide 2.043 in 
97% yield (Scheme 2.15).  Treatment of 2.043 with nitrous acid gave an acyl azide that 
underwent a Curtius rearrangement that spontaneously cyclized to afford the cyclic 
urethane 2.039 in 73% overall yield.  The amino alcohol 2.038 was then produced in 83% 
yield via base-induced hydrolysis of cyclic urethane 2.039.  Ba(OH)2 was determined to 











HONO, Et2O, H2O 0 oC;



















The L-asparaginyl-amide moiety was then introduced onto 2.038 by N-alkylation 
of the amino alcohol 2.038 with (R)-dimethylmalate triflate 2.044 in the presence of 2,6-
lutidine and iPr2NEt to give the secondary amino alcohol 2.037 in 30% yield (Scheme 





















Improving the yield of this N-alkylation step in the synthesis of the pseudopeptide 2.006 
was crucial.  It was hypothesized that protecting the seminucleophilic primary alcohol 
2.038 might help the yield of the alkylation.  Toward this end, the primary alcohol 2.038 
was protected as its TMS ether using TMS-Cl and Li2S to give ether 2.045 in 55% 
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unoptimized yield (Scheme 2.17).155  The amine 2.045 was alkylated with the triflate 
derivative of dimethylmalate 2.044 to give the secondary amine 2.037 in 42% yield.  This 





























Eventually, it was found that adding an extra equivalent of iPr2NEt to the amino 
alcohol 2.038 prior to reaction with the triflate 2.044 resulted in a reproducible yield of 























The secondary amine moiety of 2.037 was then protected with di-tert-butyl 
dicarbonate to give 2.047 in 48% yield (Scheme 2.19).  When a catalytic amount of 
DMAP was added to the reaction in an attempt to increase the yield, an unidentified 
product was obtained which had a 1HNMR spectrum similar to starting material, but the 
hydroxy methyl peaks next to the cyclopropane ring moved downfield by 0.5 ppm.  The 
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unidentified product also had a peak in the low resolution mass spectrum at 304 m/z 
corresponding that that of the product MS-56 (loss of tBu group).  I was not able to 



































The next step involved the oxidation of alcohol 2.047.  Similar cyclopropane 
alcohols with Boc-protected amines have been reported to ring open under acid oxidation 
conditions.154  Due to concern about the ring opening of the cyclopropane, non-acidic 
oxidation conditions were utilized.  The valinyl-asparaginyl mimic acid 2.048 was 
produced in 77% yield by oxidation of 2.047 with RuCl3/NaIO4. 
After discussion with fellow co-workers, the amine protecting group of 2.047 was 
changed from Boc to the benzyl carbamate (Cbz).  The Cbz group can be removed in the 
same step as the deprotection of the phosphobenzyl esters required at the end of the 
synthesis.  By switching amine protecting groups, we decrease the length of the synthesis 
by one step.  We also hoped that the new protection step would be higher yielding.  The 
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amino group of 2.037 was thus protected using Cbz-Cl and iPr2NEt to give 2.048 in 81% 
yield (Scheme 2.20).  The alcohol moiety in 2.048 was then oxidized with RuCl3/NaIO4 
providing the acid 2.049.  The yield of this oxidation was dramatically increased (from 
<5% to 97%) when CCl4 was used as a co-solvent instead of CHCl3.156,157  The acid 
group 2.049 was then converted to the Alloc-protected amine 2.050 in 44% yield using a 



































2.049 2.05044%  
 
The Alloc-carbamate of 2.050 was removed via exposure to Pd(PPh3)4 and 
Bu3SnH, and the intermediate amine was coupled in situ with N-acetyl-p-Tyr 2.030 in the 
presence of HATU to give the protected tripeptide 2.051 (Scheme 2.21).110,158  Since we 
successfully used HATU in the amino acid couplings for pseudopeptides 2.031, 2.033 
and 2.034, HATU was employed in this reaction to decrease any racemization that might 
occur during the reaction and increase the yield of the reaction.  We then intended to 
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convert the methyl esters of 2.051 into amide groups using ammonia in MeOH to give 
2.052.  However, reactions of 2.051 with ammonia in methanol with catalytic amount of 
NaCN were unsuccessful under a variety of conditions; mixtures of products were 
obtained, none of which had a signal in the 31P NMR spectra.159  It was difficult to 
determine the structure of any of these products due to the rotamers that were present in 
their 1H NMR spectra.  A hydrogenolysis was performed on this mixture to remove all 
protection groups with the intent of determining the components of the mixture, but this 
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2.4.2 Second Generation Synthesis of the 2.006 
With 2.051 in hand only two steps would remain to complete the synthesis of 
2.006.  However, it was necessary to address the problems associated with converting the 
methyl ester moieties into amides.  A model system was examined in order to determine 
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the best reagents and conditions for converting the dimethyl ester array in 2.051 to the 
corresponding diamide.   
The amino group of L-aspartic acid dimethyl ester 2.053 was protected to give the 
carbamate 2.054 in 99% yield (Scheme 2.22).  When 2.054 was exposed to NH3 in 
MeOH in the presence of a catalytic amount of NaCN, the desired diamide 2.055 was 
obtained in 78% yield; the imide 2.056 was also isolated as a side product (22% yield).  
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Hydrazine was also examined as a reagent for converting the ester group in 2.054 
to an amide (Scheme 2.23).  Although the dihydrazide 2.057 was obtained in 68% yield, 
attempts to cleave the dihydrazide N-N bond to give the desired 2.055 using Raney nickel 
were unsuccessful.160  It was apparent by the 1H NMR and mass spectra that the Cbz 
protecting group had been removed but the N-N bond was not reduced under these 






















We hoped that we could obtain the desired diamide groups by reduction of acid 
azides.161,162   However, attempts to convert the ester functionality of 2.054 to acid 




















We also examined Weinreb’s amidation conditions (Me3Al, NH4Cl) to convert methyl 
ester 2.054 to diamide 2.055 (Equation 2.2).164,165   However, these efforts led only to 








The preceding studies suggested that the conversion of esters into amides would 
best be accomplished with NH3 in MeOH with cat. NaCN.  However, as noted above, 
this did not work with the protected mimic 2.051.  We hypothesized that the 
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phosphobenzyl ester functionality might not be compatible with ammonia.  So we 
decided to examine reaction of the Alloc amine 2.050 with NH3 (Equation 2.3).  
However, treatment of 2.050 with NH3 gave recovered starting material, a monoester-
monoamide, and other unknown products; none of the desired 2.059 was obtained.  
Weinreb conditions were then employed on 2.050, but this led only to the formation of a 















AllocHNNH3, NaCN (cat.), MeOH, rt
or NH4Cl, AlMe3, toluene, 0 oC
X (2.3)
2.050 2.059  
 
We then hypothesized that the alloc carbamate in 2.050 might not be compatible 
with NH3.  Hence, we examined the reaction the N-Cbz carbamate 2.048 with NH3 
(Equation 2.4).  When 2.048 was allowed to react with NH3 in MeOH in the presence of 
catalytic NaCN, a product was recovered that showed no methyl esters in the 1H NMR 
spectrum and a peak in the low resolution mass spectrum at 376 m/z (starting material 
MW = 393, product MW = 363).  The same unidentified product was also formed when 
methyl ester 2.050 was exposed to Weinreb’s conditions (Equation 2.4). 
 
NH3, NaCN (cat.), MeOH, rt
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We suspected that the problems with our amidation attempts may have arisen 
from the presence of the Cbz moiety, since it has been reported that ammonia or 
ammonium hydroxide can react with this protecting group to give the unprotected 
amine.166  As such, attention was then turned toward the free secondary amine 2.037 
(Scheme 2.24).  Gratifyingly, 2.037 was converted to the desired diamide 2.61 using 
ammonium hydroxide (NH4OH) in MeOH in the presence of cat. NaCN to give the 
diamide 2.061 in 40% yield; the diacid 2.062 and mono acid 2.063 were also obtained as 



















2.062: R = OH 30%












The yield of 2.061 was increased to 85% when 2.037 was treated with NH3 in 
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The amino group in 2.061 was then selectively protected using Cbz-Cl and 
iPr2NEt to give the primary alcohol 2.060 in 83% yield (Scheme 2.26). Oxidation of the 
alcohol 2.060 with RuCl3/NaIO4 afforded the carboxylic acid 2.064 in 98% yield.  The 
acid 2.064 was then subjected to a modified Curtius reaction as before to afford the 
Alloc-protected amine 2.059 (36% unoptimized yield). The Alloc-carbamate 2.059 was 
reacted with the in situ generated N-acetyl-p*Y 2.030 activated ester in the presence of 
Pd(PPh3)4 and Bu3SnH to give 2.052.158  Unfortunately, it was not possible to obtain 
clean 2.052 by this procedure, and the yield of the reaction was poor (<10%).  We 









































CCl4, CH3CN, H2O, rt
EtOCOCl, Et3N,
then NaN3; then















Due to the low yield in the coupling reaction, an analogue of 2.059 was pursued 
wherein the Alloc group was replaced with a Boc group, even though this would increase 
the length of the synthesis by one step.  To this end, the Curtius rearrangement of acid 
2.064 was performed as before to form an intermediate isocyanate that was trapped with 
tBuOH to provide 2.065 in 72% yield (Scheme 2.27).  The cyclopropane 2.065 was 
deprotected with TFA to give the unstable free amine, that was immediately coupled with 
N-Ac-pTyr*-OH 2.030 in the presence of HATU to give a 60% yield of the desired 
protected tripeptide 2.066 as a single diastereomer.  Global deprotection of 2.066 under 




























2) 2.030, HATU, 2,6-Lutidine









60% over two steps
 
 
2.4.3 First Generation Synthesis of 2.007 
Attention was then turned toward the synthesis of the flexible control 2.007.  The 
dipeptide replacement 2.036 would be obtained by a reductive amination of 2.067 with 






































The synthesis of the flexible amine 2.036 was carried out by Thomas Sundberg 
and Angela Woodward, both undergraduate students under my direction.  Boc-N-Val-OH 
2.027 was first converted to the thioester 2.069 in 75% yield with DCC and EtSH 
(Scheme 2.29).  The thioester 2.069 was then reduced to the aldehyde 2.068 according to 
the Fukuyama reduction protocol.167,168  Subsequent reductive amination of aldehyde 
2.063 with asparagine amine hydrochloride (2.067) using Na(OAc)3BH gave the 




































Because the low yield in this step was thought to arise from the limited solubility 
of 2.067, L-aspartic acid dimethyl ester hydrochloride 2.053 was used instead of 2.067.  
The reductive amination of thoiester 2.069 with the L-aspartic acid dimethyl ester 2.053 
gave the secondary amine 2.071 in 55% yield over two steps (Scheme 2.30). It has been 
reported that the reduction to the aldehyde and reductive amination can be done in the 
same pot,168 but so far the one pot reaction gave only low yields (~20%) of product.  
Moreover, the aldehyde 2.068 is not stable and must to be treated immediately with the 
amine 2.053.  Attempts to isolate the aldehyde 2.068 using column chromatography 
resulted in partial racemization of the chiral center.  Storage of the aldehyde 2.068 even 
for less than 1 h at –20 oC also resulted in partial racemization.  This partial racemization 
was apparent from analysis of the 1H NMR spectrum of the reductive amination product 
2.071.  The peaks at δ 4.76 (R-H) and 4.52 (S-H) ppm represent the proton of each 
diastereomer on the carbon atom bearing the isopropyl group.  The reaction sequence was 
performed on racemic 2.027 to establish that the two epimers could be distinguished in 

















1) Et3SiH, Pd/C (10%)








The amine 2.071 was then protected using Cbz-Cl and iPr2NEt as the Cbz 
carbamate to give 2.072 in 90% yield.  Finally, the Boc group was removed with HCl to 
give the free amine 2.073.  Amine 2.073 was coupled to N-Ac-pTyr*-OH 2.030 using 
HATU to give the protected pseudopeptide 2.074 (Scheme 2.31).  Amidation of 2.074 
with NH3 and cat. NaCN was then examined.  Analysis of the 1H NMR for the crude 
reaction mixture showed loss of both dimethyl ester peaks, but low resolution mass 
spectrum analysis did not show peaks that corresponded to either starting material or the 
diamide product 2.075.  This same step also proved problematic in the synthesis of the 






































































2.4.4 Second Generation Synthesis of 2.007 
The problems with the amination of 2.074 prevented the synthesis of the pY+1 
mimic 2.007 according to the plan in Schemes 2.12 and 2.28.  However, the solution that 
was developed for the synthesis of 2.006 could also be applied to solve the present 
problem.  Dimethyl ester 2.071 was first treated with NH3 and cat. amount of NaCN to 
give the desired diamide 2.070 in 80% yield (Scheme 2.32).  We queried whether the 
protecting group for secondary amine in 2.070 was really essential, as this nitrogen 
seemed somewhat hindered and unlikely to react in the coupling reaction.  In order to 
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evaluate this hypothesis, the N-Boc protected amine 2.070 was deprotected using TFA, 
and the resultant unstable free amine, which decomposed upon standing, was 
immediately coupled with N-Ac-pY*-OH 2.030 using HATU as the coupling reagent to 
give the desired protected tripeptide 2.076 in 30% overall yield.  Global deprotection of 
2.076 by hydrogenolysis proceeded in 94% yield with the addition of HCl.  In the 
absence of HCl, the yield of 2.007 was only 18%.  Most likely, the acid was needed to 

















































2.5 SYNTHESIS OF PY+1 SECOND GENERATION LIGANDS 2.008 AND 2.009 
 As mentioned in Section 3.1, the ITC data indicated that the cis-cyclopropane 
mimic 2.006 interacts weakly (Ka < 103) with the Grb2-SH2 domain.  On the other hand, 
the flexible control 2.007 does bind to the protein, albeit with approximately 10-fold 
lower affinity than pseudopeptides 2.003-2.005 (see Chapter 3).  Because the control 
2.007 does bind to the Grb2-SH2 domain, the amine functionality present in 2.006 and 
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2.007 is not the cause for the low affinity of 2.006.  The control 2.007 is flexible and can 
therefore readily adopt the conformation required for binding.  We designed 2.006 
predicting that it would be preorganized into the β-turn conformation.  However, we 
presumed that the presence of the gem-dimethyl moiety on the cyclopropane ring of 
2.006 might sterically prevent 2.006 from adopting the proper conformation for binding 
to the domain.  To explore this possibility, we synthesized a cis-cyclopropane mimic 
containing only one methyl group 2.008 (Figure 2.8).  The appropriate acyclic control of 
2.008 is 2.009. 
 


































2.5.1  Synthesis of Mono-Methyl Cyclopropane 2.008 
The syntheses of 2.008 and 2.009 followed closely the syntheses of 2.006 and 
2.007.  Crotyl alcohol was first transformed into the diazoester 2.077, which was then 
subjected to an enantioselective cyclopropanation to give 2.078 (as a mixture of isomers 
2.078a-c) in 78% yield and 85% ee determined using 1H NMR spectra with a chiral shift 
reagent in the (Scheme 2.33).104,113,153  Unfortunately the crotyl alcohol used to prepare 
2.077 was only 90% trans, so 2.078c was also produced in the reaction.  In addition, the 
%ee for the cyclopropanation reaction was low and resulted in the formation of 2.078b.  
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The major component of the mixture was the desired lactone 2.078a.  Using column 
chromatography, we were not able to separate 2.078a-c at this time, so the mixture of 
isomers was carried on through the synthesis and separated at a later stage.  For 
simplification only the desired isomer from the mixture is shown in the following 
schemes.  The mixture of lactones 2.078 was converted to the hydrazides 2.079 (94% 
yield) upon reaction with H2NNH2.  Reaction of 2.079 with HONO gave an intermediate 
azide that underwent a Curtius rearrangement to give 2.080 in 85% yield.  Base-induced 
hydrolysis of 2.080 in gave 2.081 in 72% yield.  N-Alkylation of 2.081 with the triflate 





















HONO, Et2O, H2O 0 oC;














































The diester groups of 2.082 was converted into the desired amide 2.083 in 60% 
yield using NH3 in the presence of catalytic amounts of NaCN (Scheme 2.34).  The 
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reaction was performed in a sealed tube at 55 oC and only took 24 h for completion.  The 
secondary amine was then protected as its Cbz carbamate, providing 2.084 in 70% yield.  
Oxidation of the alcohol functionality in 2.084 gave an acid 2.085 as a mixture of isomers 
(7:3 ratio) in 78% yield.  The isomers could now be separated using flash column 
chromatography.  The mixture of isomers was not separable at any earlier stage as 
evident by TLC and HPLC analysis. 
The pure acid 2.085 was transformed into the N-Boc carbamate 2.086 in 92% 
yield via Curtius rearrangement followed by trapping of the isocyanate intermediate.  
Removal of the carbamate protecting group with TFA gave an amine that was coupled 
with N-Ac-pY*-OH 2.030 under standard coupling conditions (HATU, 2,6-lutidine, 
DMF, -10 oC to rt) to provide the protected tripeptide 2.087 in 41% yield as a single 
diastereomer.  Finally, the desired cyclopropane-containing ligand 2.008 was obtained in 


















































2) 2.030, HATU,2,6-lutidine, 




























2.5.2 Synthesis of Reduced Abu Control Ligand 2.009 
The flexible mimic 2.009 was designed as the control molecule of 2.008 for 
subsequent thermodynamic and structural evaluations.   Under my direction Neda 
Nosrati, an undergraduate student, preformed with the first two steps of the synthesis of 
ligand 2.009.  The synthesis of 2.009 began with converting 4-(tert-
butoxycarbonylamino) butyric acid (2.088) into the thioester 2.089 in nearly quantitative 
yield (Scheme 2.35).  The thioester was reduced to an aldehyde (Pd/C, Et3SiH), which 
was immediately subjected to reductive amination in the presence of Na(OAc)3BH to 
afford in 83% yield the desired amine 2.090 in 17:1 d.r. as determined by analysis of the 
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1H NMR spectrum at 500 MHz (key 1H NMR δ 4.56 and 4.52 ppm).  When this reaction 
was carried out at room temperature, a mixture of diastereomers (7:1) was obtained 
resulting from epimerization of the intermediate aldehyde.  However, if this reaction was 
carried out at 0 oC for 90 min, the ratio of diastereomers was improved to 17:1.  At -78 
oC the reaction was slow and did not proceed to completion.  The reaction sequence was 
performed on racemic 2.088 to establish that the two epimers could be distinguished by 
analysis of the 1H NMR spectrum.  The ester groups of 2.090 were converted to amides 
using NH3 with NaCN as before to provide 2.091 in 85% yield.  The N-Boc-protecting 
group was removed, and the resultant amine was immediately coupled with N-Ac-pY*-
OH 2.030 to furnish the flexible tripeptide 2.092 in 67% yield as a single diastereomer.  
Removal of the benzyl protecting groups on 2.092 via hydrogenolysis afforded the 
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    2.030, DMF, 
   -10 oC to rt
1) Et3SiH, Pd/C (10%)

















Backbone to side chain cyclopropane constraints were designed to evaluate the 
effects of introducing a conformational constraint on the enthalpy and entropy of binding 
of phosphotyrosine derived ligands to the Grb2-SH2 domain.  The cyclopropane portion 
of 2.004 was designed to enforce the extended conformation on the pTyr residue of 2.003 
while 2.006 and 2.008 were designed to mimic the β-turn at the pY+1 residue.  The 
syntheses of ligands 2.003-2.009 were completed.  Ligands 2.003, 2.004, and 2.005 were 
obtained through amino acid coupling of previously reported tyrosine acid mimics.  
Ligands 2.006 and 2.008 were synthesized utilizing two Curtius rearrangements and 
many functional group manipulations.  Ligands 2.007 and 2.009 were obtained using a 
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reductive amination as the key step.  The major obstacles in the syntheses of 2.006, 
2.007, 2.008 and 2.009 were the conversion of the methyl esters to amides and the 
epimerization during the reductive amination and coupling reaction.  In the synthetic 
route to these molecules, the amination step must precede further functionalization.  
Despite the length of the synthesis of pseudopeptide 2.006 and 2.008 enough material to 
carry out the ITC measurements was obtained.  The next step is to evaluate the 
theromdynamic binding profile for these ligands.  The energetics of binding of these 
ligands with the Grb2-SH2 domain were evaluated using ITC (Chapter 3).  The synthetic 





Chapter 3. The Thermodynamic and Structural Evaluation of 
Cyclopropane-Derived Pseudopeptides for Grb2-SH2 Domain 
3.1  INTRODUCTION 
One area of research in the Martin group has been to examine the effect of 
introducing a cyclopropane ring into the phosphotyrosine (pY) moiety of ligands that 
bind to the Src-SH2 domain.105,121  The thermodynamic profiles of the cyclopropane-
containing ligand 1.086 and its flexible analogue 1.087 binding to this protein domain 
were investigated using ITC (see Chapter 1 for more discussion).  The ITC data 
established that the two molecules have similar binding affinities for the Src-SH2 
domain.  The cyclopropane-containing ligand 1.086 was found to have a greater entropic 
advantage over its flexible partner 1.087.  This entropic advantage was, however, 
accompanied by an enthalpic disadvantage, a ubiquitous phenomenon known as 
enthalpy-entropy compensation (see Chapter 1 for discussion).  The balancing of entropy 
and enthalpy resulted in no net change in the overall binding affinity due to the 
introduction of a conformational constraint to the pY residue of the ligand.  Structural 
data revealed that the cyclopropane-containing ligand 1.086 bound to the SH2 domain in 
a similar mode as a peptide ligand; however, obtaining an X-ray structure of the flexible 
control 1.087 bound to the Src-SH2 domain for comparison with the 1.086/Src-SH2 









































1.130 1.131  
 
3.2 ISOTHERMAL MICROCALORIMETRY EVALUATIONS  
We wanted to examine another system where we could introduce a cyclopropane 
ring into a peptide ligand in order to enforce the biologically active conformation of the 
ligand.  Compounds 2.004 and 2.005 were thus prepared in order to examine the 
energetic consequences on binding caused by the introduction of a cyclopropane at the 
pY residue of ligands that bind to the Grb2-SH2 domain and to compare these results 
with the conclusions drawn from our Src-SH2 system (see Chapter 2 for syntheses of 
these ligands).  In addition, we wanted to assess the effect of introducing a cyclopropane 
ring into a system that would allow us to evaluate the use of cis-cyclopropane constraints 
to stabilize peptide turned conformations.  Pseudopeptides 2.006 and 2.007 were prepared 
in order to examine the energetic consequences on binding caused the introduction of a 
cis-cyclopropane at the pY+1 residue of the peptide that binds to the Grb2-SH2 domain.  
The thermodynamic profiles for binding of the cyclopropanes 2.004 and 2.006, the 
flexible controls 2.005 and 2.007, and peptide 2.003 to the Grb2-SH2 domain were 
determined using isothermal titration calorimetry (ITC).  ITC provides an effective 
method to obtain Ka, and to determine stoichiometry and ∆H of binding in a single 
experiment.  In a typical experiment, the ligand was titrated stepwise into a solution of 
protein at constant temperature.  The heat generated during the ligand-protein complex 
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formation was recorded.11,53,54  Ka, stoichiometry and ∆H of binding were obtained from 
the binding curve, and these values were used to calculate  ∆G and ∆S of binding.  In 
order to diminish heat exchange due to the differences between the solutions of ligand 
and protein, the ligand was dissolved in final dialysate from the Grb2-SH2 sample 
purification.  Each experiment was repeated at least three times, and the values were 
averaged.  A blank of ligand titrated into buffer solution was also obtained.  The values 
were subtracted from each ligand into protein titration to account for any heat of dilution 




























































































3.2.1  pY Pseudopeptides 
The thermodynamic profiles for compounds 2.003, 2.004 and 2.005 are 
summarized in Table 3.1.  By examining the ∆G for each ligand, one can see that all three 
ligands bind with similar overall affinities to the Grb2-SH2 domain.   
 
Table 3.1:  Thermodynamic binding parameters of phosphotyrosine mimics 2.003, 2.004 
and 2.005. 
 







 AcpYVN 2.003 4.9 (±0.4) x 105 -7.8 ±0.05 -5.9 ±0.08 6.3 ±0.4 
Cp[pY]VN 2.004 5.2 (±0.7) x 105 -7.8 ±0.08 -6.5 ±0.04 4.5 ±0.4 
Flex[pY]VN 2.005 2.9 (±0.7) x 105 -7.4 ±0.2 -5.0 ±0.2 8.1 ±1 
aReported errors are the standard deviations of three experiments.  Errors in T∆S were calculated by 
propagation of error, as the standard deviations were often smaller than expected.  Concentrations of 
ligands were 0.6-0.9 mM and protein was 0.052 mM. 
 
The differences in the thermodynamic profiles for the binding of the ligands 2.004 
and 2.005 to the Grb2-SH2 domain are listed in Table 3.2.  There was little energetic 
difference between the binding of the cyclopropane mimic 2.004 and the flexible mimic 
2.005 (∆∆G = -0.4 kcal mol-1).  However, examination of the data in Table 3.2 reveals 
the surprising result that cyclopropane-containing ligand 2.004 binds with less favorable 
entropy of binding (∆∆S = -3.7 cal mol-1 K-1) than its flexible analogue 2.005.  
However, this entropic disadvantage was accompanied by an enthalpic gain, with 2.004 
binding with more favorable enthalpy of binding (∆∆H = -1.5 kcal mol-1) than 2.005.    
This was completely the opposite of the results obtained in our Src-SH2 domain system 
where the cyclopropane-containing ligand was entropically favored and enthalpically 
disfavored.  But like before, enthalpy-entropy compensation was evident in the binding of 
2.003-2.005 to the Grb2-SH2 domain.  To the best of our knowledge, this is the only 
example where in the introduction of a conformational constraint results in an entropic 
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disadvantage in the binding event.  This unique observation may question to the validity 
of the hypothesis that introducing a conformational constraint into a peptide ligand 
should increase binding affinity by decreasing the conformational entropic penalty paid 
upon ligand binding (see Chapter 1).  Additionally, Martin Teresk and Laura Milspaugh 
have examined pseudopeptide ligands similar to 2.004 and 2.005 that contain an Ile at the 
pY+1 position.  Using ITC, they obtained the same trends for their ligands as observed 
for 2.004 and 2.005; namely, the introduction of the cyclopropane at pY residue of the 
ligand was associated with an entropic disadvantage when binding to the Grb2-SH2 
domain.   
 









(cal mol-1 K-1) 
2.004/2.005 
 -0.4 -1.5 1.1 -3.6 
a∆∆X is ∆X 2.004 - ∆X 2.005.  
  
In order to determine if the ligands have the same desolvation free energies, the 
octanol to water partition coefficients (P) for 2.004 and 2.005 were measured (see 
Chapter 5 for more details).  For any of the phosphotyrosine ligands to move from the 
aqueous to organic phases, it was critical that the pH of the aqueous phase be less than 2.  
The pKa for phosphotyrosine ligands has been report to be around 2.0 and the ligands 
need to be fully protonated in order to be dissolved in the organic phase.170,171  P values 
of 1.0 for 2.004 and 0.89 for 2.005.  The mole-fraction partition coefficients were 
calculated from the P by multiplying the value by 0.114 (the ratio of the molar volumes 
of water and octanol.  The values were then converted into free energy using ∆G = -RT ln 
(P * 0.114).35,37  The difference in the free energy of desolvation for the two ligands was 
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less than 0.1 kcal mol-1.  This suggests that the two ligands have similar interactions with 
the solvent.  However, we were unable to repeat this experiment more than once.   
3.2.2 pY+1 Pseudopeptides 
A cis-cyclopropane conformational constraint was introduced at the pY+1 residue 
of the peptide ligand with hope that the cyclopropane would enforce the desired β-turn 
present at the pY+1 and pY+2 positions when a ligand binds to the Grb2-SH2 domain 
(see Chapter 2).  The binding data is summarized in Table 3.3.  The flexible control 2.007 
binds the Grb2-SH2 domain with 10-fold less affinity than the peptide 2.003.  This 
difference might arise from the presence of the amine functionality t in 2.007.  At 
physiological pH the amine moiety has different geometry and charge than the 
corresponding amide moiety present in 2.003.  The amide and amine groups could 
interact differently with the protein and/or the solvent and result in the affinity difference 
between the two ligands.  However, examination of X-ray structures of Grb2-SH2 
domain complexed with peptide ligands revealed that the pY+1 amide NH does not 
interact with the SH2 domain.130,134  On the other hand, the cyclopropane-containing 
ligand 2.006 binds very poorly to the Grb2-SH2 domain (Ka < 1 x 103 M-1) suggesting 
that the cis-cyclopropane does not enforce the desired turned conformation for this 
residue of the ligand.  The gem dimethyls on the cyclopropane ring might sterically 
prevent the conformation required for binding because one methyl is on the same side of 
the ring as the backbone groups.  This steric crowding may force the backbone moieties 
to bend away from the desired turned conformation.  Thus, we prepared 2.008 and 2.009 
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Table 3.3:  Thermodynamic binding parameters of pY[V]N. 
 







 Ac-pYVN 2.003 4.9 (±0.4) x 105 -7.8 ±0.05 -5.9 ±0.08 6.3 ±0.4 
pY-Cp[V]N 2.006 <1 x 103    
pY-Flex[V]N 2.007 2.0(±0.5)x 104 -5.9 ± 0.1 -3.0 ± 0.2 9.5 ± 1.2 
aReported errors are the standard deviations of three experiments.  Errors in T∆S were calculated by 
propagation of error, as the standard deviations were often smaller than expected.  Concentrations of 
ligands were 0.6 mM for 2.003, 1.5 mM for 2.006, and 1.7 mM for 2.007 and protein was 0.052-0.057 
mM. 
 
3.3 X-RAY STRUCTURES 
In addition to the thermodynamic measurements, it is important to determine the 
structures of the complexes formed between the constrained and flexible ligands and the 
protein.  One must ensure that the structures of the bound forms of constrained and 
flexible control ligands are similar.  Otherwise, any differences in binding energetics 
between the two molecules could be associated with additional ligand-protein interactions 
and not to the conformational constraint itself.  Without structural information, the true 
impact of introducing a conformational constraint cannot be evaluated. 
3.3.1  Introduction 
Aaron Benfield has been successful in obtaining crystals of the cyclopropane-
derived ligand 2.004 bound to the Grb2-SH2 domain.  Unfortunately, the complex 
between the peptide 2.003 and the Grb2-SH2 domain was obtained as a domain swapped 
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dimer at poor resolution (> 3 Å) making it difficult to use for structural comparisons.  
Efforts to crystallize the flexible ligand 2.005 complexed to the Grb2-SH2 domain are in 
progress.  
3.3.2  X-ray Structures of 2.004 Bound to Grb2-SH2 Domain 
The X-ray structure of 2.004 bound to the Grb2-SH2 domain was solved to 1.9 Å 
resolution.  It had an R factor of 0.2005 and final free R of 0.2335.  In the solved 
structure, there were two complexes in the asymmetric unit, a situation that provided two 
independent views of the 2.004/Grb2-SH2 complex.  The two complexes align with an 
r.m.s deviation of 0.69 Å for all protein atoms (0.32 Å for α-carbon atoms, 0.32 Å for 
backbone atoms, and 0.91 Å for side chain atoms) meaning the two complexes are 
superimposable within approximately 0.7 Å (Figure 3.1).   
 
Figure 3.1:  Overlay of the protein backbone for the two 2.004/Grb2-SH2 complexes in 





The only significant difference between the conformations of the ligands in the 
two complexes is the conformation of the N-terminal methylamide (Me-N-C=O 
conformation) (Figure 3.2).  The carbonyls in both conformations interact through 
hydrogen bonds with Arg 67 protein residue; the oxygen atom of the carbonyl is 2.73 Å 
from one guanidinium N-H and 3.10 Å away from the other guanidinium N-H.  The 
carbonyl oxygen atom for both ligand conformations is in the same location but there are 
different positions for the N-methyl, indicating that there are two different conformations 
for this amide bond.  In one structure the conformation about this amide is cis with the N-
methyl and carbonyl almost co-planar (the dihedral angle for Me-N-C=O is -19o).  In the 
other structure, this methyl amide is in a pseudotrans-conformation (the dihedral angle 
for Me-N-C=O is 60o).  In either conformation, the methyl nitrogen is not interacting 
with the protein.  For simplification, only one conformation, the N-methylamide 
pseudotrans-conformation, will be used for the rest of the discussion.   
 
Figure 3.2:  Overlay of the two 2.004 ligands bound to Grb2-SH2 domain, one in pink 





 An X-ray structure of the cyclopropane-containing ligand 1.086 bound to the Src-
SH2 domain was previously determined.105,121  An overlay of 1.086 and 2.004 bound to 
their respective domains shows the very similar conformation for the cyclopropane 
residue of these ligands (see Figure 3.3.  There is only one N-methylamide conformations 
in 1.086/Src-SH2 complex.  There are also slight differences in the interactions found 
between the Grb2 and Src/cyclopropane-containing ligand complexes.  For example, the 
N-methylamide carbonyl of 1.086 is 2.84 Å from one guanidinium N-H of Arg 155 and 
3.10 Å away from the other guanidinium N-H.  These distances are similar to the ones 
seen for this carbonyl of 2.004 interacting with Arg 67 of the Grb2-SH2 domain.  In 
addition, the bridging phosphate oxygen of 2.004 is 3.02 Å from Ser 96 of Grb2 while 
this oxygen of 1.086 is 3.21 Å away from Cys 185 of Src.  One of the non-bridging 
phosphate oxygens of 2.004 is closer to the Arg 86 residue of Grb2 while another non-
bridging oxygen is near Arg 67, 2.75 Å and 2.73 Å, respectively.  In the Src complex, 
two of the non-bridging phosphate oxygens are both close to Arg 175, 2.69 Å and 2.78 Å 
away, respectively.  The third non-bridging phosphate oxygen of the cyclopropane-
containing ligands is 2.55 Å away from Ser 90 in the Grb2 complex, while this oxygen 
atom is 2.69 Å from Thr 179 in the Src-SH2 domain complex.  In addition, the Src 
complex contains an additional interaction between protein residue Glu 178 and a non-
bridging phosphate oxygen of 1.086 (distance between the groups if 2.78 Å).  Despite 
these slight differences, we conclude that the Src- and Grb2-SH2 domains bind the pY 
residue of the cyclopropane-containing ligands 2.004 and 1.086 in a similar manner. 
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Figure 3.3:  Overlay of 2.004 bound to Grb2-SH2 domain (in pink) and a similar 




Further inspection of the cyclopropane conformation in the X-ray structure shows 
the carbonyls on either side of the cyclopropane have distinct orientations.  The carbonyl 
(pY+1 amide) at the C-terminus clearly bisects the cyclopropane ring (Figure 3.4).  The 
same conformation was seen in a simple X-ray structure of an unbound cyclopropane-
carboxamide suggesting that it is the preferred conformation for the C-terminal 
carbonyl.103  This bisecting conformation of 2.004 in our complex has been seen in 
similar cyclopropane-containing ligands bound to proteins.104,105,121  The fact that this 
bisecting conformation was seen in both uncomplexed and complexed molecules 








On the other hand, the N-terminal carbonyl N-methylamide deviates from the 
aforementioned preferred bisecting conformation (Figure 3.5).  The conformation of this 
carbonyl in the unbound structure deviates from the bisecting orientation by 
approximately 47o.  However, the conformation of this carbonyl in the 2.004 complex is 
about 18o different from the bisecting orientation.  As mentioned before, this carbonyl is 
probably involved in hydrogen bond interactions with the Arg 67 residue of the Grb2 
SH2-domain.  This interaction may be responsible for the deviation of the carbonyl 
orientation from the bisecting conformation or the conformation seen in the unbound 
crystal structure.  A similar conformation was seen in the X-ray structure of 1.086 bound 
to the Src-SH2 domain.105,121    Thus, it is not clear that the introduction of a 








 We have been unable to solve an X-ray structure of a flexible control 2.005 bound 
to the Grb2-SH2 domain.  Thus, we can only compare our structure of the complex of 
2.004 to the Grb2-SH2 with other structures reported in the literature.  We choose two 
published structures 1TZE130 and 1JYR134 each having a peptide ligand similar to 2.003 
bound to the SH2 domain that contain.  1TZE structure was solved to 2.1 Å resolution 
and contained a 7-peptide residue ligand with an IC50 of 0.15 µM bound to the domain.  
Structure 1JYR was solved to 1.5 Å resolution and contained 9-peptide residue ligand 
with an IC50 of 72 nM and a Kd of 18 nM bound to the domain.  An overlay of the three 
structures is shown in Figure 3.6.  It is clear that the bound conformation of the pY 
residue of 2.004 deviates from the pY residue of the peptides, especially at the bridging 
phosphate oxygen moiety.   
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Figure 3.6:  Overlay of 2.004 (shown in pink) and other peptide ligands (shown in light 




The different binding modes of 2.004 and the peptide ligands can be illustrated by 
examining the X-ray structure of the complexes, specifically the residues of the Grb2-
SH2 domain that are near the phosphotyrosine ring of the ligands (Figure 3.7).  Some 
residues in the flexible loop are closer to the bridging phosphate oxygen of 2.004 than 
this oxygen moiety of the peptides.  These differences could affect the interactions 
between the ligands and the protein.  For example, the distance between hydroxyl of Ser 
96 of the SH2 domain and this oxygen of 2.004 is 3.02 Å, which is within hydrogen 
bonding distance.  However, in the structures of the peptide complexes the distance 
between these groups is 3.98 Å, which is too far to be considered a hydrogen bond 
interaction.   
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In addition, two of the three non-bridging phosphate oxygens of the ligands could 
also have different interactions with the protein.  For example, the hydroxyl residue of 
Ser 90 of the protein is 2.83 Å from one of the non-bridging oxygens of the peptide 
ligand, while this protein residue is 2.55 Å away from this oxygen in 2.004.  On the other 
hand, the distance between one of the other non-bridging oxygens of 2.004 and Ser 88 
hydroxyl is longer than the distance between this oxygen moiety in the peptides and Ser 
88 hydroxyl, 3.27 Å and 2.87 Å, respectively.  Conversely, the distance between the third 
non-bridging phosphate oxygens of 2.004 and the peptides and a guanidinium N-H group 
of domain residue Arg 86 is almost identical.   
Although the pY residue of 2.004 and the peptide ligands do not seem to bind to 
the Grb2-SH2 domain in precisely the same manner, the pY+1 Val and pY+2 Asn 
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positions of the ligands overlap nicely (Figure 3.8).  Thus, introducing a cyclopropane at 
the pY residue of the ligand does not seem to affect the way the pY+1 Val and pY+2 Asn 
residues bind and the desired β-turn conformation is maintained.   
 
Figure 3.8:  Overlay of 2.004 (shown in pink) and other peptide ligands (shown in blue) 




The difference in the distances between a functional group of the ligand and the 
protein residues that it is interacting with will affect the strength of the non-covalent 
interactions.  The resulting differences in the non-covalent interactions between the 
protein and the ligand will affect the energetics of the ligand binding.  These different 
interactions found in the 2.004 and peptide complexes make it difficult to compare the 
thermodynamic binding profiles between 2.004 and the peptide ligands.  Additionally, 
from these different binding modes of 2.004 and the peptide ligands we can conclude 
anything about the effects of introducing a cyclopropane conformational constraint.  
Instead, we would need a complex of the flexible control 2.005 bound to the Grb2-SH2 
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domain in order to compare to the 2.004/Grb2 complex.  We are currently working to 
obtain this structure. 
The crystal structure of another constrained peptide-like ligand bound to the 
Grb2-SH2 domain has been reported in the literature.  Macrocycle 2.002 has IC50 of 0.11 
µM and the 2.002/Grb2-SH2 domain complex (1BM2) was solved with 2.1 Å resolution. 
92  Macrocycle 2.002 binds to the Grb2-SH2 domain in a slightly similar manner as the 
cyclopropane containing 2.004 (Figure 3.9).  The bridging oxygen in 2.002 and 2.004 are 
in a similar location compared to the bridging oxygen found in the ligands.  The Ser 96 
hydroxyl residue of the domain and the bridging oxygen in 2.002 and 2.004 are similar 
distance apart, 3.34 and 3.02 Å, respectively.  On the other hand, the non-bridging 
oxygens are different distances from Ser 88 and Ser 90 residues of the Grb2-SH2 domain.  
For example, two of the three non-bridging oxygens of 2.002 are 2.93 and 3.04 Å away 
from Ser 88 and Ser 90 hydroxyl residue.  However, these non-bridging oxygens of 2.004 
are 3.27 and 2.55 Å away from those respective residues on the domain.   
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Figure 3.9:  Overlay of 2.004 (shown in pink) and macrocyclic peptide 2.002 (shown in 




The orientation of 2.002 bound to the SH2 domain is also slightly different than 
the orientation of a peptide bound to the domain.  This can be illustrated by the overlay of 
the two structures (1TZE130 and 1BM292, Figure 3.10)  The non-bridging oxygens of 
2.002 and the peptide ligand have similar contacts with Ser 88 and Ser 90.  For example, 
two of the three non-bridging oxygens of the peptide ligand are 2.87 and 2.83 Å from Ser 
88 and Ser 90 hydroxyl residues, respectively.  These non-bridging oxygens of 2.002 are 
2.93 and 3.04 Å apart from Ser 88 and Ser 90.  On the other hand, the bridging oxygens 
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of the two ligands make very different contact with Ser 96.  The bridging oxygen of 
2.002 is only 3.34 Å apart from the hydroxyl of Ser 96 while this oxygen in the peptide 
ligand is 3.98 Å from the residue, which is out of the range for hydrogen bonding 
interactions with the domain.  By comparing these structures, it appears that there is some 
flexibility in the Grb2-SH2 domain binding site. 
 
Figure 3.10:  Overlay of 2.002 (shown in green) 92 and peptide ligand (shown in blue) 




3.3.3  Conclusions from X-ray Structure 
The complex of 2.004 bound to the Grb2-SH2 domain provides interesting insight 
into the energetics of binding.  First, the pY residues of the cyclopropane-containing 
ligands 2.004 and 1.086 bind to their respective Grb2-SH2 and Src SH2 domains in a 
similar manner.  However, it is clear that the pY residues of the peptide ligands and 2.004 
bind to Grb2-SH2 domain in different modes.  On the other hand, constrained macrocycle 
2.002 and constrained cyclopropane-containing 2.004 bind to the domain in a somewhat 
similar manner.  This suggests that there is some flexibility in the Grb2-SH2 domain 
binding pocket.  In order to determine the structural consequences of introducing a 
cyclopropane ring, we need an X-ray structure of the flexible control 2.005 bound to the 
Grb2-SH2 domain.  Comparing the bound structures of 2.004 and 2.005 will allow us to 
further understand the consequence of introducing a cyclopropane constraint and might 
confirm our recent finding that the introduction of a conformational constraint cannot be 
associated with an entropic advantage to binding. 
3.4  SUMMARY AND CONCLUSIONS 
Many scientists have believed that introducing a conformational constraint into a 
flexible ligand will enhance binding affinity provided the two ligands bind in the same 
manner making the same contacts with the protein.  This prediction follows from the idea 
that the constrained molecule should pay a reduced entropic penalty upon binding to a 
protein.  However, the present and related work reveals that introducing a cyclopropane 
conformational constraint generally does not seem to influence the net affinity of peptide-
like ligands binding to SH2 domains (both Src and Grb2).   
Comparing the ITC data for the binding of 2.004 and 2.005 to the Grb2-SH2 
domain reveals that the introduction of a cyclopropane ring at the pY replacement in 
pYVN tripeptide actually results in entropic disadvantage.  This disadvantage is 
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completely different than results we obtained for binding of similar peptide-like ligands 
to the Src-SH2 domain.  In these cases the constrained ligand had an entropic advantage 
over its flexible partner.  It is also the first time, to our knowledge, that introducing 
conformational constraint is associated with an entropic disadvantage for binding.  The 
origin of the observed entropic disadvantage is perplexing.  We must consider the total 
entropy of the binding even, both the ligand and the protein, before and after 
complexation.  By pre-organizing the ligand into the biologically active conformation, 
the net conformational entropy required for the ligand to bind to the protein has been 
reduced.  Thus, it seems likely that this disadvantage may be associated with the 
difference in the conformational entropy of the protein before and after complexation.  
For the Grb2-SH2 domain, binding a rigid compound may reduce the flexibility of the 
protein more than the binding of a flexible analogue.  Namely, the conformational 
entropy of the protein in the complex may be dependent upon the flexibility of the bound 
ligand, and binding a less flexible ligand resulted in a complex that was more ordered and 
less entropically favored.   
An X-ray structure of 2.004 bound to the Grb2-SH2 domain reveals that 2.004 
binds in a different mode than native peptide ligands.  There are additional interactions 
between the SH2 domain and 2.004 that are not present in the structures of the bound 
peptide ligands.  These additional interactions could contribute to the enthalpic advantage 
seen for the binding of the constrained ligand.  The additional interactions between the 
constrained ligand and the protein might be expected to then result in an entropic 
disadvantage associated with the binding of the constrained ligand.  If the ligand and 
protein are held tightly together by enthalpic interactions, then the ligand and protein will 
have less freedom of motion and therefore less entropy.  Additionally, regions of the 
protein may gain or lose conformational entropy upon binding a pre-organized ligand.  
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On the other hand, it appears that constrained ligands 2.002 and 2.004 bind to the Grb2-
SH2 domain in a slightly similar manner, suggesting that there is some flexibility in the 
binding pocket.  This comparison is not completely accurate since peptide ligands are not 
the ideal control partners for 2.004.  However, we have not been able to obtain an X-ray 
structure of 2.005 bound to the Grb2-SH2 domain.  This structure is critical for 
determining whether 2.004 and 2.005 bind to the domain in a similar manner. 
It has not yet been possible to demonstrate that the introduction of a cis-
cyclopropane at the pY+1 residue in ligands that bind to the Grb2-SH2 domain can 
stabilize the  β-turn conformation required for binding.   
In general the theory of introducing a conformational constraint in order to obtain 
a ligand with higher binding affinity through an entropic advantage has been applied in 
an overly simplistic fashion (see Chapter 1 for more discussion).  The conformational 
entropy of the ligand has been the focus.  Unfortunately, this ignores the possibility that 
the protein could have different conformational entropy depending on the flexibility of 
the bound ligand and that this conformational entropy could impact the enthalpic 
interactions associated with complexation.  We now have an example where the 
introduction of a conformational constraint does not enhance binding affinity, and an 
entropic disadvantage is associated with the binding of the pre-organized ligand.  In 
addition, the theory does not account for the enthalpy-entropy compensation, a widely 
observed phenomenon. 
There are many more experiments that should be conducted within this research 
area to further probe the validity of the theory of pre-organization.  It is necessary to 
apply our conformational constraint to different biological systems.  We have only 
evaluated the thermodynamic parameters of binding constrained and flexible molecules 
to SH2 domains.  Extending this research to enthalpically or entropically driven systems 
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might provide intriguing insight into the energetics of binding.  In addition, our 
cyclopropane constraints are backbone to side chain constraints.  Evaluating other 
conformational constraints such as backbone to backbone or side chain to backbone 
cyclizations would also be interesting.  In order to determine the flexibility of the protein 
in the complex, dynamic, time-resolved NMR experiments need to be conducted.172  
These experiments will lead to a further understanding of the energetics associated with 
ligand-protein interactions and of the entropic disadvantage associated with binding our 








Chapter 4. Studies Toward the Synthesis of C-Aryl Glycosides 
4.1 INTRODUCTION OF C-ARYL GLYCOSIDES 
C-Aryl glycoside antibiotics are an important subclass of the C-glycoside family 
of natural products that have attracted considerable interest owing to their range of 
significant biological activities and resistance to enzymatic hydrolysis.173-175  C-Aryl 
glycosides are divided into four classes based on the substitution pattern of the phenolic 
hydroxy group(s) relative to the carbohydrate functionality(ies) (Figure 4.1).176  In Group 
I C-aryl glycosides, the sugar is para to the phenolic hydroxyl group, while in Group II 
the sugar is ortho to this function.  Group III C-aryl glycoside contain two carbohydrate 
moieties both ortho and para positions to the hydroxyl group, whereas group IV C-aryl 
glycosides is a 1,4-dihydroxy quinone with a sugar at the 2 position.   
 
Figure 4.1:  Different groups of C-aryl glycosides. 
 










One challenge to the synthesis of C-aryl glycoside natural products is their 
unsymmetrical substitution pattern.  For example, the pluramycins are a family of 
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antibiotic natural products belonging to the Group III class of C-aryl glycosides that 
contain highly substituted 4H-anthra[1,2-b]pyran-4,7,12-triones with two sugars attached 
(Figure 4.2).177  The sugar at position 8 is anglosamine and represents ring E.  An N,N-
dimethylvancosamine is positioned at carbon 10 and referred to as ring F.  A few 
members of the pluramycin family differ in the functionality at position 2, including 
kidamycin (4.001), pluramycin A (4.002) and hedamycin (4.003).  Kidamycin was 
isolated from a Streptomyces in 1956 and was found to possess antimicrobial and 
anticancer activity.177  The mechanism of action for the biological activity involves the 
ability of kidamycin to bind strongly to DNA.178  To date, no total synthesis has been 
reported for these C-aryl glycosides, although the synthesis of O-methylkidamycinone, an 
aglycone derivative of kidamycin, and bis-substituted C-aryl glycosides have been 
reported.176,179  In addition, Dr. David Kaelin, has explored several routes to prepare 
structures related to the kidamycin core and the synthesis of ring E and F sugars.180 
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Kidamycin, 4.001  R = H, R' =
Pluramycin A, 4.002  R = Ac, R' =




















4.2 THE TETHERED BENZYNE CYCLOADDITION METHODOLOGY 
For some time the Martin group has been interested in synthesizing C-aryl 
glycoside natural products.  Several methods were developed in our group; however, 
none provided access to the unsymmetric substitution pattern of the natural products.  
The Martin group recently disclosed two general approaches to prepare the major classes 
of C-aryl glycosides.180-182  The first method involved an acid-catalyzed ring opening of 
a benzyne-furan cycloadduct.  For example, deprotonation of 4.004 gave the benzyne that 
underwent cyclization with furan 4.005 to provide cycloadduct 4.006 in excellent yield 
(Scheme 4.1).  Acid-catalyzed ring opening of 4.006 provided the model Group I C-aryl 




































In the second developed approach to C-aryl glycosides, a palladium-catalyzed 
SN2'-type ring opening of a benzyne-furan cycloadduct with an iodoglycal, followed by 
appropriate adjustment of oxidation states provided C-aryl glycosides.  This route 
allowed for a later stage introduction of carbohydrate residues, which was especially 
useful for the synthesis of Group III C-aryl glycosides.  For example, palladium-
catalyzed ring opening of cycloadduct 4.006 with 4.008 provided the naphthol 4.009 in 
64% yield.  Reduction of 4.009 afforded 4.010, an example of a Group III C-aryl 










































In these initial studies symmetrical benzynes were universally employed as 
reaction partners, so the regioselectivity of the cycloaddition was not an issue.  Although 
unsymmetrical benzynes can undergo regioselective Diels-Alder reactions,183 such 
cycloadditions typically proceed with poor regioselectivity.184,185  For example, in our 
labs Dr. David Kaelin studied the Diels-Alder reaction between furan 4.011 and the 
benzyne 4.012 (Scheme 4.3),180 obtaining a mixture (1:1) of products 4.013a and 4.013b. 
 
























There are reports in the literature using steric bulk to direct regioselectivity in 
benzyne cycloadditions, but these were unsuccessful.  This can be illustrated by the 
cycloaddition between di-tert-butyl benzyne 4.014 and tert-butylfuran 4.015 produced a 














In addition, the lack of regiocontrol in the cycloaddition became manifest during 
recent work that culminated in a formal synthesis of the C-aryl glycoside galtamycinone 
(4.017).188  Furyl glycoside 4.018 was reacted with the benzyne generated from 4.004 
providing a mixture of diastereomeric Diels-Alder adducts 4.019 (Scheme 4.5).  Acid-
catalyzed ring opening furnished the naphthol 4.020, which underwent O-methylation 
and oxidation to give juglone 4.021.  Chlorination of 4.021 proceeded with complete 
regioselectivity to give chlorojuglone 4.022 as a single diastereomer and its preparation 










































































Next, members of the Martin group investigated whether glycosyl juglones like 
4.021 would undergo a regioselective Diels-Alder reaction with isobenzofuran 4.023 to 
provide access to galtamycinone (Scheme 4.6).  An exploratory study in which juglone 
4.021 was allowed to react with isobenzofuran was conducted, but this reaction gave an 
uncharacterized mixture of regio- and stereoisomeric products.  Due to this limitation, 
benzyne Diels-Alder reactions alone cannot be used to access unsymmetrical C-aryl 
glycosides.  Nevertheless, the mixture was carried on to provide a separable mixture 
(1.1:1) of the regiomers 4.024 and 4.025.  The preparation of the C-aryl glycoside 4.024 











































In order to apply our benzyne Diels-Alder methodology to the synthesis of 
naturally occurring C-aryl glycosides, which are all unsymmetrically substituted, it is 
essential to control the regiochemistry of the pivotal benzyne-furan cycloadditions.  It 
was discovered that a disposable silicon tether could be exploited to control the 
regiochemistry of benzyne-furan cycloadditions that led to the major groups of C-aryl 
glycosides.180,189 
Two protocols, differing only in the number of carbon atoms in the tether, were 
envisioned (Scheme 4.7).  In the first method, the regioselective metallation of glycosyl 
furan derivatives 4.026 followed by trapping the carbanions with an appropriate 
chlorosilane, followed by refunctionalization as needed would lead to the silanes 4.027 
which would be coupled with halophenols to give 4.028.  Selective deprotonation of 
4.028 followed by expulsion of the ortho chloride would generate the benzynes 4.029, 
and a subsequent intramolecular Diels-Alder reaction would furnish the cycloadducts 
 145
4.030.  Based upon the prior art of Rickborn and Stork,190-192 it was anticipated that 
fluoride ion would induce the cleavage of the silicon–carbon bonds in the tethers of 4.030 
to give intermediates that could undergo acid-catalyzed opening of the oxabicyclic ring to 
deliver either glycosyl naphthol 4.031 (R3 = H or Me), depending on the nature of the 










































4.2.1 Application to Group I C-Aryl Glycosides 
The use of silicon tethers to access Group I C-aryl glycosides is illustrated by two 
related strategies.  In the first of these, Dr. David Kaelin converted the known glycosyl 
furan 4.005181 into the furylsilane 4.032 by sequential metallation (LDA, THF, –78 oC) 
and reaction with bromomethylchlorodimethylsilane to afford the furylsilane 4.032 in 
73% yield (Scheme 4.8).180  O-Alkylation of 2,6-dichloro-4-methoxyphenol (4.033)193 
with 4.032 provided the Diels-Alder precursor 4.034 in 85% yield.  When 4.034 was 
treated with s-BuLi in THF at –95 oC, facile deprotonation ortho to methoxy group 
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ensued.  The resultant anion underwent elimination upon warming to generate an 
intermediate benzyne that cyclized with the pendant glycosyl furan to provide 





































s-BuLi, THF, –95 oC; 








4.034 4.035  
 
Two tactics were developed for converting the cycloadduct 4.035 into substituted 
naphthols.  In the event, reaction of 4.035 with excess Bu4NF (TBAF) in DMF cleaved 
both carbon-silicon bonds to afford 4.036 (79% yield), which underwent acid-catalyzed 
ring opening to furnish quantitatively 4.037, a representative Group I C-aryl glycoside 
(Scheme 4.9).  Alternatively, when 4.035 was treated with TBAF in THF, only the 
bridgehead carbon-silicon bond was cleaved.  Subsequent Tamao oxidation (H2O2, 
KHCO3, CH3OH) furnished the phenol 4.038 in 75% yield.194-196  Dr. Steve Sparks 
found that O-alkylation of 4.038 followed by acid-catalyzed ring opening gave 4.039 
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(86% overall yield) in which each of the phenolic hydroxyls is nicely differentiated for 























































It was found that O-alkylations of other phenols with bromomethyl silanes like 
4.028 may be problematic due to competing nucleophilic attack on silicon.197  For 






























In addition, Dr. Steve Sparks discovered a problem in the cycloaddition of 4.043.  
When 4.043 was treated with n-BuLi low yields of cycloadduct 4.044 were obtained and 
the 1H NMR spectra of the crude reaction mixture contained multiple peaks at δ 5.7 to 
6.0 ppm, which were in indication of the presence of bridge head protons (Equation 4.2).  




















Dr. Steve Sparks hypothesized that ring strain might be the reason for the low 
yield of this reaction and developed a solution to this problem that featured the use of a 
tether containing an additional carbon atom.189,199  Thus, 4.005 was converted into the 
vinylsilane 4.045 through metallation and trapping the resultant anion with 
chlorodimethylvinyl silane (Scheme 4.10).  Regioselective hydroboration and oxidation 
of 4.045 afforded the alcohol 4.046 in 77% yield.200  Mitsunobu coupling (DIAD, PPh3, 
THF) of alcohol 4.046 with phenol 4.033 then afforded 4.047 in 75% yield.201  
Deprotonation of 4.047 with t-BuLi led to the formation of an intermediate benzyne that 
underwent cycloaddition to deliver 4.048 in 80% yield.  When 4.048 was treated with 
TBAF in DMF at 70 oC, the tether, which resembles a SEM protecting group, was 
cleaved, and 4.038 was obtained in 80% yield.  Our group is currently applying this two-
carbon silicon tether strategy to the synthesis of vineomycinone B2 methyl ester, a 























t-BuLi, THF, – 95 oC; 














































4.2.2 Application to Group II C-Aryl Glycosides 
Having developed an effective strategy for the regioselective preparation of 
Group I C-aryl glycosides, it remained to extend this approach to representative 
glycosides of Groups II and III.  Toward this goal Dr. David Kaelin converted the known 
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glycosyl furan 4.049181 into 4.050 by directed metallation (LDA, THF, –78 oC) and 
reaction with bromomethylchlorodimethylsilane to provide 4.043 in 88% yield (Scheme 
4.11).  O-Alkylation of phenol 4.033 with 4.050 afforded 4.051 in 78% yield.  The 
benzyne generated in situ cyclized from 4.051 as before to provide cycloadduct 4.052 in 
91% yield as a mixture of diastereomers.  Cleavage of both carbon-silicon bonds using 
TBAF in DMF provided intermediate dimethyl ether that underwent ring opening upon 
































–95 oC to rt
1) Bu4NF, DMF, rt
 
































4.2.3 Conclusions  
Drs. David Kaelin and Steve Sparks were able to apply the tether methodology to 
the synthesis of Group I and Group II C-aryl glycosides.  This method could now be used 
to access unsymmetric C-aryl glycoside natural products.  However, it was imperative to 
extend this method to Group III C-aryl glycosides of which kidamycin is a member of. 
 
4.3 STUDIES TOWARD THE SYNTHESIS OF KIDAMYCIN 
It was previously demonstrated that a disposable tether can be used to produce 
Group I and II C-aryl glycosides in a regioselective manner (see Sections 4.2.1 and 
4.2.2).  A primary objective of research in the group is to apply this methodology to the 
synthesis of natural products.  This novel tether strategy could be applied to the total 
synthesis of kidamycin.   
4.3.1 Retrosynthesis 
 Due to instability of the side chain olefin, which was shown to easily isomerize, 
we planned to install ring 2 at a late stage in the synthesis.180  Thus, kidamycin (4.001) 
could arise from 4.054 (Scheme 4.12).  We envisioned that a benzyne-glycosylfuran 
cycloaddition using a tether linkage to enforce the correct regiochemistry could afford 
4.055.  Cleavage of the tether followed by ring opening would provide phenol 4.054  The 
cycloaddition precursor 4.056 can be accessed by coupling 3,5-bis-sugar furan 4.059 with 

































































































































4.3.2 Application of the Tether Methodology to Group III C-Aryl Glycosides 
Before undertaking the total synthesis of kidamycin, we wanted to extend our 
tether methodology previously used to control the regioselectivity in the benzyne 
cycloadditions to Group III C-aryl glycosides.  A bis-substituted furan with sugars in the 
3- and 5- positions was needed to apply this strategy.  The known bromofuran 4.060202 
was deprotonated with LDA, and the anion was treated with sugar lactone 4.061203 
(Scheme 4.13).180  The mixture of lactols obtained was reduced with NaBH3CN in 
ethanolic HCl at 50 oC.  This reaction yielded a mixture of the desired sugar furan 4.062 
along with the bis-furan 4.063 and the diol 4.064, which were identified by analysis of 
the 1H NMR spectra and low resolution mass spectra.  In order to prevent formation of 
the bis-furan sugar 4.063, the order of addition was modified so that the anion derived 


























2) NaBH3CN, EtOH, H+




















The diol 4.064, presumably arose from reduction of the open-form of 
hydroxyketone 4.066 that was in equilibrium with the lactols 4.065 (Scheme 4.14).  To 
prevent the formation of 4.064, this mixture of 4.065 and 4.066 was treated with 
ethanolic HCl (cat.), forming the ethyl glycoside.  At this point, the reaction was worked 
up and the ethyl acetals 4.067 were characterized by 1H NMR spectra and peaks in the 
low resolution mass spectrum.  A one pot procedure was also devised that avoided the 
problems encounter in the previous experiment.  It was discovered that the ethyl acetal 
can be formed in situ by stirring the lactol mixture in acidic EtOH.  Thus, deprotonated 
bromofuran 4.060 was reacted with 4.061.  The products were dissolved in acidic EtOH 
and reduced with NaBH3CN in the same pot to afford 4.062 (Scheme 4.15).  These 













































1) LDA, then 4.061
2) EtOH, H+
    then NaBH3CN, H+,
    EtOH, 50 oC4.060
4.06272%  
 
The 2-position of furan 4.062 is blocked by a TMS group and this group needed 
to be removed.  However, cleaving the TMS blocking group at the 2-position of 4.062 to 
produce the desired bromofuran 4.068 proved problematic (Scheme 4.16).  Exposure of 
4.062 to TBAF resulted in recovered starting material.204  Treatment of 4.062 with 
ethanolic HCl also provided no reaction after 12 h as apparent by TLC and 1H NMR 
spectra of the crude material.  Decomposition of starting material was observed upon 
prolonged exposure to HCl and TFA.  Interestingly, the desired product 4.068 was once 
isolated in 47% yield after treatment with TFA for 2 days, but this result could not be 
reproduced.  Reaction of 4.062 with TfOH at rt or at 0 oC also resulted in decomposition.  
Eventually it was found that reaction of 4.062 with TfOH at –78 oC with slow warming 


















Conditions:                                                  Result:
TBAF, THF, rt                                          no reaction
H+, EtOH, rt                                             no reaction or decomposition
TFA, DCM, 0 oC or rt                               no reaction or decomposition
TfOH, DCM, 0 oC or rt                             only decomposition




A single diastereomer of 4.068 was obtained that likely resulted from 
epimerization under the acidic conditions to form the more thermodynamically stable 
product (Scheme 4.17).  The 1H NMR spectra of 4.068 clearly shows only one 
diastereomer with spectra similar to those reported for other β-glycosides (δ 4.38 ppm as 


























Addition of the anion derived from 4.068 by treating with n-BuLi to the lactone 
4.069205 gave a mixture of anomeric lactols.  These were converted in situ to the ethyl 
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acetals that were reduced with acidic NaBH3CN to provide the bis-sugar furan 4.070 in 
60% overall yield (Scheme 4.18).  David Kaelin previously reported the synthesis 
glycosyl furan 4.070.180,181  Even though he reported that 4.070 was found as a single 
isomer, closer inspection of the 1H NMR spectra indicated that 4.070 was actually a 6:1 
mixture of epimers (β:α).  The mixture could not be separated using column 
chromatography., but is easily distinguishable by peaks in the 1H NMR spectra.  Namely, 
the β-anomeric proton in 4.070 is a doublet at 4.6 ppm while the α-anomeric proton is a 
broad doublet at 5.4 ppm.  The ratio of this mixture of anomers could also be determined 
using HPLC, which gave approximately the same 6:1 ratio.  It was of no consequence 
that 4.070 is an anomeric mixture of compounds because the mixture was expected to 












1) nBuLi, -78oC, then
2) H+, EtOH,
    then NaBH3CN,
























With the bis-sugar furan 4.070 in hand, work was directed toward installation of 
the silyl tether.  The mixture of anomers of 4.070 was converted in 82% yield to the 
furylsilanes 4.071 by metallation and silylation as before (Scheme 4.19).  The epimeric 
 158
mixture could be separated at this stage using column chromatography; however, the 
mixture was carried forward to demonstrate that the acid-catalyzed ring opening would 
be accompanied by epimerization to afford a single isomer.  Thus, O-alkylation of 4.071 
in the presence of TBAI and K2CO3 with phenol 4.033 provided 4.072 in 88% yield.  
Deprotonation of 4.072 with s-BuLi at –95 oC followed by warming furnished 
cycloadduct 4.073 as a complex mixture of diastereomers in 61% yield.  All carbon-
silicon bonds were cleaved with TBAF in DMF to afford 4.074 in 72% yield.  Acid-
catalyzed ring opening of 4.074 quantitatively furnished the Group III C-aryl glycoside 
4.075 as a single isomer based on 1H NMR spectra.  Thus, the 6:1 ratio of β:α anomers 
of 4.070 was epimerized to afford the β-C-aryl glycoside 4.075.  Chemical shifts and 
coupling constants in the 1H NMR are indicative of a β-anomer for both sugars, one 
anomeric proton is a broad doublet at 5.21 ppm (J = 10.2 Hz) while the other is a doublet 
of doublets at 5.01 ppm (J = 11.2, 1.8 Hz).  The resonance of the anomeric proton on a α-
glycoside is further downfield than the anomeric proton on a β-glycoside due to overlap 
with the ring oxygen’s lone pairs of electrons.  In addition, the anomeric proton of a β-
glycoside should have two coupling constants, one big (J = 10 – 13 Hz) and one small; 
where as the anomeric proton of a α-glycoside should have only small coupling 
constant(s).  Due to the resolution of the NMR, one of the doublet of doublets is an 
apparent broad doublet because the second coupling constant is too small to be seen.  
Now that we have applied the tether methodology to the synthesis of Group III C-aryl 




















































































































4.3.3 Problem with Tether Methodology 
One major hurdle in the proposed synthesis of kidamycin (4.001) will be 
controlling the stereochemistry of the α-anomeric center on the N,N-dimethyl 
vancosamine sugar position 6” (Figure 4.3).  Analysis of an X-ray structure of triacetyl 
methoxykidamycin reveals that the F ring is in a twist boat conformation (Figure 4.3).206  
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However, heating kidamycin in the presence of acid causes epimerization at position 6” 
to form the more stable β-anomer of ring F and gives isokidamycin 4.076, which has 
reduced biological activity.  An X-ray structure of a derivative of isokidamycin 
(isokidamycin bis(m-bromobenzoate) confirms this conformation (Figure 4.3).207  The 
conformation of the E ring sugar is not effected by these acidic conditions because it is 
already in a stable conformation.   
 
 






































































Since the less thermodynamically stable form of ring F is present in the final 
product, we were concerned that the acid-catalyzed opening of the oxobicycloheptadiene 
ring to furnish the glycosyl naphthol in our benzyne-cycloaddition tether methodology 
might result in the epimerization of C6” on ring F and form the undesired and unnatural 
 161
derivative, even though the condition for our ring opening are milder than the conditions 
reported for epimerization of 4.001.  For example, reacting cycloadduct 4.077 with TBAF 
followed by TFA might produce either 4.078 or 4.079 (Scheme 4.20).  As we continued 
to explore our tether strategy toward the synthesis of 4.001 we also began to look at other 
methods to install the ring F sugar; however, procedures yielding only α-C-aryl 
























































One recent approach to the less stable α-C-aryl glycosides involves 
intramolecular delivery of an aromatic ring to the anomeric center in the presence of a 
mild Lewis acid.211  For example, glucopyranoside 4.080 was converted to the arylsilyl 
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derivative 4.081 via deprotonation, silylation with Et2SiCl2 and treatment with a suitable 
aryl lithium derivative (Scheme 4.21).  When silyl ether 4.081 was reacted sequentially 
with iodonium dicollidine perchlorate (IDCP), and then Bu4NF, the α-C-aryl glycoside 
4.082 was obtained in 72% yield; no β-anomer was isolated.  The authors suggested that 
the glycosylation reaction occurred by internal substitution of the Ar-Si bond by the 
electrophilic anomeric carbon atom generated from activation of the pentenyl group with 
IDCP, thus providing intermediate 4.083.  While this is a useful procedure for the 
synthesis of gluco derivatives, it cannot be applied to the synthesis of kidamycin without 
a deoxygenation step since the required substitution on the C2-position of the pyranose 
ring of both sugars in kidamycin are deoxy;  therefore, a different method to install the 




































OBn 1) BuLi, THF, -78 oC; 
    then Et2SiCl2




Suzuki has also developed a nice method for preparing C-aryl glycosides via an O 
→   C glycoside rearrangement.  This process involves a two-step reaction that proceeds 
in one pot in the presence of a Lewis acid, such as Cp2HfCl2—AgClO4 or BF3.OEt2.  
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The first step features O-glycosidation of a sugar derivative like 4.084a or b with phenol 
4.084 at low temperature to give the O-glycoside 4.086 (Scheme 4.22).212,213  4.086 was 
then converted in situ into ortho C-aryl glycoside 4.088 by raising the reaction 
temperature.  Warming can allow the reaction to equilibrate, and the α:β ratio of 4.088 
could be determined not only by kinetics but also by possible contribution of the ortho-




























4.084a X = F





For example, coupling sugar 4.089 with naphthol 4.090 provided the C-glycoside 
4.090.  When Cp2HfCl2—AgClO4 was used as the promoter, the β anomer 4.091 was 
isolated in 98% yield (Equation 4.3).  However, when BF3.OEt2 was used as the 
promoter, 4.091 was obtained in 70% yield as a 3.4:1 (α:β) ratio; 28% of the O-glycoside 


























Although acetyl protected sugars are less reactive than fluoro sugars, 1-O-acetyl 
sugars 4.084b are shelf stable, readily available, and nicely serve as efficient glycosyl 
donors in the O → C glycoside rearrangement.  For example, 4.93 and 4.090 were 
coupled to provide the C-aryl glycoside 4.094 in 99% yield (Equation 4.4).215  The 
product could be enriched in the α-anomer if the reaction was quenched at low-
temperature.  Amino sugars have also been shown to work well in the O → C 
rearrangement under specific conditions (1:3 molar ration of amino sugar to naphthol and 


















4.3.4 Synthetic Studies of Ring E: Anglosamine 
We felt that O  →  C glycoside rearrangement could be utilized to install the α-
glycoside ring F if we encounter problem with epimerization in our tether approach.  
Using Suzuki’s method could provide an alternative route to kidamycin.  Namely, 
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kidamycin (4.001) would arise from the coupling of sugar 4.095 and phenol 4.096 using 
Suzuki’s O → C rearrangement procedure (Scheme 4.23).  Phenol 4.097 could be 
obtained from cycloadduct 4.097 though tether cleavage and ring opening.  Cycloadduct 
4.097 could come from a benzyne Diels-Alder reaction using our newly developed tether 
protocol to control the regiochemistry of the cycloaddition.  Thus, it remained to 






























































The methyl ether 4.100 can be converted into ring A in a few steps (Scheme 
2.24).  Deprotection and oxidation should provide aldehyde 4.101.  Next, alkylation of 
the aldehyde will install the ene-enyne functionality in 4.102.  Oxidation to the ketone 
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followed by deprotection of the methyl ether should allow for the intramolecular 















































































P = protecting group  
 
No one has shown that benzyne chemistry is incompatible with the N,N-
dimethylamine functionality in ring E of kidamycin.  In 2000, Suzuki stated “benzyne 
chemistry…might be precluded by the presence of a dimethylamine function” in his 
synthesis of ravidomycin with no reference or reason given.216  However, this has not 
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been established in the literature that a dialkyl amino group would interfere with the 4+2 
cycloaddition.  Since this benzyne chemistry is unprecedented with amino sugars, we 
undertook a model study to prepare phenol 4.105 via the benzyne cycloaddition of amino 




















P = protecting group  
 
Due to the cost of L-rhamnal, we began with D-rhamnal, even thought it is the 
wrong enantiomer for the natural product (Scheme 4.26).  Diacetoxy D-rhamnal 4.108 
was deprotected using K2CO3 and MeOH to provide rhamnal (4.109) in quantitative 













K2CO3, MeOH MnO2, CH2Cl2
quant. 78%




The next step was the installation of an oxygen functionality at the anomeric 
position of 4.110.  A Michael-type addition was envisioned to achieve this conversion as 
such reactions had been reported in the literature using both acidic and basic 
conditions.218-220  However, attempts to prepare 4.111 from 4.110 via Michael addition 
failed under all conditions (Equation 4.5).  The most promising experiment involved 
stirring 4.110 with Ph3PHBr in MeOH until all starting material disappeared (3 days).  
An unidentified product was isolated that contained the desired C2 protons, anomeric 
proton(s) and methoxy peaks in the 1H NMR, but the peaks in the low resolution mass 




















Attempts to protect the C4 hydroxy moiety of 4.110 to provide 4.112 failed under 
standard conditions (BnBr, NaH) (Equation 4.6).  We recovered a compound that was 
missing signals for the C4 and C5 protons, and the olefinic protons for C1 and C2 were 
shifted downfield in the 1H NMR.  In the low resolution mass spectrum there was a peak 
corresponding to product minus 2 protons.  The structure of this product has tentatively 
been assigned as the dienone 4.113.  We suspect that hydroxy ketones are difficult to 
alkylate due to their low nucleophilicity.  In the future, the protection under acidic 




















We also tried to effect the reductive amination condition of the enone 4.110 to 
produce the desired N,N-dimethylamine 4.114 using Na(OAc)3BH; however, nothing 
useful was recovered (Equation 4.7).221  There are no reported examples of vinylogous 

















In the face these obstacles, this route to furylanglosamine 4.106 was abandoned.  
In the future it might be possible to convert the azide 4.116, which was previously 
obtained in 3 steps from 4.115 in 60% yield,180 to the desired N,N-dimethylamine 4.106 



















4.115 4.116 4.106  
 
4.3.5 Synthetic Studies of Ring F: N,N-Dimethylvancosamine 
We planned to obtain the 1-O-acetyl-vancosamine (4.095) required to apply 
Suzuki’s method to the synthesis of kidamycin through degradation of vancomycin.  1-O-
Methoxy-N-alloc carbamate vancosamine (4.118) has been previously obtained by 
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degradation of vancomycin (Equation 4.8).223  Thus, vancomycin hydrochloride was 
reacted with N-allyloxy(carbonyloxy) succinimide (4.117) under basic conditions, the 
product was precipitated from solution by adding acetone, and collected by filtration to 
give N,N’-dialloc vancomycin.  The crude material was then subjected to aqueous 
methanolysis under acidic conditions, and the byproducts were precipitated by adding 
acetone.  The filtrate was further purified using chromatography to give 4.118 together 
with a number of side products that remained on the baseline.  In the literature, the yield 
reported for this sequence is 115%.223  Further purification of the product using flash 



















After contacting the Kahne research group, which reported the N-alloc 
vancosamine work, they informed us that they now employ N-Cbz derivative in order to 
obtain the vancosamine sugar from vancomycin.  We, therefore, investigated the N-Cbz 
derivative.224  Thus, vancomycin hydrochloride was allowed to react with N-Cbz 
succinimide (4.119) under basic conditions.  Adding acetone precipitated the N,N’-diCbz 
vancomycin.  The solid then was subjected to acid methanolysis under anhydrous 
conditions.  Once the reaction was complete, the mixture was neutralized with 
bicarbonate, and the byproducts were precipitated with acetone.  The filtrate was purified 
using flash column chromatography to afford 4.120 in 71% yield as a mixture (1:1.5) of 




















We then decided to install a large silyl protecting group on the 4-hydroxy group  
because it is reported that large silylethers on pyranosides favor an axial disposition due 
to the gauche interaction when in the equatorial position (Figure 4.4)  In fact a 
triphenylsilylether has a surprisingly small A value (OSiMe3: A = 1.31 kcal mol-1 and 
OSiPh3: A = 0.71 kcal mol-1).225 
 




















The propensity for bulky silyl-protected hydroxyl groups to prefer axial 
orientation is exemplified by Suzuki’s use a large silyl protecting group to make the α-C-
aryl glycoside 4.121 as the sole detectable product in 91% yield;  an X-ray structure 
















We thus set out to convert 4.120 to 4.122.  However, under varied reaction 
conditions (Ph3SiCl, pyridine or Ph3SiCl, imidazole, DMAP227), substantial quantities of 
unreacted starting material were recovered (at least 34% recovered)  as shown in Scheme 
4.28.  In the future, the 1-methoxy group of 4.122 will be converted to the acetate 4.123.  
The yield of the silyation may also be improved by heating the reaction or modification 


















Someone may be able to apply Suzuki’s method in order to couple acetate 4.123 


































The α/β ratio for this reaction could be obtained at this point.  Additional steps for 
the synthesis of 4.095 include removal of the N-Cbz carbamate with hydrogenolysis 

















Hopefully in the future, we will attempt the O → C glycoside rearrangement to 























4.4 CONCLUSIONS AND FUTURE DIRECTIONS 
The Martin group has developed a facile approach to C-aryl glycosides using a 
disposable tether to control the regiochemistry of a benzyne cycloaddition that allows 
access to unsymmetrically substituted Group I and II C-aryl glycoside natural products.  
In the present work, this methodology was applied to the synthesis of Group III C-aryl 
glycosides.  The synthesis of the bis-sugar furan 4.070 was improved, and 4.070 was 
found to be a mixture of anomers.  The application of this method to the synthesis of 
kidamycin is underway.  Toward that end, some potential precursors for the ring E 
anglosamine and ring F N,N’-dimethylvancosamine were prepared.  In the future, 
Suzuki’s O → C glycoside rearrangement may be used to obtain the desired 
stereochemistry of the ring F sugar.  In addition, an unprecedented benzyne Diels-Alder 
cycloaddition in the presence of an amine might be used to install ring E.  It is still 
unknown if novel tether methodology can be applied to the synthesis of this interesting 




Chapter 5. Experimentals 
5.1  BIOLOGICAL MATERIALS AND METHODS 
 
5.1.1  Materials 
Escherichia coli cells, (SG13009, lon-) containing the GE-60 plasmid, were 
obtained from Schering-Plough Research Institute (Kenilworth, NJ).  Isopropyl-β-D-
thiogalactopyranoside (IPTG), was obtained from Acros/Fischer Scientific (Houston, 
TX).  Ethylenediaminetetraacetic acid (EDTA) was obtained from Fischer Scientific 
(Houston, TX). Kanamycin was purchased from SIGMA (St. Louis, MO).  The 
phosphotyrosine affinity column was synthesized using NHS-activated Sepharose 4 Fast 
Flow (Pharmacia Biotech, Piscataway, NJ) as described in the instruction manual (NHS-
activated Sepharose 4 Fast Flow INSTRUCTIONS).  The MCS isothermal titration 
calorimeter was obtained from MicroCal Corp. (Northampton, MA) 
5.1.2  Methods 
Bacterial Expression.  E coli cells, (SG13009, lon-) containing the GE-60 plasmid 
with a T5 promoter and the grb2-sh2 domain gene (primary amino acid sequence 53-163) 
were spread onto LB plates with kanamycin at 50 µg/mL and ampicillin at 100 µg/mL 
(LBkan50/amp100) and incubated at 37 °C for 24 h.  One colony from the plate was 
selected and grown in 30 mL  LBkan50/amp100 at 30 °C overnight (18 h) to make a starter 
culture that was poured into 1 L LBkan50/amp100 and grown at 30 °C at 225 rpm until an 
OD600 of 0.5 - 0.8  was obtained (approximately 3 - 4 h).  The cultures were induced with 
1 mM IPTG (234 mg) and grown at 30 °C and 225 rpm for 7 - 18 h.  The cells were 
centrifuged, and the pellet was stored at –78 °C.   
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Purification of the Isolated Grb2-SH2 domain from E coli.53  The pellet was 
resuspended in buffer A (25 mM Tris, pH 7.5) (22 mL) containing 1 mM EDTA.  A 
French Press (2 passages with 1,000 pressure each time) was used to lyse the cells 
(Sonication was an irreproducible method for lysing the cells).  Following centrifugation 
of the cell lysate, the supernatant containing soluble Grb2-SH2 protein was applied to a 
Q-Sepharose column using FPLC.  The column was washed with 10 mL buffer A, and 
sample containing Grb2-SH2 protein was recovered from unbound fractions.  These 
fractions were directly applied to the phosphotyrosine affinity column using FPLC.  This 
column was washed with buffer A, and the protein was eluted with buffer B (25 mM Tris, 
200 mM NaCl, pH 7.5).  The Grb2-SH2 fractions were > 98% pure, based on SDS-PAGE 
Coomassie-stained gels.  The fractions were pooled, concentrated and dialyzed against 50 
mM HEPES, 150 mM NaCl, pH 7.5. (ε = 15600 M -1 mL -1 or 1.2 mg -1 mL -1).  In a 
typical experiment, purification would yield approximately 15 – 30 mg of protein per L 
of LB broth.  
 
5.1.3  Isothermal Titration Calorimetry: 
Calorimetry experiments were preformed with an MCS titration calorimeter 
(Microcal Inc., Northhampton, MA) as described.53,54,105,121  Grb2-SH2 was dialyzed 
for 48 h with two exchanges of buffer (50 mM HEPES, 150 mM NaCl, pH 7.5) (1/1000 
v/v).  To reduce errors arising from heats of dilution due to buffer differences between 
samples in the syringe and the stirred vessel, lyophilized peptide ligands were suspended 
in the final dialysate from the Grb2-SH2 sample.  Protein and ligand solutions were 
degassed with stirring under reduced pressure for 15 min.  For a typical titration, Grb2-
SH2 domain (50 µM) was placed in the 1.4 mL reaction cell, and the ligand (0.7 mM) 
was loaded into the 250 µL injection syringe.  The solutions of ligands were injected in 4-
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6 µL increments.  At least five injections were typically preformed after saturation was 
observed.  All values are the result of at least three independent titration experiments.  
The data for each titration were collected and processed with the ORIGIN software 
provided with the calorimeter. The titration curves were fit using the same software to 
give ∆H and Ka (see Appendix for examples).  For each ligand, at each experimental 
temperature, a blank was run where the ligand was injected into buffer alone to establish 
the nonzero heat of dilution for the ligand.  This heat was subtracted from the raw 
titration data prior to fitting.  The integrated data from all experiments fits the single-site 
binding model with the stoichiometry of binding being between 0.95 and 1.12 for all 
titrations.  The estimated experimental error associated with each titration experiment is 
approximately 5 – 10%.228-230  
5.1.4  ln P: 
Volume fraction octanol to water partition coefficients were measured.  
Pseudopeptides were dissolved dialysate buffer from the Grb2-SH2 samples (See Section 
5.1.3).  Due to the pKa of phosphotyrosine, the pH of the buffer was changed from 7.5 to 
2.0 by adding HCl.170,171  At pH 7.5, no pseudopeptide was present in the octanol phase.  
The final concentration of the buffer solutions was 0.7 mM.  The buffer ligand solution 
was saturated with octanol by adding 10 µL of octanol to the solution to provide the 
pseudopeptide stock solution.  Octanol was also saturated with buffer by adding 10 µL of 
the buffer to the octanol to provide the octanol solution.  Solutions of pseudopeptide 
stock (1 mL) and octanol (1 mL) were placed in a screw cap vial mixed for 12 h at 225 
rpm and 25 oC.  After equilibration, the concentrations of the pseudopeptide in the buffer 
phase and in the pseudopeptide stock solution were measured using a UV/vis 
spectrometer.  The A280 was recorded in triplicate and averaged.  The volume formation 
partition coefficients are defined by P = Pb/Po where Pb and Po are the pseudopeptide 
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concentrations in the buffer and octanol phases, respectively.  The pseudopeptide 
concentration in the octanol phase was determined indirectly by comparing the 
concentration in the buffer phase with that of the pseudopeptide stock solution so that P = 
Pb/(Ps - Pb) where Ps is the relative concentration of the pseudopeptide in the stock 
solution.  The mole-fraction partition coefficients were calculated from the P by 
multiplying the value by 0.114 (the ratio of the molar volumes of water and octanol.  The 
values were then converted into free energy using ∆G = -RT ln (P * 0.114) and shown in 
Table 5.1.35,37 
 
Table 5.1:  Partition Coefficients for pseudopeptides. 
 
compound P ∆G kcal mol-1
2.004 1.03 1.28
2.005 0.886 1.37
difference -0.09  
  
5.2  ORGANIC SYNTHESIS 
5.2.1  General 
Solvents and reagents were reagent grade and were used without purification 
unless noted otherwise.  Tetrahydrofuran (THF) and ether (Et2O) were dried by passage 
through two columns of activated neutral alumina.  Methanol (MeOH), acetonitrile 
(CH3CN) and N, N-dimethylformamide (DMF) were dried by passage through two 
columns of activated molecular sieves. Triethylamine (Et3N), N-methylmorpholine 
(NMM), 2.6-lutidine and diisopropylethylamine (iPr2NEt) were distilled from calcium 
hydride.  Trifluoromethanesulfonic anhydride (Tf2O) was distilled from phosphorus 
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pentoxide.  Trifluoroacetic acid (TFA) was distilled prior to use.  Toluene was dried by 
sequential passage through a column of activated neutral alumina followed by a column 
of Q5 reactant.  Reactions involving air- or moisture-sensitive reagents or intermediates 
were performed under argon in glassware that had been flame-dried.  Solvents were 
removed under reduced pressure with rotary evaporation at 15 mm Hg (30 oC bath temp).  
Flash chromatography was preformed following the Still231 protocol with the indicated 
solvents and Merck 250-400 mesh silica gel.  Analytical TLC was preformed with 
Merck-60 TLC plates and the indicated solvents. 
Melting points were determined on a Thomas-Hoover melting point apparatus and 
are uncorrected.  Infrared (IR) spectra were obtained using a Perkin-Elmer FTIR 1600 
series spectrometer as solutions in CHCl3 or CDCl3.  Proton (1H) and Carbon 13 (13C) 
nuclear magnetic resonance (NMR) were obtained using a Varian Unity Plus (300 MHz) 
or Varian Unity Plus (500 MHz) spectrometer as solutions in CDCl3, unless otherwise 
indicated.  Chemical shifts are reported in parts per million (ppm, δ) and are referenced 
relative to the 7.26 ppm resonance of CDCl3 for 1H and center of the triplet resonance of 
CDCl3 at 77.0 ppm unless otherwise indicated.  Coupling constants are reported in hertz 
(Hz).  Splitting patterns are designated as s, singlet; d, doublet; t, triplet; q, quartet; p, 
pentuplet; hep, heptet; m, multiplet; comp, complex multiplet; br, broad; app apparent.  
Low-resolution chemical ionization mass (CI) or fragment atomic bombardment (FAB) 
spectra were obtained on a Finnigan TSQ-70 instrument.  High-resolution chemical 











3-(4-tert-Butoxyphenyl)acrylic acid. (hrp1-045).  A mixture of Na2CO3 (3.22 g, 
30.4 mmol), acrylic acid (1.03 mL, 15 mmol), tert-butylammonium bromide (161.19 mg, 
0.5 mmol), palladium (II) chloride (18 mg, 0.1 mmol) and 4-tert-butoxyphenyl bromide 
(2.019) (2.29 g, 10 mmol) in freshly distilled H2O (59 mL) under argon was stirred 
vigorously at rt for 15 min and then heated under reflux for 14.5 h.  The reaction mixture 
was then cooled to rt and filtered through a pad of Celite.  The pad was washed with sat. 
NaHCO3 (2 x 25 mL).  The filtrate and washings were washed with Et2O (1 x 25 mL) 
and then acidified with 1 M HCl to pH 1.0.  The aqueous layer was extracted with Et2O 
(3 x 25 mL).  The organic layers were combined, washed with brine (1 x 25 mL), dried 
(NaSO4) and concentrated under reduced pressure to yield 1.89 g of 3-(4-tert-





















2-Bromo-N-(2,4-dimethoxybenzyl)-N-methyl acetamide (2.022).  Et3N (20 
mL, 150 mmol) and bromoacetyl bromide (2.18 mL, 25 mmol) were added to 2.021121 
(5.4 g, 25 mmol) in CHCl3 (200 mL) at –78 °C.  The reaction was stirred at –78 °C for 30 
min and then the cold bath was removed and the reaction slowly warmed to rt over 1 h.  
H2O (50 mL) was then added and the layers were separated.  The organic layer was 
washed with 2 M HCl (1 x 50 mL), sat. NaHCO3 (1 x 50 mL), brine (1 x 50 mL), dried 
(MgSO4) and then concentrated under reduced pressure to yield 4.65 g of 2.022 as a 
yellow oil (62%).  Compound exists as a mixture (40:60) of 2 rotamers at rt; 1H NMR 
(500 MHz) δ 7.15, (d, J = 8.9 Hz, 0.4 H), 7.00 (d, J = 8.7 Hz, 0.6 H), 6.47- 6.44 (comp, 2 
H), 4.54 (s, 0.8 H), 4.46 (s, 1.2 H), 4.03 (s, 1.2 H), 3.89 (s, 0.8 H), 3.80-3.78 (comp, 6 H), 
3.00 (s, 0.8 H), 2.88 (s, 1.2 H); 13C NMR (125 MHz) δ 166.8, 166.4, 160.7, 160.2, 158.3, 
158.4, 130.1, 129.0, 116.8, 115.8, 104.1, 103.9, 98.5, 98.1, 55.1, 49.6, 45.3, 41.4, 35.4, 
33.3, 26.6, 26.4; IR (CHCl3) 3003, 1645, 1614, 1507, 1464, 1158 cm-1; mass spectrum 
(CI) m/z 302.0396 [C12H17NO3Br (M+1) requires 302.0392], 302, 222. 
 NMR Assignments.  Rotamer 1 (40%) 1H NMR (500 MHz) δ 7.15, (d, J 
= 8.9 Hz, 0.4 H, C7-H), 6.47-6.44 (comp, 2 H, C9-H & C10-H), 4.54 (s, 0.8 H, C4-H), 
3.89 (s, 0.8 H, C1-H), 3.80-3.78 (comp, 6 H, C11-H & C12-H), 3.00 (s, 0.8 H, C3-H); 
13C NMR (125 MHz) δ 166.4 (C2), 160.2 (C8, C6 or C5), 158.3 (C8, C6 or C5), 130.1 
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(C7), 116.8 (C8, C6 or C5), 103.9 (C9 or C10), 98.1 (C9 or C10), 55.1 (C11 & C12), 
45.3 (C4), 35.4 (C3), 26.6 (C1). 
NMR Assignments. Rotamer 2 (60%) 1H NMR (500 MHz) δ 7.00 (d, J = 8.7 Hz, 
0.6 H, C7-H), 6.47- 6.44 (comp, 2 H, C9-H & C10-H), 4.46 (s, 1.2 H, C4-H), 4.03 (s, 1.2 
H, C1-H), 3.80-3.78 (comp, 6 H, C11-H & C12-H), 2.88 (s, 1.2 H, C3-H); 13C NMR 
(125 MHz) δ 166.8 (C2), 160.7 (C8, C6 or C5), 158.4 (C8, C6 or C5), 129.0 (C7), 115.8 
(C8, C6 or C5), 104.1 (C9 or C10), 98.5 (C9 or C10), 49.6 (C11 & C12), 41.4 (C4), 33.3 























(1S, 1’S)-[1-(1, 2)-Dicarbamoylethylcarbamoyl)-2-methylpropyl]carbamic 
acid tert-butyl ester (2.029). (hrp1-084).  N-Methylmorpholine (NMM) (0.3 mL, 3.0 
mmol), 1-(3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC) (210 mg, 
1.1 mmol) and 1-hydroxybenzotriazole hydrate (HOBT) (270 mg, 2 mmol) were added to 
a solution of Boc-Valine (217 mg, 1.0 mmol) in DMF (30 mL) at –10 °C (ice-salt bath) .  
The mixture was stirred at –10 °C for 1 h, and then asparagine-amide-HCl salt (218 mg, 
1.3 mmol) was added.  The mixture was stirred at –10 °C for 30 min and then at rt for 16 
h.  The mixture was concentrated under reduced pressure, and the yellow residue was 
triturated with sat. NaHCO3 (2 x 15 mL), 0.5 M HCl (2 x 15 mL), and H2O (1 x 10 mL) 
to yield 237 mg of 2.029 (72%) as a white solid: mp 200-205 °C, dec; 1H NMR (300 
MHz, CD3OD) δ 4.70 (t, J = 5.7 Hz, 1 H), 3.80 (d, J = 6.0 Hz, 1 H), 2.81-2.66 (comp, 2 
 183
H), 2.10-2.01 (comp, 1 H), 1.45 (s, 9 H), 0.95 (dd, J = 9.0, 6.9 Hz, 6 H); 13C NMR (75 
MHz, DMSO-d6) δ 172.8, 171.8, 171.0, 155.9, 78.4, 60.3, 49.4, 36.6, 29.9, 28.2, 19.1, 
18.0; mass spectrum (CI) m/z 331.1975 [C14H27N4O5 (M+1) requires 331.1981], 275 
(base), 231. 
NMR Assignments. 1H NMR (300 MHz, CD3OD) δ 4.70 (t, J = 5.7 Hz, 1 H, C5-
H), 3.80 (d, J = 6.0 Hz, 1 H, C1-H), 2.81-2.66 (comp, 2 H, C7-H), 2.10-2.01 (comp, 1 H, 
C2-H), 1.45 (s, 9 H, C11-H), 0.95 (dd, J = 7.0, 9.0 Hz, 6 H, C3-H & C3’-H); 13C NMR 
(75 MHz, DMSO) δ 172.8 (C6, C8 or C4), 171.8 (C6, C8 or C4), 171.0 (C6, C8 or C4), 
155.9 (C9), 78.4 (C10), 60.3 (C1), 49.4 (C5), 36.6 (C7), 29.9 (C2), 28.2 (C11), 19.1 (C3), 
18.0 (C3’). 
 















(1S, 1’S)-1-(1, 2)-Dicarbamoylethylcarbamol)-2-methylpropyl ammonium 
trifluoroacetate salt (2.012). (hrp1-157).  A solution of 2.029 (94 mg, 0.285 mmol) in 
neat TFA (1 mL) was stirred for 2 h at rt.  The reaction mixture was concentrated under 
reduced pressure.  The white foam residue was recrystallized in hot isopropyl alcohol (3 
mL) to yield 94 mg of 2.012 (96%) as a white powder: mp 125-127 oC; 1H NMR (300 
MHz, CD3OD) δ 4.77 (dd, J = 8.2, 5.8 Hz, 1 H), 3.70 (d, J = 6.8 Hz, 1 H), 2.78 (dd, J = 
15.9, 5.8 Hz, 1 H), 2.67 (d, J = 15.9, 8.2 Hz, 1 H ), 2.21 (app hep, J = 6.9 Hz, 1 H), 1.04 
(t, J = 6.9 Hz, 6 H); 13C NMR (75 MHz, CD3OD) δ 175.0, 174.6, 169.5, 59.7, 51.4, 37.8, 
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31.5, 18.9, 17.9; IR 3407, 1668, 1208, 1138 cm-1, mass spectrum (CI) m/z 231.1457 
[C9H19N4O3 (M+1) requires 231.1457], 232, 246, 214, 115. 
NMR Assignments.  1H NMR (300 MHz, CD3OD) δ 4.77 (dd, J = 8.2, 5.8 Hz, 1 
H, C5), 3.70 (d, J =  6.8 Hz, 1 H, C1), 2.78 (dd, J = 15.9, 5.8 Hz, 1 H, C7-H), 2.67 (d, J = 
15.9, 8.2 Hz, 1 H, C7’-H ), 2.21 (app hep, J = 6.9 Hz, 1 H, C2), 1.04 (t, J = 6.9 Hz, C3 & 
C3’); 13C NMR (75 MHz, CD3OD) δ 175.0 (C6, C8 or C4), 174.6 (C6, C8 or C4), 169.5 



















































(1R, 2S, 3R, 1S’, 1S’’) Phosphoric acid dibenzyl ester 4-{2-[1-(1,2-
dicarbamoylethylcarbamoyl)-2-methylpropylcarbamoyl]-3-methylcarbamoyl 
cyclopropyl}phenyl ester (2.033). (hrp1-187).  2,6-Lutidine (14 mg, 15 µL, 0.13 mmol) 
and then HATU (16 mg, 0.042 mmol) were added to a solution of 2.012 (15 mg, 0.042 
mmol) and 2.012 (21 mg, 0.042 mmol) in DMF (1 mL) at –10 oC (ice-salt bath).  The 
mixture was stirred at –10 oC for 1 h and then stirred at rt for 12 h.  The mixture was 
concentrated under reduced pressure, and the yellow residue was triturated with sat. 
NaHCO3 (2 x 15 mL), 0.5 M HCl (2 x 15 mL), and H2O (1 x 10 mL) to yield 26 mg of # 
(87%) as a white solid:  mp 226-227 oC, dec; 1H NMR (300 MHz, DMSO-d6) δ 8.53 (d, 
 185
J = 7.6 Hz, 1 H), 8.11 (d, J = 8.0 Hz, 1 H), 8.09-8.06 (m, 1 H), 7.41-7.35 (comp, 10 H), 
7.29-7.28 (comp, 3 H), 7.06-7.00 (comp, 4 H) 6.82 (br s, 1 H), 5.12 (d, J = 8.2 Hz, 4 H), 
4.44 (dd, J = 14.0, 6.0 Hz, 1 H), 4.07 (t, J = 6.6 Hz, 1 H), 3.02-2.99 (m, 1 H), 2.59 (dd, J 
= 9.6, 6.0 Hz, 1 H),  2.61-2.43 (comp, 5 H), 2.38-2.35 (m, 1 H), 2.00 (app hep, J = 6.6 
Hz, 1 H), 0.88 (d, J = 6.6 Hz, 6 H); 13C NMR (75 MHz, DMSO-d6) δ 172.8, 171.7, 
171.0, 170.6, 167.3, 148.6, 135.7, 135.6, 133.2, 130.4, 128.5, 128.0, 119.0, 69.3, 58.8, 
49.5, 36.6, 30.1, 29.9, 25.7, 25.6, 19.1, 18.1; mass spectrum (CI) m/z 708.2789 
[C35H43N5O9P (M+1) requires 708.2798], 273 (base), 545. 
NMR Assignments. 1H NMR (300 MHz, DMSO) δ 8.53 (d, J = 7.6 Hz, 1 H, N-
H), 8.11 (d, J = 8.0 Hz, 1 H, N-H), 8.09-8.06 (m, 1 H, N-H), 7.41-7.35 (comp, 10 H, 
C21-H & C21’-H, C22-H & C22’-H & C23-H), 7.29-7.28 (comp, 3 H, C7-H, C7’-H or 
C8-H, C8’-H & N-H), 7.06-7.00 (comp, 4 H, C7-H, C7’-H or C8-H, C8’-H & N-H) 6.82 
(br, 1 H, N-H), 5.12 (d, J = 8.2 Hz, 4 H, C19-H), 4.44 (dd, J = 6.0, 14.0 Hz, C15-H), 
4.07 (t, J = 6.6 Hz, 1 H, C11-H), 3.02-2.99 (m, 1 H, C4-H) 2.59 (dd, J = 9.6, 6.0 Hz,1 H, 
C5-H), 2.61-2.43 (comp, 5 H, C16-H & C1-H), 2.38-2.35 (m, 1 H, C3-H), 2.00, (app hep, 
J = 6.6 1 H, C12-H), 0.88 (d, J = 6.8 Hz, 6 H, C13-H & C13’-H); 13C NMR (75 MHz, 
DMSO) δ 172.8 (C2, C10, C14, C17 or C18), 171.7 (C2, C10, C14, C17 or C18), 171.0 
(C2, C10, C14, C17 or C18), 170.6 (C2, C10, C14, C17 or C18), 167.3 (C2, C10, C14, 
C17 or C18), 148.6 (C6, C9, C21, C21’, C22, C22’ or C23), 135.7 (C6, C9, C21, C21’, 
C22, C22’ or C23), 135.6 (C6, C9, C21, C21’, C22, C22’ or C23), 133.2 (C6, C9, C21, 
C21’, C22, C22’ or C23), 130.4 (C8 & C8’), 128.5 (C21, C21’, C22, C22’ or C23), 128.0 
(C21, C21’, C22, C22’ or C23), 119.0 (C7 & C7’), 69.3 (C19), 58.8 (C11), 49.5 (C15), 







































(1R, 2S, 3R, 1S’, 1S’’) Phosphoric acid mono-(4-{2-[1-(1,2-dicarbamoyl 
ethylcarbamoyl)-2-methylpropylcarbamoyl]-3-methylcarbamoylcyclopropyl} 
phenyl) ester (2.004). (hrp1-191)  A solution of 2.033 (5 mg, 0.007 mmol) in EtOH and 
H2O (1:1, 2 mL) containing 10 % Pd/C (5 mg) was stirred under H2 (1 atm) for 13 h.  
The catalyst was removed by filtration through a pad of celite, and the filtrate was 
concentrated under reduced pressure to yield 4 mg of 2.004 (100%) as a white solid:  mp 
262-265 oC, dec; 1H NMR (500 MHz, D2O) δ 7.27 (d, J = 8.7 Hz, 2 H), 7.12 (d, J = 7.4 
Hz, 2 H), 4.73-4.70 (m, 1 H), 4.13 (d, J = 6.9 Hz, 1 H), 2.96-2.94 (m, 1 H), 2.87-2.84 
(comp, 2 H), 2.76-2.74 (m, 1 H), 2.60 (s, 3 H), 2.54 (dd, J = 10.0, 4.8 Hz, 1 H), 2.17-2.08 
(m, 1 H), 0.99 (d , J = 8.1 Hz, 3 H), 0.97 (d , J = 8.1 Hz, 3 H);13C NMR (125 MHz, D2O) 
δ 174.7, 174.4, 173.6, 173.4, 170.3, 150.8, 130.5, 129.8, 120.2, 60.3, 50.0, 36.0, 30.0, 
29.9, 29.5, 25.7, 25.6, 18.0, 17.4; mass spectrum (FAB +) m/z 528.1867 [C21H31N5O9P 
(M+1) requires 528.1859], 275 (base), 526. 
NMR Assignments.  1H NMR (300 MHz, D2O) δ 7.27 (d, J = 8.7 Hz, 2 H, C7-H, 
C7’-H or C8-H, C8’-H), 7.12 (d, J = 7.4 Hz, 2 H, C7-H, C7’-H or C8-H, C8’-H), 4.73-
4.70 (m, 1 H, C15-H), 4.13 (d, J = 6.9 Hz, 1 H, C11-H), 2.96-2.94 (m, 1 H, C4-H), 2.87-
2.84 (comp, 2 H, C5-H & C16-H), 2.76-2.74 (m, 1 H, C16-H), 2.60 (s, 3 H, C1-H), 2.54 
(dd, J = 10.0, 4.8 Hz, 1 H, C3-H), 2.17-2.08 (m, 1 H, C12-H), 0.99 (d , J = 8.1 Hz, 3 H, 
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C13-H), 0.97 (d , J = 8.1 Hz, 3 H, C13’-H);13C NMR (75 MHz, D2O) δ 174.7 (C2, C10, 
C14, C17 or C18), 174.4 (C2, C10, C14, C17 or C18), 173.6 (C2, C10, C14, C17 or 
C18), 173.4 (C2, C10, C14, C17 or C18), 170.3 (C2, C10, C14, C17 or C18), 150.8 (C6 
or C9), 130.5 (C6 or C9), 129.8 (C7, C7’ or C8, C8’), 120.2 (C7, C7’ or C8, C8’), 60.3 
(C11), 50.0 (C15), 36.0 (C16), 30.0 (C3), 29.9 (C5), 29.5 (C12), 25.7 (C4), 25.6 (C11), 

















































(2S, 1S’, 1S’’) Phosphoric acid dibenzyl ester 4-{2-[1-(1,2-dicarbamoyl 
ethylcarbamoyl)-2-methylpropylcarbamoyl]-3-methylcarbamoylpropyl}phenyl ester 
(2.034). (hrp2-188)  2,6-Lutidine (12 mg, 13 µL, 0.11 mmol) and HATU (14 mg, 0.036 
mmol) were added to a solution of 2.012 (12 mg, 0.036 mmol) and 2.011 (18 mg, 0.036 
mmol) in DMF (1 mL) at –10 oC (ice-salt bath).  The mixture was stirred at –10 oC for 1 
h and then at rt for 12 h.  The mixture was concentrated under reduced pressure, and the 
yellow residue was triturated with sat. NaHCO3 (2 x 15 mL), 0.5 M HCl (2 x 15 mL), 
and H2O (1 x 10 mL) to yield 20 mg of 2.034 (77%) as a white solid:  mp 119-201 oC; 
1H NMR (500 MHz, DMSO-d6) δ 7.99 (d, J = 7.9 Hz, 1 H), 7.91 (d, J = 8.0 Hz, 1 H), 
7.67-7.65 (m, 1 H), 7.38-7.31 (comp, 10 H), 7.30-7.29 (m, 1 H), 7.18 (d, J = 8.5 Hz, 2 
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H), 7.07 (d, J = 8.3 Hz, 2 H), 6.86 (br s, 1 H), 5.13 (d, J = 8.2 Hz, 4 H), 4.43 (dd, J = 
14.0, 7.0  Hz, 1 H), 4.03 (dd, J = 7.8, 6.4 Hz, 1 H), 3.07-3.05 (m, 1 H), 2.94-2.90 (m, 1 
H), 2.50-2.47 (comp, 5 H), 2.33 (dd, J = 14.5, 9.6 Hz, 1 H), 2.00-1.94 (comp, 1 H), 0.83 
(t, J = 6.0 Hz, 6 H); 13C NMR (125 MHz, DMSO-d6) δ 174.2, 172.7, 171.7, 170.9, 170.6, 
148.5, 148.4, , 136.4, 135.7, 135.6, 130.3, 128.5, 127.9, 119.6, 69.3, 58.3, 49.4, 42.9, 
36.8, 36.6, 36.55, 30.1, 25.4, 19.0, 17.9; mass spectrum (CI) m/z 710.2942 
[C35H45N5O9P (M+1) requires 710.2955], 570 (base), 693, 710. 
NMR Assignments. 1H NMR (300 MHz, DMSO-d6) 7.99 (d, J = 7.9 Hz, 1 H, N-
H), 7.91 (d, J = 8.0 Hz, 1 H, N-H), 7.67-7.65 (m, 1 H, N-H), 7.38-7.31 (comp, 10 H, 
C21-H & C21’-H, C22-H & C22’-H & C23-H), 7.30-7.29 (m, 1 H, N-H), 7.18 (d, J = 8.5 
Hz, 2 H, C7-H, C7’-H or C8-H, C8’-H), 7.07 (d, J = 8.3 Hz, 2 H, C7-H, C7’-H or C8-H, 
C8’-H), 6.86 (br, 1 H, N-H), 5.13 (d, J = 8.2 Hz, 4 H, C19-H), 4.43 (dd, J = 7.0, 14.0 Hz, 
C15-H), 4.03 (dd, J = 7.8, 6.4 Hz,1 H, 11-H), 3.07-3.05 (m, 1 H, C4-H), 2.94-2.90 (m, 1 
H, C5-H), 2.50-2.47 (comp, 5 H, C16-H & C1-H), 2.33 (dd, J = 14.5, 9.6 Hz, 1 H, C3-H), 
2.00-1.94, (comp, 3 H, C3-H, C5-H & C12-H), 0.83 (t, J = 6.0 Hz, 6 H, C13-H & C13’-
H); 13C NMR (75 MHz, DMSO) δ 174.2 (C2, C10, C14, C17 or C18), 172.7(C2, C10, 
C14, C17 or C18), 171.7(C2, C10, C14, C17 or C18), 170.9(C2, C10, C14, C17 or C18), 
170.6 (C2, C10, C14, C17 or C18), 148.5 (C6, C9, C21, C21’, C22, C22’ or C23), 148.4 
(C6, C9, C21, C21’, C22, C22’ or C23), 136.4 (C6, C9, C21, C21’, C22, C22’ or C23), 
135.7 (C6, C9, C21, C21’, C22, C22’ or C23), 135.6 (C6, C9, C21, C21’, C22, C22’ or 
C23), 130.3 (C8 & C8’), 128.5 (C21, C21’, C22, C22’ or C23), 127.9 (C21, C21’, C22, 
C22’ or C23), 119.6 (C7 & C7’), 69.3 (C19), 58.3 (C11), 49.4 (C15), 42.9 (C4), 36.8 



































(2S, 1S’, 1S’’) Phosphoric acid mono-(4-{2-[1-(1,2-dicarbamoyl 
ethylcarbamoyl)-2-methylpropylcarbamoyl]-3-methylcarbamoylpropyl}phenyl) 
ester (2.005). (hrp1-196).  A solution of 2.034 (29 mg, 0.041 mmol) in EtOH and H2O 
(1:1, 10 mL) containing 10 % Pd/C (10 mg) was stirred under H2 (1 atm) for 13 h.  The 
catalyst was removed by filtration through a pad of celite, and the filtrate was 
concentrated under reduced pressure to yield 22 mg of 2.005 (100%) as a white solid:  
mp 179-181 oC, dec; 1H NMR (500 MHz, D2O) δ 7.17-7.09 (comp, 4 H), 4.57 (dd, J = 
7.7, 6.1 Hz, 1 H), 3.96 (d, J = 7.8 Hz, 1 H), 3.13-3.08 (m, 1 H), 2.81-2.77 (comp, 3 H), 
2.68-2.65 (m, 1 H), 2.64 (s, 3 H), 2.53-2.41 (comp, 2 H), 1.93 (app hep, J = 6.8 Hz, 1 H), 
0.85 (d, J = 6.8 Hz, 6 H);13C NMR (125 MHz, D2O) δ 179.1, 177.4, 177.1, 176.7, 175.5, 
136.2, 133.0, 132.8, 123.1, 62.2, 52.9, 47.8, 40.8, 39.9, 38.9, 32.8, 28.6, 20.9, 20.4; mass 
spectrum (FAB +) m/z 530.2009 [C21H33N5O9P (M+1) requires 530.2000], 531 (base). 
NMR Assignments. 1H NMR (500 MHz, D2O) δ 7.17-7.09 (comp, 4 H, C7-H & 
C8-H) 4.57 (dd, J = 7.7, 6.1 Hz, 1 H, C15-H), 3.96 (d, J = 7.8 Hz, 1 H, C11-H), 3.13-3.08 
(m, 1 H, C4-H), 2.81-2.77 (comp, 3 H, C1-H & C16-H), 2.68-2.65 (m, 1 H, C16’-H), 
2.64 (s, 3 H, C1-H), 2.53-2.41 (comp, 2 H, C3-H), 1.93 (app hep, J = 6.8 Hz, 1 H, C12-
H), 0.85 (d, J = 6.8 Hz, 6 H, C13-H);13C NMR (125 MHz, D2O) δ 179.1, 177.4, 177.1, 

















































(2S, 1S’, 1S’’) Phosphoric acid 4-{acetylamino-[1-[(1,2-
dicarbamoylethylcarbamoyl)-2-methylpropylcarbamoyl]methyl}phenyl)ester benzyl 
ester methyl ester (2.031). (hrp1-228)  2,6-Lutidine (40 µL, 0.36 mmol) and HATU (46 
mg, 0.12 mmol) were added to a solution of 2.012 (58 mg, 0.12 mmol) and 2.030 (41 mg, 
0.12 mmol) in DMF (1 mL) at –10 oC (ice-salt bath).  The mixture was stirred at –10 oC 
for 1 h and then rt for 12 h.  The mixture was concentrated under reduced pressure to 
yield a yellow solid that was triturated with CHCl3 (1 x 5 mL), 0.5 M HCl (1 x 5 mL), 
and H2O (1 x 5 mL) to give a white solid.  The crude material was purified by flash 
column chromatography eluting with CH3Cl/ MeOH (7:1) to yield 33 mg (40%) of 2.031 
as a white solid:  mp 208-211 oC; 1H NMR (500 MHz, DMSO-d6) δ 8.10 (d, J = 8.3 Hz, 
1 H), 8.06 (d, J = 7.8 Hz, 1 H), 8.00 (d, J = 8.1 Hz, 1 H) 7.39-7.32 (comp, 11 H), 7.26 (d, 
J = 8.6 Hz, 2 H), 7.07 (d, J = 7.8 Hz, 2 H), 7.02 (d, J = 17.3 Hz, 2 H), 6.87 (br s, 1 H), 
5.14 (d, J = 8.3 Hz, 2 H), 5.12 (d, J = 8.3 Hz, 2 H), 4.57, (ddd, J = 10.5, 8.3, 3.7 Hz, 1 H), 
4.45 (dd, J = 14.0, 6.4 Hz, 1 H), 4.10 (dd, J = 8.1, 6.6 Hz, 1 H) 3.01 (dd, J = 14.1, 3.7 Hz, 
1 H), 2.70 (dd, J = 14.1, 10.5 Hz, 1 H), 2.53-2.43 (m, 2 H), 2.00 (ap hep, J = 6.6 Hz, 1 
H), 1.73 (s, 3 H), 0.86 (d, J = 6.6 Hz, 3 H), 0.84 (d, J = 6.6 Hz, 3 H); 13C NMR (125 
MHz, DMSO-d6) δ 172.7, 171.8, 171.6, 170.4, 169.2, 135.7, 135.6, 135.2, 130.5, 128.5, 
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127.9, 119.4, 69.3, 58.0, 53.7, 49.5, 36.7, 36.4, 30.3, 22.3, 19.1, 17.9; mass spectrum (CI) 
m/z 696.2801 [C34H42N5O9P (M+1) requires 696.2798], 574 (base), 484, 466. 
NMR Assignments. 1H NMR (500 MHz, DMSO-d6) δ 8.10 (d, J = 8.3 Hz, 1 H, 
N-H), 8.06 (d, J = 7.8 Hz, 1 H, N-H), 8.00 (d, J = 8.1 Hz, 1 H, N-H) 7.39-7.32 (comp, 11 
H, C20-H, C20’-H, C21-H, C21’-H, C22-H, & N-H), 7.26 (d, J = 8.6 Hz, 2 H, C15-H & 
C15’-H or C16-H & C16’-H), 7.07 (d, J = 7.8 Hz, 2 H, C15-H & C15’-H or C16-H & 
C16’-H), 7.02 (d, J = 17.3 Hz, 2 H, N-H), 6.87 (br s, 1 H, N-H), 5.14 (d, J = 8.3 Hz, 2 H, 
C18-H), 5.12 (d, J = 8.3 Hz, 2 H, C18’-H), 4.57, (ddd, J = 10.5, 8.3, 3.7 Hz, 1 H, C10-H), 
4.45 (dd, J = 14.0, 6.4 Hz, 1 H, C4-H), 4.10 (dd, J = 8.1, 6.6 Hz, 1 H, C6-H) 3.01 (dd, J = 
14.1, 3.7 Hz, 1 H, C11-H), 2.70 (dd, J = 14.1, 10.5 Hz, 1 H, C11-H), 2.53-2.43 (m, 2 H,  
C3-H), 2.00 (ap hep, J = 6.6 Hz, 1 H, C7-H), 1.73 (s, 3 H, C13-H), 0.86 (d, J = 6.6 Hz, 3 
H, C8-H), 0.84 (d, J = 6.6 Hz, 3 H, C8’-H); 13C NMR (125 MHz, DMSO-d6) δ 172.7 
(C1, C2, C5, C9, or C12), 171.8 (C1, C2, C5, C9, or C12), 171.6 (C1, C2, C5, C9, or 
C12), 170.4 (C1, C2, C5, C9, or C12), 169.2 (C1, C2, C5, C9, or C12), 135.7 (C14, C17 
or C19), 135.6 (C14, C17 or C19), 135.2 (C14, C17 or C19), 130.5 (C15 or C16), 128.5 
(C20 & C21 or C22), 127.9 (C20 & C21 or C22), 119.4 (C15 or C16), 69.3 (C18), 58.0 





































(2S, 1S’, 1S’’) Phosphoric acid mono-(4-{acetylamino-[1-[(1,2-
dicarbamoylethylcarbamoyl)-2-methylpropylcarbamoyl]methyl}phenyl)ester 
(2.003). (hrp1-238)  A mixture of 2.031 (20 mg, 0.029 mmol) in EtOH and H2O (1:1, 4 
mL total) containing 10% Pd/C (10 mg) was stirred under H2 (1 atm) for 13 h.  The 
mixture was then filtered through a pad of celite.  The filtrate was concentrated under 
reduced pressure to yield 23 mg (89%)of 2.003 as a white solid:  mp 208-211 oC; 1H 
NMR (500 MHz, D2O) δ 7.20 (d, J =  8.6 Hz, 2 H), 7.14-7.12 (comp, 2 H), 4.63 (dd, J = 
8.0, 6.0 Hz, 1 H), 4.58 (dd, J = 8.0, 7.0 Hz, 1 H), 4.06 (d, J = 7.6 Hz, 1 H), 3.05 (dd, J = 
13.9, 7.0 Hz, 1 H), 2.96 (dd, J = 13.9, 8.0 Hz, 1 H), 2.81 (dd, J = 15.5, 6.0 Hz, , 1 H), 
2.75-2.71 (m, 1 H), 2.00 (ap hep, J =6.8 Hz, 1 H), 1.95 (s, 3 H), 0.90 (d, J = 6.8 Hz, 3 H), 
0.89 (d, J = 6.8 Hz, 3 H); 13C NMR (125 MHz, D2O) δ 177.4, , 177.1, 176.8, 176.2, 
175.4, 153.7, 134.7, 133.0, 123.2, 62.1, 57.8, 53.0, 39.0, 38.9, 33.0, 24.3, 20.9, 20.3; 
mass spectrum (FAB -) m/z 515.1776 [C20H30N5O9P (M-1) requires 515.1781], 245 
(base) 275. 
NMR Assignments. 1H NMR (500 MHz, D2O) δ 7.20 (d, J =  8.6 Hz, 2 H, C15-
H & C15’-H or C16-H & C16’-H), 7.14-7.12 (comp, 2 H, C15-H & C15’-H or C16-H & 
C16’-H), 4.63 (dd, J = 8.0, 6.0 Hz, 1 H, C4-H), 4.58 (dd, J = 8.0, 7.0 Hz, 1 H, C10-H), 
4.06 (d, J = 7.6 Hz, 1 H, C6-H), 3.05 (dd, J = 13.9, 7.0 Hz, 1 H, C11-H), 2.96 (dd, J = 
13.9, 8.0 Hz, 1 H, C11-H), 2.81 (dd, J = 15.5, 6.0 Hz, , 1 H, C3-H), 2.75-2.71 (m, 1 H, 
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C3-H), 2.00 (ap hep, J = 6.8 Hz, 1 H, C7-H), 1.95 (s, 3 H, C13-H), 0.90 (d, J = 6.8 Hz, 3 
H, C8-H), 0.89 (d, J = 6.8 Hz, 3 H, C8’-H); 13C NMR (125 MHz, D2O) δ 177.4 (C1, C2, 
C5, C9,or C12), 177.1 (C1, C2, C5, C9,or C12), 176.8 (C1, C2, C5, C9,or C12), 176.2 
(C1, C2, C5, C9,or C12), 175.4 (C1, C2, C5, C9,or C12), 153.7 (C14 or C17), 134.7 
(C14 or C17), 133.0 (C15 or C16), 123.2 (C15 or C16), 62.1 (C6), 57.8 (C10), 53.0 (C4), 
















(1S, 3R)-3-Hydroxymethyl-2,2-dimethyl-1-cyclopropane carboxylic acid 
hydrazide (2.043). (hrp1-110).  Hydrazine monohydrate (1.5 mL, 30.2 mmol) was 
added over 15 min to a solution of lactone 2.040 (646 mg, 5.12 mmol) in MeOH (18 mL) 
at rt .  The reaction was stirred at rt for 3 d and then concentrated under reduced pressure.  
Residual solvent was removed using azeotropic distillation with toluene (2 x 10 mL) to 
yield 786 mg of 2.043 (97%) as an off-white solid:  mp 71-72°C; 1H NMR (500 MHz, 
CD3OD) δ 3.95 (dd, J = 11.7, 7.7 Hz, 1 H), 3.84 (dd, J = 11.7, 7.2 Hz, 1 H), 1.40 (d, J = 
8.8 Hz, 1 H), 1.30-1.26 (comp, 1 H), 1.22 (s, 3 H), 1.16 (s, 3 H); 13C NMR (125 MHz, 
CD3OD) δ 175.2, 58.8, 43.0, 29.7, 29.1, 24.6, 14.8; mass spectrum (CI) m/z 159.1133 
[C7H15N2O2 (M+1) requires 159.1134], 141 (base) , 127, 83. 
NMR Assignments. 1H NMR (500 MHz, CD3OD) δ 3.95 (dd, J = 7.7, 11.7 Hz, 
1 H, C5-H), 3.84 (dd, J = 7.2, 11.7 Hz, 1 H, C5-H), 1.40 (d, J = 8.8 Hz, 1 H, C1-H), 
1.30-1.26 (comp, 1 H, C2-H), 1.22 (s, 3 H, C4-H), 1.16 (s, 3 H, C4’-H); 13C NMR (125 















(1R, 6S)-7,7 Dimethyl-4-oxa-2-azabicyclo[4.1.0]heptane-3-one (2.039). (hrp2-
117)  6 N aqueous HCl (2.2 mL, 13.3 mmol) was added dropwise to a vigorously stirred 
mixture of NaNO2 (916 mg, 13.3 mmol) and hydrazide 2.043 (1.4 g, 8.9 mmol) in Et2O 
and H2O (1:1, 40 mL) at 0 °C.  The yellow mixture was stirred vigorously at 0 °C for 45 
min and then cold toluene (20 mL) was added.  The layers were separated and the 
aqueous layer was extracted with toluene (3 x 20 mL).  The organic layers were 
combined, washed with brine (1 x 20 mL), dried (Na2SO4) and concentrated under 
reduced pressure to approximately 30 mL.  A stir bar was added and the mixture was 
heated at 80 °C for 1.5 h.  After cooling to rt, the solvent was removed under reduced 
pressure and the residue purified with flash column chromatography eluting with 
EtOAc/hexanes (2:1) to yield 1.17 g of 2.039 (94%) as an off-yellow solid:  mp 95-97 
°C; 1H NMR (500 MHz) δ 6.75 (br s, 1 H), 4.26 (dd, J = 12.6, 8.7 Hz, 1 H), 4.05 (dd, J = 
12.6, 5.5 Hz, 1 H), 2.58 (dd, J = 8.7, 2.0 Hz, 1 H), 1.20 (app dt, J = 8.7, 5.5 Hz, 1 H), 
1.04 (s, 3 H), 1.00 (s, 3 H); 13C NMR (125 MHz) δ 155.3, 65.6, 37.3, 24.3, 22.1, 16.0, 
13.0; IR (CHCl3) 2253, 1710, 1465, 1074, 910, 649 cm-1; mass spectrum (CI) m/z 
142.0866 [C7H12NO2 (M+1) requires 142.0867], 143, 98. 
NMR Assignments. 1H NMR (500 MHz) δ 6.75 (br s, 1 H, N-H), 4.26 (dd, J = 
8.7, 12.6 Hz, 1 H, C5-H), 4.05 (dd, J = 5.5, 12.6 Hz, 1 H, C5-H), 2.58 (dd, J = 2.0, 8.7 
Hz, 1 H, C1-H), 1.20 (ap dt, J = 5.5, 8.7 Hz, 1 H, C2-H), 1.04 (s, 3 H, C4-H), 1.00 (s, 3 
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H, C4’-H); 13C NMR (125 MHz) δ 155.3 (C6), 65.6 (C5), 37.3 (C1), 24.3 (C4), 22.1 












(1R, 3S)-(3-Amino-2,2-dimethylcyclopropyl)-1-methanol (2.038). (hrp1-107)  
A mixture of Ba(OH)2 . 8 H2O (2.73 g, 8.67 mmol) and urethane 2.039 (612 mg, 4.33 
mmol) in dioxane and H2O (2:1, 30 mL) was heated under reflux for 90 min with 
vigorous stirring.  After cooling to rt, the reaction mixture was filtered through a pad of 
celite.  The celite pad was washed with CH2Cl2 (2 x 10 mL)  and the combined filtrate 
and washes were washed with brine (30 mL).  The aqueous layer was extracted with 
CH2Cl2 (5 x 30 mL).  The organic layers were combined, dried (Na2SO4), and 
concentrated under reduced pressure to yield 414 mg of 2.038 (83%) as a yellow oil.  
This material was shown to be > 95% pure by 1H NMR and was used without further 
purification; 1H NMR (300 MHz) δ 3.87 (dd, J = 11.3, 6.4 Hz, 1 H), 3.81 (dd, J = 11.3, 
7.7 Hz, 1 H), 3.70 (s, 1 H), 2.23 (d, J = 7.2 Hz, 1 H), 1.70 (br s, 2 H), 1.10 (s, 3 H), 1.00 
(s, 3 H), 0.77-0.70 (m, 1 H); 13C NMR (65 MHz,) δ 58.0, 37.6, 28.8, 27.1, 18.9, 13.3; IR 
(CHCl3) 3552, 3020, 2254, 1469, 1385, 1215, 908, 734, 647 cm-1; mass spectrum (CI) 
m/z 116.1078 [C6H14NO (M+1) requires 116.1075], 114, 98 (base). 
NMR Assignments. 1H (300 MHz) δ 3.87 (dd, J = 6.4, 11.3 Hz, 1 H, C5-H), 
3.81 (dd, J = 7.7, 11.3 Hz, 1 H, C5-H), 3.70 (s, 1 H, O-H), 2.23 (d, J = 7.2 Hz, 1 H, C1-
H), 1.70 (br s, 2 H, N-H), 1.10 (s, 3 H, C4-H), 1.00 (s, 3 H, C4’-H), 0.77-0.70 (m, 1 H, 
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2S, 1’S, 3’R)-2-(3-Hydroxymethyl-2,2-dimethyl-1-cyclopropanylamino) 
succinic acid dimethyl ester (2.037). (hrp2-152)  Freshly distilled Tf2O (1.92 g, 1.15 
mL, 6.82 mmol) was added dropwise to a solution of (R)-dimethylmalate (1.23 g, 1.0 mL, 
7.58 mmol) in CH2Cl2 (11 mL) at 0 °C.  This mixture was stirred at 0 °C for 5 min, and 
2,6-lutidine (739 mg, 0.794 mL, 6.82 mmol) was added.  This mixture was stirred at 0 °C 
for an additional 10 min, and then iPr2NEt (928 mg, 1.25 mL, 7.20 mmol) was added.  
Then, a mixture of amino alcohol 2.038 (436 mg, 3.79 mmol) and iPr2NEt (490 mg, 
0.660 mL, 3.79 mmol) in CH2Cl2 (6 mL) was then added dropwise.  The reaction was 
stirred at 0 oC for 1 h and then warmed to rt for 30 min.  CH2Cl2 (20 mL) was added, and 
the mixture was washed with brine (20 mL).  The aqueous layer was extracted with 
CH2Cl2 (1 x 20 mL).  The combined organic layers were washed with sat. NaHCO3 (1 x 
20 mL), dried (Na2SO4) and concentrated under reduced pressure.  The residue was 
purified by flash column chromatography eluting with EtOAc/hexanes (1:1) to yield 524 
mg 2.037 (54%) as a yellow oil; 1H NMR (300 MHz) δ 3.79-3.65 (comp, 8 H), 3.53 (dd, 
J = 7.2, 5.9 Hz, 1 H), 2.67 (dd, J = 15.8, 5.9 Hz, 1 H), 2.58 (dd, J = 15.8, 7.2 Hz, 1 H), 
2.02 (br s, 2 H), 1.97 (d, J = 7.4 Hz, 1 H), 1.04 (s, 3 H), 0.98 (s, 3 H), 0.78 (dd, J = 14.1, 
7.4 Hz, 1 H); 13C NMR (75 MHz,) δ 174.2, 171.2, 58.9, 58.3, 52.1, 51.8, 42.6, 38.0, 29.9, 
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27.2, 20.0, 13.7; IR 3448, 2954, 2254, 1738, 1459, 1438, 1374, 1282, 1222, 1170, 1096, 
1013, 992, 908, 774, 738, 669, 650 cm-1; mass spectrum (CI) m/z 260.1506 [C12H22NO5 
(M+1) requires 260.1498], 242, 228, 163 
NMR Assignments. 1H NMR (300 MHz) δ 3.79-3.65 (comp, 8 H, C5-H, C10-H 
& C11-H), 3.53 (dd, J = 5.9, 7.2 Hz, 1 H, C6-H), 2.67 (dd, J = 15.8, 5.9 Hz, 1 H, C7-H), 
2.58 (dd, J = 15.8, 7.2 Hz, 1 H, C7-H), 2.02 (br s, 2 H, O-H & N-H), 1.97 (d, J = 7.4 Hz, 
1 H, C1-H), 1.04 (s, 3 H, C4-H), 0.98 (s, 3 H, C4’-H), 0.78 (dd, J = 14.1, 7.4 Hz, 1 H, 
C2-H); 13C NMR (75 MHz,) δ 174.2 (C9 or C8), 171.2 (C8 or C9), 58.9 (C6), 58.3 (C5), 
52.1 (C11 or C10), 51.8 (C10 or C11), 42.6 (C1), 38.0 (C7), 29.9 (C2), 27.2 (C4), 20.0 




























cyclopropanyl)amino]succinic acid dimethyl ester (2.047). (hrp1-112).  Boc2O (128 
mg, 0.590 mmol) was added to a solution of 2.037 (51 mg, 0.196 mmol) in CH3CN (2 
mL) at rt, and the reaction mixture was stirred at rt for 90 min.  The mixture was then 
heated at 50 °C for 1 d, whereupon more Boc2O (128 mg, 0.567 mmol) was added, and 
the heating continued for 3 d.  The crude reaction mixture was concentrated under 
reduced pressure, and the residue was purified by flash column chromatography eluting 
with EtOAc/hexanes (1:1) to yield 2.037 as a clear oil (34 mg, 48%); 1H NMR (500 
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MHz, DMSO-d6) δ 4.46 (dd, J = 5.5, 8.2 Hz, 1 H), 3.65-3.58 (comp, 7 H), 3.55-3.51 (m, 
1 H), 3.31 (br s, 1 H), 2.97 (dd, J = 8.2, 15.8 Hz, 1 H), 2.73 (dd, J = 5.5, 15.8 Hz, 1 H), 
2.35, (d, J = 7.0 Hz, 1 H), 1.37  (s, 9 H), 1.04 (s, 3 H), 1.00 (s, 3 H), 0.86 (dd, J = 7.0, 
14.6 Hz, 1 H); 13C NMR (125 MHz, DMSO) δ 171, 156, 79.7, 58.8, 56.4, 52.0, 51.4, 
44.5, 33.4, 29.8, 27.7, 26.5, 20.9, 14.4; IR (CHCl3) 3398, 2980, 2955, 1741, 1609, 1154, 
1025 cm-1; mass spectrum (CI) m/z 360.2005 [C17H30NO7 (M+1) requires 360.2022], 
286, 260 (base), 242, 228. 
NMR Assignments. 1H NMR (500 MHz, DMSO-d6) δ 4.46 (dd, J = 5.5, 8.2 Hz, 
1 H, C6-H), 3.65-3.58 (comp, 7 H, C5-H, C10-H & C11-H), 3.55-3.51 (m, 1 H, C5’-H), 
3.31 (br s, 1 H, O-H), 2.97 (dd, J = 8.2, 15.8 Hz, 1 H, C7-H), 2.73 (dd, J = 5.5, 15.8 Hz, 
1 H, C7’-H), 2.35, (d, J = 7.0 Hz, 1 H, C1-H), 1.37  (s, 9 H, C14-H), 1.04 (s, 3 H, C4-H), 
1.00 (s, 3 H, C4’-H), 0.86 (dd, J = 7.0, 14.6 Hz, 1 H, C2-H); 13C NMR (125 MHz, 
DMSO) δ 171.0 (C9 or C8), 170.7 (C8 or C9), 156 (C12), 79.7 (C13), 58.8 (C6), 56.4 
(C5), 52.0 (C11 or C10), 51.4 (C10 or C11), 44.5 (C1), 33.4 (C7), 29.8 (C2), 27.7 (C14), 
































dimethylcyclopropylamino)]succinic acid dimethyl ester (2.048). (hrp1-255).  iPr2NEt 
(197 µL,  1.13 mmol) and then Cbz-Cl (135 µL, 0.94 mmol) were added to a stirred 
solution of 2.037 (163 mg, 0.63 mmol) in CH2Cl2  (7 mL) at rt.  The reaction mixture 
was heated under reflux for 40 h. The reaction was cooled to rt, and the crude reaction 
mixture was concentrated under reduced pressure.  The light yellow residue was purified 
by flash column chromatography eluting with hexanes/EtOAc (2:1) to yield 200 mg 
(81%) of 2.048 as a yellow oil; 1H NMR (500 MHz, DMSO-d6, 383K) δ 7.38-7.30 
(comp, 5 H), 5.09 (d, J = 12.3 Hz, 1 H), 5.03 (d, J = 12.3 Hz, 1 H), 4.49 (dd, J = 7.4, 6.0 
Hz, 1 H), 3.63-3.54 (comp, 8 H) 3.05 (dd, J = 15.9, 7.4 Hz, 1 H), 2.77 (dd, J = 15.9, 6.0 
Hz, 1 H), 2.47 (d, J = 7.6 Hz, 1 H), 1.0 (s, 3 H), 0.98 (s, 3 H), 0.96-0.93 (m, 1 H); 13C 
NMR (125 MHz, DMSO-d6, 383K) δ 170.2, 169.2, 159.3, 135.7, 127.6, 127.3, 78.4, 
66.5, 58.9, 56.2, 51.2, 50.6, 45.2, 34.0, 30.1, 25.9, 20.4, 13.6; IR (CHCl3) 2253, 1740, 
1699, 1458, 1378, 1351, 1149, 1098, 904, 650 cm-1; mass spectrum (CI) m/z 394.1860 
[C20H27NO7 (M+1) requires 394.1866], 376 (base), 332. 
NMR Assignments. 1H NMR (500 MHz, DMSO-d6, 383K) δ 7.38-7.30 (comp, 5 
H, C15-H, C15’-H, C16-H, C16’-H & C17-H), 5.09 (d, J = 12.3 Hz, 1 H, C13-H), 5.03 
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(d, J = 12.3 Hz, 1 H, C13-H), 4.49 (dd, J = 7.4, 6.0 Hz, 1 H, C6-H), 3.63-3.54 (comp, 8 
H, C5-H, C10-H & C11-H), 3.05 (dd, J = 15.9, 7.4 Hz, 1 H, C7-H), 2.77 (dd, J = 15.9, 
6.0 Hz, 1 H, C7-H), 2.47 (d, J = 7.6 Hz, 1 H, C1-H), 1.0 (s, 3 H, C4-H), 0.98 (s, 3 H, 
C4’-H), 0.96-0.93 (m, 1 H, C2-H); 13C NMR (125 MHz, DMSO-d6, 383K) δ 170.2 (C8, 
C9 or C12), 169.2 (C8, C9 or C12), 159.3(C8, C9 or C12), 135.7 (C15, C16 or C17), 
127.6 (C15, C16 or C17), 127.3 (C15, C16 or C17), 78.4 (C14), 66.5 (C13), 58.9 (C6), 
56.2 (C5), 51.2 (C10 or C11), 50.6 (C10 or C11), 45.2 (C1), 34.0 (C7), 30.1 (C2), 25.9 































dimethylcyclopropylamino)] succinic acid dimethyl ester (2.049). (hrp1-236).  
NaHCO3 (34 mg,  0.41 mmol), NaIO4 (74 mg, 0.35 mmol), and RuCl3 (1 mg, 0.0062 
mmol) were added to a solution of  2.048 (24 mg, 0.062 mmol) in CH3CN, CCl4, H2O 
(1:1:2, 3 mL total) at rt.  The orange emulsion reaction mixture was stirred vigorously for 
30 min, whereupon an additional 0.1 equivalent of RuCl3 was added. The reaction 
mixture was vigorously stirred for 1 h at rt.  The reaction mixture was diluted with 
EtOAc (5 mL), and 3 M HCl sat. with NaCl was added until aqueous layer was pH = 1.0.  
The layers were separated, and the aqueous layer was back extracted EtOAc (1 x 5 mL).  
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The organic layers were combined and dried (Na2SO4) and concentrated under reduced 
pressure.  The orange residue was purified by filtering through a pad of silica eluting with  
EtOAc to yield 24 mg (94%) of 2.049 as a orange oil; 1H NMR (500 MHz, DMSO-d6, 
383K) δ 7.37-7.29 (comp, 5 H), 5.11 (d, J = 12.6 Hz, 1 H), 4.94 (d, J = 12.6 Hz, 1 H), 
4.29 (dd, J = 8.9, 3.6 Hz, 1 H), 3.65 (s, 3 H), 3.58 (s, 3 H), 3.24 (dd, J = 16.8, 8.9 Hz, 1 
H), 2.92 (d, J = 7.6 Hz, 1 H), 2.76 (dd, J = 16.8, 3.6 Hz, 1 H), 1.70 (d, J = 7.6 Hz, 1 H), 
1.29 (s, 3 H), 1.15 (s, 3 H); 13C NMR (125 MHz, DMSO-d6, 383K) δ 170.3, 169.9, 
169.1, 155.9, 135.7, 127.6, 127.1, 127.0, 66.3, 58.9, 51.3, 50.8, 48.0, 35.5, 30.9, 25.9, 
25.8, 14.0; IR (CHCl3) 3001, 2956, 1734, 1455, 1438, 1328, 1306, 1240, 1026, 1012 cm-
1; mass spectrum (CI) m/z 408.1660 [C20H25NO8 (M+1) requires 408.1658], 390, 364. 
 NMR Assignments. 1H NMR (500 MHz, DMSO-d6, 383K) δ 7.37-7.29 (comp, 5 
H, C15-H, C15’-H, C16-H, C16’-H & C17-H), 5.11 (d, J = 12.6 Hz, 1 H, C13-H), 4.94 
(d, J = 12.6 Hz, 1 H, C13-H), 4.29 (dd, J = 8.9, 3.6 Hz, 1 H, C6-H), 3.65 (s, 3 H, C10-H 
or C11-H), 3.58 (s, 3 H, C10-H or C11-H), 3.24 (dd, J = 16.8, 8.9 Hz, 1 H, C7-H), 2.92 
(d, J = 7.6 Hz, 1 H, C1-H), 2.76 (dd, J = 16.8, 3.6 Hz, 1 H, C7-H), 1.70 (d, J = 7.6 Hz, 1 
H, C2-H), 1.29 (s, 3 H, C4-H), 1.15 (s, 3 H, C4’-H); 13C NMR (125 MHz, DMSO-d6, 
383K) δ 170.3 (C8, C9 or C12), 169.9 (C5), 169.1 (C8, C9 or C12), 155.9 (C8, C9 or 
C12), 135.7 (C15, C16 or C17), 127.6 (C15, C16 or C17), 127.1(C15, C16 or C17), 127.0 
(C14) 66.3 (C13), 58.9 (C6) , 51.3 (C10 or C11), 50.8 (C10 or C11), 48.0 (C1), 35.5 






































benzyloxycarbonylamino] succinic acid dimethyl ester (2.050). (hrp1-257).  Ethyl 
chloroformate (51 µL, 0.53 mmol) and Et3N (68 µL, 0.49 mmol) were added to a 
solution of 2.049 (166 mg, 0.41 mmol) in acetone:H2O (10:1, 4 mL total) at rt.  The 
mixture was stirred at rt for 1 h, and NaN3 was added (40 mg, 0.61 mmol).  The mixture 
was stirred at rt for 1 h, and cold toluene (20 mL) was then added.  The mixture was 
washed with brine (1 x 20 mL), and the aqueous layer was back extracted with toluene (1 
x 20 mL).  The organic phases were combined, dried (Na2SO4) and concentrated to ca. 3 
mL under reduced pressure.  Allyl alcohol (1 mL) was added, and the reaction was heated 
under reflux for 22 h.  The reaction was then concentrated under reduced pressure, and 
the yellow residue was purified by flash column chromatography eluting with 
hexanes/EtOAc (2:1) to yield 84 mg (44%) of 12 as a yellow oil; 1H NMR (500 MHz, 
DMSO-d6, 383K) δ 7.38-7.30 (comp, 5 H), 5.93 (br s, 1 H), 5.90 (ddt, J = 17.2, 10.5, 5.5 
Hz, 1 H), 5.27 (dq, J = 17.2, 1.6 Hz, 1 H) 5.17 (dq, J = 10.5, 1.6 Hz, 1 H), 5.10 (d, J = 
12.4 Hz, 1 H), 5.05 (d, J = 12.4 Hz, 1 H), 4.50 (dq, J = 5.5, 1.6 Hz, 2 H), 4.23 (dd, J = 
7.9, 5.3 Hz, 1 H), 3.63 (s, 3 H), 3.59 (s, 3 H), 3.10 (dd, J = 7.9, 16.4 Hz, 1 H), 2.84-2.83 
(m, 1 H), 2.67 (dd, J = 6.8, 5.7 Hz, 1 H), 2.56 (d, J = 6.8 Hz, 1 H), 1.04 (s, 3 H), 0.98 (s, 
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3 H); 13C NMR (125 MHz, DMSO-d6, 383K) δ 170.2, 169.9, 156.2, 155.9, 135.5, 132.9, 
127.7, 127.3, 127.2, 116.3, 66.7, 64.1, 58.6, 51.5, 50.8, 43.7, 38.4, 28.2, 23.9, 20.5, 13.3; 
IR (CHCl3) 3404, 2992, 2956, 1732, 1490, 1456, 1439, 1411, 1311, 1269, 1154 cm-1; 
mass spectrum (CI) m/z 463.2068 [C23H30N2O8 (M+1) requires 463.2080]. 
 NMR Assignments. 1H NMR (500 MHz, DMSO-d6, 383K) δ 7.38-7.30 (comp, 5 
H, C15-H, C16-H , C15’-H, C16’-H & C17-H), 5.93 (br s, 1 H, N-H), 5.90 (ddt, J = 17.2, 
10.5, 5.5 Hz, 1 H, C19-H), 5.27 (dq, J = 17.2, 1.6 Hz, 1 H, C20-H) 5.17 (dq, J = 10.5, 
1.6, Hz, 1 H, C20-H), 5.10 (d, J = 12.4 Hz, 1 H, C13-H), 5.05 (d, J = 12.4 Hz, 1 H, C13-
H), 4.50 (dq, J = 5.5, 1.6, Hz, 2 H, C18-H), 4.23 (dd, J = 7.9, 5.3 Hz, 1 H, C6-H), 3.63 (s, 
3 H, C10-H or C11-H), 3.59 (s, 3 H, C10-H or C11-H), 3.10 (dd, J = 16.4, 7.9 Hz, 1 H, 
C7-H), 2.84-2.83 (m, 1 H, C7-H), 2.67 (dd, J = 6.8, 5.7 Hz 1 H, C2-H), 2.56 (d, J = 6.8 
Hz, 1 H, C1-H), 1.04 (s, 3 H, C4-H), 0.98 (s, 3 H, C4’-H); 13C NMR (125 MHz, DMSO-
d6, 383K) δ 170.2 (C8, C9, or C12), 169.92 (C8, C9, or C12), 156.22 (C5), 155.92 (C8, 
C9, or C12), 135.5 (C15, C16, or C17), 132.9 (C20), 127.7 (C15, C16, or C17), 127.3 
(C14), 127.2 (C15, C16, or C17), 116.3 (C19), 66.7 (C13), 64.1 (C18), 58.6 (C6), 51.5 
























succinic amide (2.061). (hrp2-108).  A mixture of 2.037 (311 mg, 1.2 mmol) in MeOH 
(12 mL) containing NaCN (6 mg, 0.12 mmol) at rt was saturated with NH3 by bubbling 
the gas into solution for 20 min at rt.  The mixture was stirred at 50 oC for 3 d, during 
which time it was resaturated with NH3 every 12 h.  The mixture was then concentrated 
under reduced pressure, and the residue was recrystallized from minimal amounts of hot 
MeOH, EtOAc (1:50, 10 mL total) to yield 239 mg of 2.061 (85%) as an off white solid: 
mp 134-136 oC; 1H NMR (500 MHz, CD3OD) δ 3.70-3.64 (comp, 2 H), 3.42 (dd, J = 
7.9, 5.4 Hz, 1 H), 2.48 (dd, J = 14.7, 5.4, 1 H), 2.44 (dd, J = 14.7, 7.9 Hz, 1 H), 1.94 (d, J 
= 7.4 Hz, 1 H), 1.09 (s, 3 H), 1.01 (s, 3 H), 0.75 (dd, J = 14.5, 7.4, 1 H); 13C NMR (125 
MHz, CD3OD) δ 179.1, 176.1, 60.5, 59.1, 43.3, 39.8, 31.0, 27.7, 20.8, 14.1; IR 3430, 
1713 cm-1, mass spectrum (CI) m/z 230.1510 [C10H19N3O3 (M+1) requires 230.1505], 
198, 212 (base), 230. 
NMR Assignments. 1H NMR (500 MHz, CD3OD) δ 3.70-3.64 (comp, 2 H, C5-
H), 3.42 (dd, J = 7.9, 5.4 Hz, 1 H, C6-H), 2.48 (dd, J = 14.7, 5.4, 1 H, C7-H), 2.44 (dd, J 
= 14.7, 7.9 Hz, 1 H, C7’-H), 1.94 (d, J = 7.4 Hz, 1 H, C1-H), 1.09 (s, 3 H, C4-H), 1.01 (s, 
3 H, C4’-H), 0.75 (dd, J = 14.5, 7.4, 1 H, C2-H); 13C NMR (125 MHz, CD3OD) δ 179.1 
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(C8 or C9), 176.1 (C8 or C9), 60.5 (C6), 59.1 (C5), 43.3 (C1), 39.8 (C7), 31.0 (C2), 27.7 





























dimethylcyclopropyl) carbamic acid benzyl ester (2.061). (hrp2-194).  iPr2NEt (14 
mg, 19 µL,  0.11 mmol) and Cbz-Cl (16 mg, 13 µL, 0.09 mmol) were added to a stirred 
solution of  2.061 (23 mg, 0.1 mmol) in THF, CH3CN (1:1, 2 mL total) at rt.  The 
reaction was sonicated at rt for 1 h and then heated under reflux for 3 h. The mixture was 
cooled to rt, and EtOAc (5 mL) was added.  The mixture was washed with 1 M HCl sat. 
with NaCl (1 x 5 mL), and the aqueous layer was back extracted with EtOAc (2 x 5 mL).   
The organic layers were combined and washed with sat. Na2CO3 (2 x 5 mL), and the 
aqueous layer was back extracted with EtOAc (2 x 5mL).  The organic layers were 
combined, dried (Na2SO4) and concentrated under reduced pressure to yield 30 mg of 
2.061 (83%) as a yellow oil; 1H NMR (500 MHz, DMSO-d6, 383K) δ 7.39-7.28 (comp, 5 
H), 6.79-6.67 (comp, 3 H), 5.63 (s, 1 H), 5.06 (d, J = 12.5 Hz, 2 H) , 4.10 (dd, J = 7.0, 
5.6 Hz, 1 H), 3.60 (dd, J = 11.5, 7.0 Hz, 1 H), 3.44 (dd, J = 11.5, 5.6 Hz, 1 H), 2.96 (dd, J 
= 15.8, 7.0 Hz, 1 H), 2.87 (br s, 1 H), 2.66 (dd, J = 15.8, 7.0 Hz, 1 H), 2.51 (d, J = 7.8 
Hz, 1 H), 1.02 (s, 3 H), 0.99 (s, 3 H), 0.93-0.90 (m, 1 H); 13C NMR (125 MHz, DMSO-
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d6, 383K) δ 172.2, 171.3, 157.3, 136.0, 127.5, 127.1, 66.2, 60.7, 56.8, 53.9, 46.0, 36.5, 
30.4, 26.2, 19.8, 14.0; IR 3475, 3408, 3350, 2956, 1682, 1592, 1403, 1296, 1150, 1023, 
909 cm-1; mass spectrum (CI) m/z 364.1875 [C18H25N3O5 (M+1) requires 364.1872], 
329, 346, 365. 
NMR Assignments. 1H NMR (500 MHz, DMSO-d6, 383K) δ 7.39-7.28 (comp, 5 
H, C13-H, C13’-H, C14-H, C14’-H & C15-H), 6.79-6.67 (comp, 3 H, N-H), 5.63 (s, 1 H, 
N-H), 5.06 (d, J = 12.5 Hz, 2 H, C11-H) , 4.10 (dd, J = 7.0, 5.6 Hz, 1 H, C6-H), 3.60 (dd, 
J = 11.5, 7.0 Hz, 1 H, C5-H), 3.44 (dd, J = 11.5, 7.5 Hz, 1 H, C5’-H), 2.96 (dd, J = 15.8, 
7.0 Hz, 1 H, C7-H), 2.87 (br, 1 H, O-H), 2.66 (dd, J = 15.8, 7.0 Hz, 1 H, C7’-H), 2.51 (d, 
J = 7.8 Hz, 1 H, C1-H), 1.02 (s, 3 H, C4-H), 0.99 (s, 3 H, C4’-H), 0.93-0.90 (m, 1 H, C2-
H); 13C NMR (125 MHz, DMSO-d6, 383K)δ 172.2 (C8, C9 or C10), 171.3 (C8, C9 or 
C10), 157.3 (C8, C9 or C10), 136.0 (C13, C14 or C15), 127.5 (C13, C14 or C15), 127.1 
(C13, C14 or C15), 66.2 (C11), 60.7 (C6), 56.8 (C5), 53.9 (C12), 46.0 (C1), 36.5 (C7), 































dimethyl cyclopropanecarboxylic acid (2.064). (hrp2-156).  A mixture of NaHCO3 
(144 mg, 1.72 mmol), NaIO4 (311 mg, 1.46 mmol), RuCl3 (5 mg, 0.26 mmol) and 2.060 
(95 mg, 0.260 mmol) in CH3CN, CCl4, H2O  (1:1:2, 20 mL total) was stirred vigorously 
for 30 min at rt.  An additional 0.1 equivalent of RuCl3 was then added, and the reaction 
mixture was stirred vigorously for 1 h at rt.  The reaction mixture was diluted with 
CH2Cl2 (20 mL), and the layers were separated.  The aqueous layer was washed with 
CH2Cl2 (3 x 20 mL).  The aqueous layer was acidified with 1 M HCl sat. with NaCl.  The 
aqueous layer was then extracted with EtOAc (3 x 20 mL).  The organic layers were 
combined, dried (Na2SO4) and concentrated under reduced pressure to yield 93 mg of 
2.064 (95%) as a white solid: 124 – 126 oC;1H NMR (500 MHz, DMSO-d6, 383K) δ 
7.38-7.28 (comp, 6 H), 6.79, (br s, 2 H), 5.10-5.08 (comp, 2 H), 5.00-4.98 (m, 1 H), 4.12 
(dd, J = 6.9, 5.7 Hz, 1 H), 3.06 (dd, J = 16.1, 6.9 Hz, 1 H), 2.82 (d, J = 7.6 Hz, 1 H), 2.47 
(dd, J = 17.3, 5.7 Hz, 1 H), 1.64 (d, J = 7.6 Hz, 1 H), 1.21 (s, 3 H), 1.11 (s, 3 H); 13C 
NMR (125 MHz, DMSO-d6, 383K) δ 172.1, 171.2, 170.6, 156.3, 135.9, 127.6, 127.1, 
127.0, 66.4, 59.4, 47.6, 34.6, 29.9, 27.4, 26.1, 14.2; mass spectrum (CI) m/z 378.1664 
[C18H25N3O6 (M+1) requires 378.1665], 361, 378 (base), 468. 
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NMR Assignments. 1H NMR (500 MHz, DMSO-d6, 383K) δ 7.38-7.28 (comp, 6 
H, N-H, C13-H, C13’-H, C14-H, C14’-H & C15-H), 6.79, (br s, 2 H, N-H), 5.1-5.08 
(comp, 2 H, C11-H & N-H), 5.00-4.98 (m, 1 H, C11’-H), 4.12 (dd, J = 6.9, 5.7 Hz, 1 H, 
C6-H), 3.06 (dd, J = 16.1, 6.9 Hz, 1 H, C7-H), 2.82 (d, J = 7.6 Hz, 1 H, C1-H), 2.47 (dd, 
J = 17.3, 5.7 Hz, 1 H, C7’-H), 1.64 (d, J = 7.6 Hz, 1 H, C2-H), 1.21 (s, 3 H, C4-H), 1.11 
(s, 3 H, C4’-H); 13C NMR (125 MHz, DMSO-d6, 383K) δ 172.1 (C5, C8, C9 or C10), 
171.2 (C5, C8, C9 or C10), 170.6 (C5, C8, C9 or C10), 156.3 (C5, C8, C9 or C10), 135.9 
(C12), 127.6 (C13, C14 or C15), 127.1 (C13, C14 or C15), 127.0 (C13, C14 or C15), 


































dicarbamoylethyl)carbamic acid benzyl ester (2.065). (hrp2-127).  Ethyl 
chloroformate (12 mg, 11 µL, 0.114 mmol) and Et3N (11 mg, 15 µL, 0.104 mmol) were 
added to a solution of 2.064 (33 mg, 0.087 mmol) in aqueous acetone (10:1, 2 mL total) 
at 0 oC, and the mixture was stirred at 0 oC for 30 min.  A solution of NaN3 (8 mg, 0.131 
mmol) dissolved in H2O (200 µL) was then added, and the mixture was stirred at 0 oC for 
30 min.  Cold H2O  (2 mL) was added, and the mixture was extracted with CH2Cl2 (3 x 5 
mL).  The organic layers were combined, dried (Na2SO4) and concentrated to ca. 2 mL 
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under reduced pressure, tert-Butyl alcohol (2 mL) was added, and the reaction was heated 
under reflux for 13 h.  The reaction was then concentrated under reduced pressure to 
yield 27 mg of 2.065 (70%) as a yellow oil; 1H NMR (500 MHz, DMSO-d6, 373K) δ 
7.39-7.30 (comp, 5 H),6.90 (br s, 1 H), 6.15 (br s, 1 H), 5.10 (d, J = 12.5 Hz, 1 H), 5.03 
(d, J = 12.5 Hz, 1 H), 4.07 (dd, J = 6.9, 6.1 Hz, 1 H), 3.48-3.45 (m, 1 H), 2.97-2.92, (m, 1 
H), 2.66 (dd, J = 15.6, 6.1 Hz, 1 H), 2.51-2.49 (m, 1 H), 1.39 (s, 9 H), 0.98 (s, 3 H), 0.93 
(s, 3 H);13C NMR (125 MHz, DMSO-d6, 373K) δ 171.9 171.8, 156.7, 155.8, 135.9, 
127.7, 127.2, 127.1, 78.5, 66.4, 60.0, 43.8, 38.0, 35.8, 27.6, 24.0, 20.6, 13.6; IR 3476, 
3408, 2960, 1720, 1687, 1592, 1367, 1161 cm-1; mass spectrum (CI) m/z 449.2403 
[C22H33N4O6 (M+1) requires 499.2400], 393 (base), 349.   
NMR Assignments.  1H NMR (500 MHz, DMSO-d6, 373K) δ 7.39-7.30 (comp, 
5 H, C13-H, C13’-H, C14-H C14’-H, C15-H),6.90 (br s, 1 H, N-H), 6.15 (br s, 1 H, N-
H), 5.10 (d, J = 12.5 Hz, 1 H, C11-H), 5.03 (d, J = 12.5 Hz, 1 H, C11-H), 4.07 (dd, J = 
6.9, 6.1 Hz, 1 H, C6-H), 3.48-3.45 (m, 1 H, C1-H), 2.97-2.92, (m, 1 H, C7-H), 2.66 (dd, J 
= 15.6, 6.1 Hz, 1 H, C7’-H), 2.51-2.49 (m, 1 H, C2-H), 1.39 (s, 9 H, C17-H), 0.98 (s, 3 
H, C4-H), 0.93 (s, 3 H, C4’-H);13C NMR (125 MHz, DMSO-d6, 373K) δ 171.9 (C10 or 
C9 or C8, or C5), 171.8 (C10 or C9 or C8, or C5), 156.7 (C10 or C9 or C8, or C5), 155.8 
(C10 or C9 or C8, or C5), 135.9 (C12), 127.7 (C13 or C14 or C15), 127.2 (C13 or C14 or 
C15), 127.1 (C13 or C14 or C15), 78.5 (C16), 66.4 (C11), 60.0 (C6), 43.8 (C1), 38.0 
























































propionylamino}-2,2-dimethylcyclopropyl-1,2-dicarbamoylethyl) carbamic acid 
benzyl ester (2.066). (hrp2-158 & 159).  A solution of 2.065 (76 mg, 0.169 mmol) in 
neat TFA (1.5 mL) was stirred for 90 min.  The reaction mixture was concentrated under 
reduced pressure, and the residue was triturated with Et2O (3 x 2 mL) to give an off white 
solid.(62 mg)  This crude amine was dissolved in DMF (2 mL) containing 2.030 (65 mg, 
0.134 mmol) at –10 °C, and 2,6-lutidine (43 mg, 47 µL, 0.402 mmol) and HATU (51 mg, 
0.134 mmol) were added.  The mixture was stirred at –10 °C for 1 h and then at rt for 1h.  
EtOAc (10 mL) was added, and the organic layer was washed with sat. NaHCO3 (10 
mL), 1 M HCl sat. with NaCl (10 mL) and brine (10 mL).  The organic layer was dried 
(Na2SO4) and concentrated under reduced pressure.  The crude residue was purified by 
flash chromatography, eluting with CH2Cl2/MeOH (15:1) to yield 65 mg of 2.066 (60%) 
as a yellow oil: 1H NMR (500 MHz, DMSO-d6, 373K) δ 8.10 (br s, 1 H), 7.91 (d, J = 
8.3, 1 H) 7.38-7.28 (comp, 16 H), 7.19 (d, J = 11.5, 4 H), 7.06-7.04 (m, 2 H), 6.83 (br s, 1 
H), 5.12-5.01 (comp, 6 H), 4.44-4.39 (m, 1 H), 3.98 (t, J = 6.7, 1 H), 2.91-2.87 (m, 2 H), 
2.79 (t, J = 7.0, 1 H), 2.72-2.68 (m, 2 H), 2.52 (d, J = 7.0, 1 H), 1.74 (s, 3 H), 0.95 (s, 3 
H), 0.84 (s, 3 H);13C NMR (125 MHz, DMSO-d6, 373K) δ 173.0, 172.2, 171.9, 169.3, 
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156.7, 148.6, 136.2, 135.6, 134.9, 130.4, 128.4, 128.2, 128.1, 127.9, 127.8, 126.6, 127.2, 
119.3, 72.1, 66.8, 60.0, 54.0, 36.8, 36.6, 24.2, 22.2, 21.4, 14.1; IR 3476, 3408, 2960, 
1720, 1687, 1592, 1367, 1161 cm-1;mass spectrum (CI) m/z 814.3217 [C42H49N5O10P 
(M+1) requires 814.3246].   
NMR Assignments.  1H NMR (500 MHz, DMSO-d6, 373K) d 8.10 (br s, 1 H, N-
H), 7.91 (d, J = 8.3, 1 H, N-H) 7.38-7.28 (comp, 16 H, C21-H, C22-H, C23-H, C24-H, 
C24’-H, C25-H, C25’-H, C26-H), 7.19 (d, J = 11.5, 4 H, C13-H or C14-H, N-H), 7.06-
7.04 (m, 2 H, C13-H or C14-H), 6.83 (br s, 1 H, N-H), 5.12-5.01 (comp, 6 H, C24-H, 
C24’-H, C19-H), 4.44-4.39 (m, 1 H, C10-H), 3.98 (t, J = 6.7, 1 H, C6-H), 2.91-2.87 (m, 2 
H, C7-H), 2.79 (t, J = 7.0, 1 H, C2-H), 2.72-2.68 (m, 2 H, C11-H), 2.52 (d, J = 7.0, 1 H, 
C1-H), 1.74 (s, 3 H, C17-H), 0.95 (s, 3 H, C4-H), 0.84 (s, 3 H, C4’-H);13C NMR (125 
MHz, DMSO-d6, 373K) δ 173.0 (C5 orC8 or C9 or C16 or C18), 172.2 (C5 orC8 or C9 
or C16 or C18), 171.9 (C5 orC8 or C9 or C16 or C18), 169.3 (C5 orC8 or C9 or C16 or 
C18), 156.7 (C5 orC8 or C9 or C16 or C18), 148.6 (C12 or C15 or C20 or C25), 136.2 
(C12 or C15 or C20 or C25), 135.6 (C12 or C15 or C20 or C25), 134.9 (C12 or C15 or 
C20 or C25), 130.4 (C13 or C14), 128.4 (C26, C26’, C27 C27’, C21, C22), 128.2 (C26, 
C26’, C27 C27’, C21, C22), 128.1 (C26, C26’, C27 C27’, C21, C22), 127.9 (C26, C26’, 
C27 C27’, C21, C22), 127.8 (C26, C26’, C27 C27’, C21, C22), 126.6 (C26, C26’, C27 
C27’, C21, C22), 127.2 (C26, C26’, C27 C27’, C21, C22), 119.3 (C13 or C14), 72.1 
(C19 or C24), 66.8 (C19 or C24), 60.0 (C6), 54.0 (C10) ,36.8 (C7, C2, C11), 36.6 (C7, 





































(1’’S,2S,2’S,3’S)-Phosphoric Acid mono 4-{2-acetylamino-2-[3-(1,2-
dicarbamoylethylamino-2,2-dimethylcyclopropylcarbamoyl]ethyl}phenyl)ester 
(2.006). (hrp2-211).  A solution of 2.066 (4 mg, 0.0172 mmol) in EtOH (2 mL) 
containing 10% Pd/C (10 mg) was stirred under H2 (1 atm) for 12 h.  The catalyst was 
removed by filtration through a pad of celite, and the filtrate was concentrated under 
reduced pressure to yield 10 mg of 3 (100%) as a white solid: mp 88 - 90 oC; 1H NMR 
(500 MHz, D2O) δ 7.22 (d, J = 8.5 Hz, 2 H), 7.19 (d, J = 8.5 Hz, 2 H), 4.52-4.49 (m, 1 
H), 3.52-3.49 (m, 1 H), 3.14-2.89 (comp, 2 H), 2.62 (dd, J = 15.0, 5.7, 1 H), 2.53 (dd, J = 
15.0, 8.0 Hz, 1 H), 2.30 (d, J = 6.0 Hz, 1 H), 2.00 (d, J = 6.0 Hz, 1 H), 1.95 (s, 3 H), 1.03 
(s, 3 H), 0.93 (s, 3 H); 13C NMR (125 MHz, D2O) δ 181.6, 178.1, 177.7, 176.7, 134.7, 
133.1, 132.9, 123.2, 61.2, 58.0, 43.7, 40.5, 39.2, 38.3, 26.6, 24.3, 23.1, 15.0; mass 
spectrum (FAB +) m/z 500.1903 [C20H31N5O9P (M+1) requires 500.1910], 461, 369, 
277 (base). 
NMR Assignments.  1H NMR (500 MHz, D2O) δ 7.22 (d, J = 8.5 Hz, 2 H, C 15-H 
or C16-H), 7.19 (d, J = 8.5 Hz, 2 H, C15-H or C16-H), 4.52-4.49 (m, 1 H, C12-H), 3.52-
3.49 (m, 1 H, C6-H), 3.14-2.89 (comp, 2 H, C13-H), 2.62 (dd, J = 15.0, 5.7, 1 H, C7-H), 
2.53 (dd, J = 15.0, 8.0 Hz, 1 H, C7’-H), 2.30 (d, J = 6.0 Hz, 1 H, C1-H or C2-H), 2.00 (d, 
J = 6.0 Hz, 1 H, C1-H or C2-H), 1.95 (s, 3 H, C4-H), 1.03 (s, 3 H, C4’-H), 0.93 (s, 3 H); 
13C NMR (125 MHz, D2O) δ 181.6 (C5 or C8 or C9 or C10), 178.1 (C5 or C8 or C9 or 
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C10), 177.7 (C5 or C8 or C9 or C10), 176.7 (C5 or C8 or C9 or C10), 134.7 (C14 or 
C17), 133.1 (C14 or C17), 132.9 (C15 or C16), 123.2 (C15 or C16), 61.2 (C6), 58.0 
(C12), 43.7 (C1 or C2), 40.5 (C7),39.2 (C13), 38.3 (C1 or C2), 26.6 (C4), 24.3 (C11), 



















(2S)-2-tert-Butyoxycarbonylamino-3-methylthiobutyric acid S-ethyl ether 
(2.069). (tbs112).  4-Dimethylaminopyridine (DMAP) (40 mg, 0.3 mmol), ethanethiol 
(0.25 mL, 3.3 mmol), and dicyclohexylcarbodiimide (DCC) (681 mg, 3.3 mmol) were 
added to a solution of 2.027 (651 mg, 3.0 mmol) in CH2Cl2 (5 mL) at rt.  The mixture 
was stirred at rt for 0.5 h and then filtered through a cotton plug.  The filtrate was 
concentrated under reduced pressure to yield a white residue.  The residue was purified 
by flash chromatography eluting with hexanes/EtOAc (5:1) to yield 582 mg of 2.069 
(75%) as a white solid: mp 62-64 °C; 1H NMR (125 MHz, CDCl3) δ 4.95 (d, J = 8.9 Hz, 
1 H), 4.23 (dd, J = 8.9 Hz, 5.0 Hz, 1 H), 2.85 (q, J = 7.4 Hz, 2 H), 2.27-2.20 (m, 1 H), 
1.43 (s, 9 H), 1.21 (t, J = 7.4 Hz, 3 H), 0.95 (d, J = 6.8 Hz, 3 H), 0.83 (d, J = 6.8 Hz, 3 
H); 13C NMR (75 MHz, CDCl3) δ 201.1, 155.5, 80.1, 65.3, 31.1, 28.3, 23.2, 19.4, 16.7, 
14.5; IR (CDCl3) 2253, 1714, 1681, 1493, 1369 cm-1; mass spectrum (CI) m/z 261.1470 
[C12H24NO3S (M+1) requires 262.1477], 206 (base), 144. 
NMR Assignments. 1H NMR (500 MHz, CDCl3) δ 4.95 (d, J = 8.9 Hz, 1 H, N-
H), 4.23 (dd, J = 8.9 Hz, 5.0 Hz, 1 H, C1-H), 2.85 (q, J = 7.4 , 2 H, C5-H), 2.27-2.20 (m, 
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1 H, C2-H), 1.43 (s, 9 H, C10-H), 1.21 (t, J = 7.4 Hz, 3 H, C6-H), 0.95 (d, J = 6.8 Hz, 3 
H, C3-H), 0.83 (d, J = 6.8 Hz, 3 H, C3’-H); 13C NMR (125 MHz, CDCl3) δ 201.1 (C8), 























(2S, 2S’)-2-(2-tert-butoxycarbonylamino-3-methylbutylamino)succinic acid 
dimethyl ester (2.071). (tbs153 & 154)  Triethylsilane (Et3SiH) (0.61 mL, 3.8 mmol) 
was added quickly to a solution of 2.069 (200 mg, 0.76 mmol) and 10% Pd/C (ca 10 mg) 
in CH2Cl2 (2 mL) at rt.  The mixture was stirred at rt for 0.5 h and then filtered through a 
pad of celite.  The filtrate was concentrated under reduced pressure, and the residue was 
diluted with DMF (1.5 mL).  L-Aspartic acid dimethyl ester hydrochloride (180 mg, 0.91 
mmol) and sodium triacetoxyborohydride (Na(OAc)3BH) (322 mg, 1.52) were added, 
and the mixture was stirred for 0.5 h at rt.  Et2O (8 mL) was added, and the organic layer 
was washed with saturated aqueous NaHCO3 (3 x 5 mL) and brine (2 x 5 mL).  The 
combined organic layers were dried (Na2SO4) and concentrated under reduced pressure 
to give a dark yellow oil.  The residue was purified by flash chromatography eluting with 
hexanes/EtOAc (1.5:1) to give 224 mg of 2.071 (85%) as a pale yellow oil; 1H NMR 
(500 MHz, CDCl3) δ 4.60-4.54 (br s, 1 H), 3.71 (s, 3 H), 3.68-3.64 (m, 1 H), 3.66 (s, 3 
H), 3.46-3.38 (br s, 1 H), 2.79-2.74 (comp, 2 H), 2.63 (dd, J = 16.1 Hz, 7.2 Hz, 1 H), 
2.54-2.50 (br s, 1 H), 1.81-1.74 (m, 1 H), 1.41 (s, 9 H), 0.87 (d, J = 6.9 Hz, 3 H), 0.84 (d, 
 215
J = 6.9 Hz, 3 H); 13C NMR (125 MHz) δ 173.4, 171.2, 156.2, 79.1, 57.7, 55.5, 52.2, 
51.9, 49.2, 37.3, 30.0, 28.4, 19.3, 18.0; IR 3378, 2959, 1738, 1504, 1360, 1247, 1171, 
1003, 866, 733 cm-1; mass spectrum (CI) m/z 347.2182 (base) [C16H30N2O6 (M+1) 
requires 347.2104], 291, 247.  
NMR Assignments: 1H NMR (500 MHz, CDCl3) δ 4.60-4.54 (br s, 1 H, N-H), 
3.71 (s, 3 H, C10-H or C7-H), 3.68-3.64 (m, 1 H, C5-H), 3.66 (s, 3 H, C10-H or C7-H), 
3.46-3.38 (br s, 1 H, C1-H), 2.79-2.74 (comp, 2 H, C8-H & C4-H), 2.63 (dd, J = 16.1 Hz, 
7.2 Hz, 1 H, C8-H), 2.54-2.50 (br s, 1 H, C4-H), 1.81-1.74 (m, 1 H, C2-H), 1.41 (s, 9 H, 
C13-H), 0.87 (d, J = 6.9 Hz, 3 H, C3-H), 0.84 (d, J = 6.9 Hz, 3 H, C3’-H); 13C NMR (75 
MHz) δ 173.4 (C11), 171.2 (C9), 156.2 (C6), 79.1 (C12), 57.7 (C5), 55.5 (C1), 52.2 (C10 
































methylbutylamino)succinic acid dimethyl ester (2.072). (tbs132)  iPr2NEt (46 µL, 0.32 
mmol) and benzyl chloroformate (51 µL, 0.29 mmol) were added to a solution of 2.071 
(56 mg, 0.16 mmol) in CH2Cl2 (2.0 mL) at rt.  After stirring 2 h at rt, the reaction mixture 
was concentrated under reduced pressure.  The residue was purified by flash 
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chromatography eluting with hexanes/EtOAc (2:1) to give 70 mg (90%) of 2.072 as a 
pale yellow oil; 1H NMR (500 MHz, DMSO-d6, 373K) δ 7.37-7.29 (comp, 5 H), 5.95-
5.92 (br s, 1 H), 5.08 (s, 2 H), 4.50 (qt, J = 4.0 Hz, 1 H), 3.63 (s, 3 H), 3.58-3.56 (m, 1 
H), 3.57-3.54 (m, 1 H), 3.56 (s, 1 H), 3.17 (dd, J = 17.2, 5.8 Hz, 1 H), 3.16 (d, J = 9.1 Hz, 
1 H), 2.69 (dd, J = 17.2, 5.8 Hz, 1 H), 1.69 (hept, J = 5.0 Hz, 1 H), 1.37 (s, 9 H), 0.85 (d, 
J = 6.8 Hz, 3 H), 0.82 (d, J = 6.8 Hz, 3 H); 13C NMR (125 MHz, DMSO, 100 °C) δ 
169.9, 169.6, 154.9, 154.7, 135.8, 127.5, 127.1, 126.9, 77.1, 66.3, 58.0, 55.0, 51.3, 50.9, 
50.6, 34.6, 29.7, 27.54, 18.4, 16.9: mass spectrum (CI) m/z 480.2550 [C24H36N2O8 
(M+1) requires 481.2548], 425, 381 (base). 
NMR Assignments: 1H NMR (500 MHz, DMSO-d6, 373K) δ 7.37-7.29 (comp, 5 
H, C17-H, C18-H, & C19-H), 5.95-5.92 (br s, 1 H, N-H), 5.08 (s, 2 H, C15-H), 4.50 (qt, 
J = 4.0 Hz, 1 H, C5-H), 3.63 (s, 3 H, C10-H or C7-H), 3.58-3.56 (m, 1 H, C1-H), 3.57-
3.54 (m, 1 H, C4-H), 3.56 (s, 1 H, C10-H or C7-H), 3.17 (dd, J = 17.2, 5.8 Hz, 1 H, C8-
H), 3.16 (d, 1 H, J = 9.1 Hz, C4’-H), 2.69 (dd, J = 17.2, 5.8 Hz, 1 H, C8’-H), 1.69 (hept, 
J = 5.0 Hz, 1 H, C2-H), 1.37 (s, 9 H, C13-H), 0.85 (d, J = 6.8 Hz, 3 H, C3-H), 0.82 (d, J 
= 6.8 Hz, 3 H, C3’-H); 13C NMR (125 MHz, DMSO, 100 °C) δ 169.9 (C9 or C6), 169.6 
(C9 or C6), 154.9 (C14 or C11), 154.7 (C14or C11), 135.8 (C16), 127.5 (C17, C18, or 
C19), 127.1 (C17, C18, or C19), 126.9 (C17, C18, or C19), 77.1 (C12), 66.3 (C15), 58.0 
(C5), 55.0 (C1), 51.3 (C4), 50.9 (C10 or C7), 50.6 (C10 or C7), 34.6 (C8), 29.7 (C2), 
























(2S, 2S’)-2-[(tert-butoxycarbonyl)amino]-3-methylbutyl}aspartamide (2.070). 
(aw1-81).  NaCN (5 mg, 0.09 mmol) was added to a stirred solution of 2.071 (290 mg, 
0.92 mmol) in MeOH (10 mL) at rt.  The reaction mixture was saturated with NH3 by 
bubbling the gas into solution for 20 min at rt.  The reaction was stirred at 50 oC for 3 d, 
during which time it was resaturated with NH3 every 12 h.  The mixture was then 
concentrated under reduced pressure, and the residue was recrystallized from minimal 
amounts of hot CH3CN (ca. 7 mL) to yield 200 mg of 2.070 (69%) as a off white solid: 
mp 175-177 oC; 1H NMR (500 MHz, CD3OD) δ 3.39-3.37 (comp, 2 H), 2.64 (dd, J = 
11.8. 4.2 Hz, 1 H), 2.57 (dd, J = 15.3, 4.2 Hz, 1 H), 2.54 (dd, J = 11.7, 4.1 Hz, 1 H), 2.45 
(dd, J = 15.3, 4.2 Hz, 1 H), 1.73 (app hep, J = 6.8 Hz, 1 H), 1.44 (s, 9 H), 0.90 (d, J = 6.8 
Hz, 3 H), 0.88 (d, J = 6.8 Hz, 3 H); 13C NMR (125 MHz, CD3OD) δ 178.9, 176.0, 158.8, 
79.9, 60.8, 57.6, 50.8, 38.8, 31.8, 28.8, 19.9, 18.7; IR 3292, 2361, 1664 cm-1, mass 
spectrum (CI) m/z 317.2194 [C14H29N4O4 (M+1) requires 317.2189], 200 (base), 182. 
NMR Assignments:  1H NMR (500 MHz, CD3OD) δ 3.39-3.37 (comp, 2 H, C1-
H & C5-H), 2.64 (dd, J = 11.8. 4.2 Hz, 1 H, C6-H), 2.57 (dd, J = 15.3, 4.2 Hz, 1 H, C4-
H), 2.54 (dd, J = 11.7, 4.1 Hz, 1 H, C6’-H), 2.45 (dd, J = 15.3, 4.2 Hz, 1 H, C4’-H), 1.73 
(app hep, J = 6.8 Hz, 1 H, C2-H), 1.44 (s, 9 H, C11-H), 0.90 (d, J = 6.8 Hz, 3 H, C3-H), 
0.88 (d, J = 6.8 Hz, 3 H, C3’-H); 13C NMR (125 MHz, CD3OD) δ 178.9 (C7 or C8), 
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176.0 (C7 or C8), 158.8 (C9), 79.9 (C10), 60.8 (C1 or C5), 57.6 (C1 or C5), 50.8 (C6), 













































(2S,2S’,1S’’) Phosphoric acid 4-(2-acetylamino-2-1{-[1,2-
dicarbamoylethylamino)methyl]-2-methylpropylcarbamoyl}ethyl)phenyl ester 
dibenzyl ester (2.076). (aw1-73).  A solution of 2.070 (85 mg, 0.20 mmol) neat in TFA 
(1 mL) was stirred for 90 min.  The reaction mixture was concentrated under reduced 
pressure, and the residue was triturated with Et2O (3 x 2 mL) to give an off-white solid.  
This crude amine was dissolved in DMF (2 mL) containing 2.030 (97 mg, 0.20 mmol) at 
–10 oC, and 2,6-lutidine (70 µL, 0.60 mmol), and HATU (76 mg, 0.20 mmol) were 
added.  The cooling bath was removed, and the mixture was slowly warmed to rt over 1 h 
and stirred at rt for 15 h.  The mixture was concentrated under reduced pressure, and the 
residue was dissolved in EtOAc (10 mL).  The mixture was washed with saturated 
NaHCO3 (3 x 10 mL) and brine (10 mL), dried (Na2SO4), and concentrated under 
reduced pressure.  The crude residue was purified by flash chromatography, eluting with 
CH2Cl2/MeOH (19:1) to yield 40 mg of 2.076 (30%) as a clear solid: mp 69 – 74 oC; 1H 
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NMR (500 MHz, DMSO-d6) δ 8.04-8.03 (d, J = 8.5 Hz, 1 H), 7.50 (br d, J = 9.0 Hz, 1 
H), 7.39-7.34 (comp, 12 H), 7.26 (d, J = 8.5 Hz, 2 H), 7.07-7.04 (comp, 3 H), 6.81 (s br, 
1 H), 5.13 (s, 2 H), 5.12 (s 2 H), 4.48 (ddd, J = 10.3, 8.5, 4.0 Hz, 1 H), 3.62-3.57 (m, 1 
H), 3.19 (br s, 1 H), 2.95 (dd, J = 13.9, 4.0 Hz, 1 H), 2.71 (dd, J = 13.9, 10.3 Hz, 1 H), 
2.47-2.44 (m, 2 H), 2.36 (dd, J = 14.9, 4.0 Hz, 1 H), 2.22 (dd, J = 14.9, 8.6 Hz, 1 H), 
1.77-1.70 (comp, 4 H), 0.81 (dd, J = 9.8, 6.8 Hz, 6 H); 13C NMR (125 MHz, DMSO- d6) 
δ 172.6, 171.3, 169.0, 166.3, 148.6, 135.7, 135.6, 135.3, 130.5, 128.5, 127.9, 119.4, 
119.3, 69.3, 69.2, 59.2, 54.0, 53.7, 48.9, 37.7, 36.9, 29.2, 22.4 19.4, 18.3; IR 3010, 2395, 
1217, 777. 666 cm-1; mass spectrum (FAB) m/z 682.3031 [C34H44N5O8P (M+1) requires 
682.3001], 289, 307, 682 (base).   
NMR Assignments. 1H NMR (500 MHz, DMSO-d6) δ 8.04–8.03 (d, J = 8.5 Hz, 
1 H, N-H), 7.50 (br d, J = 9.0 Hz, 1 H, N-H), 7.39–7.34 (comp, 12 H, C20-H & C20’-H, 
C21-H & C21’-H, C22-H & C22’-H, C23-H & C23’-H, C24-H & C24’-H, N-H), 7.26 (d, 
J = 8.5 Hz, 2 H, C15-H & C15’-H or C16-H & C16’-H), 7.07–7.04 (comp, 3 H, C15-H & 
C15’-H or C16-H & C16’-H, N-H), 6.81 (s br, 1 H, N-H), 5.13 (s, 2 H,  C18-H or C18’-
H), 5.12 ( s, 2 H, C18-H or C18’-H), 4.48 (ddd, J = 4.0, 8.5, 10.3 Hz, 1 H, C10-H), 3.62–
3.57 (m, 1 H, C2-H), 3.19 (s br, 1 H, C5-H), 2.95 (dd, J = 4.0, 13.9 Hz, 1 H, C13-H or 
C13’-H), 2.71 (dd, J = 10.3, 13.9 Hz, 1 H, C13-H or C13’-H), 2.45 (m, 2 H, C1-H), 2.36 
(dd, J = 14.8, 15.1 Hz, 1 H, C7-H or C7’-H), 2.22 (dd, J = 14.8, 15.1 Hz, 1 H, C7-H or 
C7’-H), 1.77–1.70 (comp, 4 H, C3-H and C12-H), 0.81 (dd, J = 9.8, 6.8 Hz, 6 H, C4-H);  
13C NMR (125 MHz, DMSO) δ 172.6 (C8), 171.3 (C9), 169.0 (C11), 166.3 (C6), 148.6 
(C14 or C17), 135.7 (C19, C19’, C20, C20’, C21, C21’, C22, C22’, C23, C23’, C24, or 
C24’), 135.6 (C19, C19’, C20, C20’, C21, C21’, C22, C22’, C23, C23’, C24, or C24’), 
135.3 (C14 or C17), 130.5 (C19, C19’, C20, C20’, C21, C21’, C22, C22’, C23, C23’, 
C24, or C24’), 128.5 (C19, C19’, C20, C20’, C21, C21’, C22, C22’, C23, C23’, C24, or 
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C24’), 127.9 (C19, C19’, C20, C20’, C21, C21’, C22, C22’, C23, C23’, C24, or C24’), 
119.4 (C15 & C15’ or C16 & C16’), 119.3 (C15 & C15’ or C16 & C16’), 69.3 (C18 or 
C18’), 69.2 (C18 or C18’), 59.2 (C5), 54.0 (C10), 53.7 (C2), 48.9 (C1), 37.7 (C7), 36.9 



































(2S, 2S’, 1S’’) Phosphoric acid mono-[4-(2-acetylamino-2-{1-[(1,2-
dicarbamoyl ethylamino) methyl]-2-methyl propylcarbamoyl} ethyl) phenyl] ester 
(2.007). (aw2-45).  A solution of 2.076 (25 mg, 0.04 mmol) in EtOH and H2O (1:1, 2 
mL) containing 10 % Pd/C (10 mg) and 0.5 M HCl (37 µL) was stirred under H2 (1 atm) 
at rt for 2 h.  The catalyst was removed by filtration through a pad of celite, and the 
filtrate was concentrated to yield 17 mg (94%)of 5 as a white solid: mp 204-206 dec oC; 
1H NMR (500 MHz, D2O) δ 7.27 (d, J = 8.2 Hz, 2 H), 7.17 (d, J = 8.2 Hz, 2 H), 4.57 (dd, 
J = 8.4, 7.0 Hz, 1 H), 4.26 (dd, J = 7.7, 4.9 Hz, 1 H), 3.98–3.94 (m, 1 H), 3.21 (dd, J = 
12.9, 4.3 Hz, 1 H), 3.13 (dd, J = 13.9, 7.0 Hz, 1 H), 3.05–2.97 (comp, 2 H), 2.95–2.87 
(comp, 2 H), 1.96 (s, 3 H), 1.90–1.84 (m, 1 H), 0.88 (dd, J = 16.9, 6.8 Hz, 6 H); 13C 
NMR (125 MHz, D2O) δ 177.0, 176.9, 175.7, 172.3, 133.1, 123.2, 60.0, 58.1, 55.0, 51.1, 
38.7, 36.4, 32.5, 24.3, 21.0, 19.4; mass spectrum (FAB) m/z 500.1930 [C20H32N5O8P 
(M-1) requires 500.1910], 275, 386, 500 (base). 
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NMR Assignments.  1H NMR (500 MHz, D2O) δ 7.27 (d, J = 8.2 Hz, 2 H, C13-
H or C14-H), 7.17 (d, J = 8.2 Hz, 2 H, C13-H or C14-H), 4.57 (dd, J = 8.4, 7.0 Hz, 1 H, 
C10-H), 4.26 (dd, J = 7.7, 4.9 Hz, 1 H, C6-H), 3.98-3.94 (m, 1 H, C2-H), 3.21 (dd, J = 
12.9, 4.3 Hz, 1 H, C1-H), 3.13 (dd, J = 13.9, 7.0 Hz, 1 H, C11-H), 3.05-2.97 (comp, 2 H, 
C7-H & C11’-H), 2.95-2.87 (comp, 2 H, C1’-H & C7’-H), 1.96 (s, 3 H, C17-H), 1.90-
1.84 (m, 1 H, C3-H), 0.88 (dd, J = 16.9, 6.8 Hz, 6 H, C4-H); 13C NMR (125 MHz, D2O) 
δ 177.0 (C5 or C8 or C9 or C16), 176.9 (C5 or C8 or C9 or C16), 175.7 (C5 or C8 or C9 
or C16), 172.3 (C5 or C8 or C9 or C16), 153.8 (C12 or C15), 153.7 (C12 or C15), 133.1 
(C13 or C14), 123.2 (Cy13 or C14), 60.0 (C6), 58.1 (C10), 55.0 (C2), 51.1 (C1), 38.7 


















hydrazide (2.079). (hrp3-168)  Hydrazine monohydrate (1.33 mL, 27.5 mmol) was 
added over 15 min to a solution of lactone 2.078 (522 mg, 4.66 mmol) in MeOH (50 mL) 
at rt .  The reaction was stirred at rt for 1 d and then concentrated under reduced pressure 
to give a white solid that was recrystallized from hot isopropanol to yield 631 mg (94%) 
of 2.079 as a white solid: mp 92-95 oC; 1H NMR (500 MHz, CD3OD) δ 3.78 (dd, J = 
11.4, 6,2 Hz, 1 H), 3.36 (dd, J = 11.4, 7.6 Hz, 1 H), 1.42-1.36 (comp, 2 H), 1.27-1.21 (m, 
1 H), 1.1 (d, J = 5.8 Hz, 3 H); 13C NMR (125 MHz, CD3OD) δ 173.9, 60.6, 32.0, 26.6, 
19.5, 17.8; IR 1608, 1518, 1435, 1260, 1014 cm-1, mass spectrum (CI) m/z 145.0975 
[C6H12N2O2 (M+1) requires 145.0977], 127. 
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NMR Assignments.  1H NMR (500 MHz, CD3OD) δ 3.78 (dd, J = 11.4, 6,2 Hz, 
1 H, C5-H), 3.36 (dd, J = 11.4, 7.6 Hz, 1 H, C5’-H), 1.42-1.36 (comp, 2 H, 1-H & C3-H), 
1.27-1.21 (m, 1 H, C2-H), 1.1 (d, J = 5.8 Hz, 3 H, C4-H); 13C NMR (125 MHz, CD3OD) 















052).  6 N aqueous HCl (2.0 mL, 12.0 mmol) was added dropwise to a vigorously stirred 
mixture of NaNO2 (833 mg, 12.0 mmol) and hydrazide 2.079 (1.16 g, 8.05 mmol) in a 
mixture of Et2O (20 mL) and H2O (20 mL) at 0 °C.  The yellow mixture was stirred 
vigorously at 0 °C for 45 min, and then cold toluene (20 mL) was added.  The layers 
were separated, and the aqueous layer was extracted with toluene (3 x 20 mL).  The 
organic layers were combined, washed with brine (1 x 20 mL), dried (Na2SO4) and 
concentrated under reduced pressure to approximately 50 mL.  A stirbar was added, and 
the mixture was heated at 80 °C for 2 h.  After cooling to rt, the solvent was removed 
under reduced pressure to yield 867 mg (85%) of 2.080 as an orange-yellow oil.   This 
material was shown to be >95% pure by 1H NMR and was used without further 
purification:  1H NMR (500 MHz, CDCl3) δ 6.00 (br s, 1 H), 4.68 (dd, J = 11.9, 6.8 Hz, 1 
H), 4.05 (dd, J = 11.9, 5.4 Hz, 1 H), 2.54 (dt, J = 8.7, 2.4 Hz, 1 H), 1.29-1.24 (m, 1 H), 
1.04-0.98 (comp, 4 H); 13C NMR (125 MHz, CDCl3) δ 155.19, 69.3, 34.24, 23.9, 15.8, 
15.2; IR (CDCl3) 3019, 2253, 1715, 1469, 1213, 908, 789, 734, 651 cm-1; mass spectrum 
(CI) m/z 128.0718 [C6H9NO2 (M+1) requires 128.0711], 110, 84. 
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NMR Assignments.  1H NMR (500 MHz, CDCl3) δ 6.00 (br s, 1 H, N-H), 4.68 
(dd, J = 11.9, 6.8 Hz, 1 H, C5-H), 4.05 (dd, J = 11.9, 5.4 Hz, 1 H, C5-H), 2.54 (dt, J = 
8.7, 2.4 Hz, 1 H, C3-H), 1.29-1.24 (m, 1 H, C2-H), 1.04-0.98 (comp, 4 H, C1-H & C4-
H); 13C NMR (125 MHz, CDCl3) δ 155.19 (C6), 69.3 (C5), 34.2 (C3), 23.9 (C1), 15.8 





















(2S, 1’S, 2’R, 3’S)-2-(2-Hydroxymethyl-3-methyl-1-cyclopropylamino) 
succinic acid dimethyl ester (2.082). (hrp4-53 & hrp4-54).  Ba(OH)2 . 8 H2O (4.30 g, 
13.64 mmol) was added to a mixture of urethane 2.080 (867 mg, 6.82 mmol) in dioxane 
and H2O (2:1, 37 mL).  The mixture was heated under reflux for 90 min with vigorous 
stirring.  The mixture was cooled and filtered through a pad of celite.  The pad was then 
washed with CH2Cl2 (2 x 40 mL) washes, and the combined filtrate and washing were 
concentrated to ~ 5 mL and CH2Cl2 (100 mL) was added.  The solution was dried 
(Na2SO4) and concentrated under reduced pressure to yield 498 mg of crude 2.081 (72%) 
as a yellow oil.  Freshly distilled Tf2O (2.50 g, 1.5 mL, 8.86 mmol) was added dropwise 
to a solution of  (R)-dimethylmalate (1.710 g, 1.4 mL, 10.6 mmol) in CH2Cl2 (30 mL) at 
0 °C.  This mixture was stirred at 0 °C for 5 min, and 2,6-lutidine (948 mg, 1.03 mL, 8.86 
mmol) was added.  This mixture was stirred at 0 °C for an additional 10 min, and then 
iPr2NEt (1.21 g, 1.63 mL, 9.35 mmol) was added.  A mixture of amino alcohol 2.081 
(498 mg, 4.92 mmol) and iPr2NEt (769 mg, 0.857 mL, 4.92 mmol) in CH2Cl2 (10 mL) 
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was added dropwise.  The mixture was stirred at 0 oC for 1 h and then stirred to rt for 30 
min.  CH2Cl2 (20 mL) was added, and the mixture was washed with brine (20 mL).  The 
aqueous layer was extracted with CH2Cl2 (1 x 20 mL), and the combined organic layers 
were dried (Na2SO4) and concentrated under reduced pressure.  The residue was purified 
by flash column chromatography eluting with EtOAc/hexanes (1:1 to 2:1) to yield 712 
mg 2.082 (59%) as a yellow oil; 1H NMR (500 MHz) δ 3.94 (dd, J = 11.3, 3.1 Hz, 1 H) 
3.80 (dd, J = 11.3, 5.3 Hz, 1 H), 3.77 (s, 3 H), 3.72 (dd, J = 7.9, 5.2 Hz, 1 H) 3.68 (s, 3 
H), 2.71 (d, J = 15.9, 5.2 Hz, 1 H), 2.68-2.57 (br s, 1 H), 2.60 (dd, J = 15.9, 7.9 Hz, 1 H), 
2.11 (dd, J = 6.9, 3.2 Hz, 1 H), 1.02 (d, J = 6.1, 3 H), 0.99-0.95 (m, 1 H), 0.77-0.73 (m, 1 
H); 13C NMR (125 MHz,) δ 173.8, 171.1, 59.9, 58.1, 52.2, 51.9, 40.6, 37.8, 27.6, 16.8, 
15.2; IR 3019, 2400, 2253, 1735, 1522, 1475, 1436, 1216, 908 cm-1; mass spectrum (CI) 
m/z 246.1348 [C11H19NO5 (M+1) requires 246.1341], 228, 214. 
NMR Assignments.  1H NMR (500 MHz) δ 3.94 (dd, J = 11.3, 3.1 Hz, 1 H, C5-
H) 3.80 (dd, J = 11.3, 5.3 Hz, 1 H, C5-H), 3.77 (s, 3 H, C10-H or C11-H), 3.72 (dd, J = 
7.9, 5.2 Hz, 1 H, C6-H) 3.68 (s, 3 H, C10-H or C11-H), 2.71 (d, J = 15.9, 5.2 Hz, 1 H, 
C7-H), 2.68-2.57 (br s, 1 H, N-H), 2.60 (dd, J = 15.9, 7.9 Hz, 1 H, C7-H), 2.11 (dd, J = 
6.9, 3.2 Hz, 1 H, C2-H), 1.02 (d, J = 6.1, 3 H, C4-H), 0.99-0.95 (m, 1 H, C3-H), 0.77-
0.73 (m, 1 H, C1-H); 13C NMR (125 MHz,) δ 173.8 (C8 or C9), 171.1 (C8 or C9), 59.9 
(C5), 58.1 (C6), 52.2 (C10 or C11), 51.9 (C10 or C11), 40.6 (C2), 37.8 (C7), 27.6 (C1), 




















(2S, 1’S, 2’R, 3’S)-2-(2-Hydroxymethyl-3-methylcyclopropylamino) 
succinamide (2.083). (hrp4-055). NaCN (9 mg, 0.188 mmol) was added to a stirred 
solution of 14 (461 mg, 1.88 mmol) in MeOH (19 mL) at rt.  The reaction mixture was 
saturated with NH3 by bubbling the gas into the solution for 20 min at rt.  The reaction 
was stirred at 55 oC for 3 d during which time it was resaturated with NH3 every 12 h.  
The mixture was concentrated under reduced pressure, and the residue was recrystallized 
from minimal amounts of hot CH3CN (10 mL total) to yield 242 mg of 2.083 (60%) as an 
off white solid: mp 153-156 oC; 1H NMR (500 MHz, CD3OD) δ 3.76 (dd, J = 11.2, 5.2 
Hz, 1 H), 3.61 (dd, J = 11.2, 8.0 Hz, 1 H), 3.55 (dd, J = 8.6, 5.0 Hz, 1 H), 2.48 (dd, J = 
15.0, 5.0 Hz, 1 H), 2.42 (dd, J = 15.0, 8.6 Hz, 1 H), 2.00 (dd, J = 7.1, 3.4 Hz, 1 H), 1.03 
(d, J = 6.2 Hz, 1 H), 0.82-0.76 (m, 1 H), 0.67-0.62 (m, 1 H); 13C NMR (125 MHz, 
CD3OD) δ 178.9, 176.1, 61.5, 60.2, 41.9, 35.5, 30.0, 18.8, 17.3; IR 2361, 1655, 1408 cm-
1, mass spectrum (CI) m/z 216.1341 [C9H18N3O3 (M+1) requires 216.1348], 198, 133. 
NMR Assignments.  1H NMR (500 MHz, CD3OD) δ 3.76 (dd, J = 11.2, 5.2 Hz, 
1 H, C5-H), 3.61 (dd, J = 11.2, 8.0 Hz, 1 H, C5-H), 3.55 (dd, J = 8.6, 5.0 Hz, 1 H, C6-H), 
2.48 (dd, J = 15.0, 5.0 Hz, 1 H, C7-H), 2.42 (dd, J = 15.0, 8.6 Hz, 1 H, C7-H), 2.00 (dd, J 
= 7.1, 3.4 Hz, 1 H, C1-H), 1.03 (d, J = 6.2 Hz, 1 H, C4-H), 0.82-0.76 (m, 1 H, C2-H), 
0.67-0.62 (m, 1 H, C3-H); 13C NMR (125 MHz, CD3OD) δ 178.9 (C8  or C9), 176.1 (C8  





























(2S, 1’S, 2’R, 3’S)-(1,2-Dicarbamoylethyl)-(2-hydroxymethyl-3-
methylcyclopropyl) carbamic acid benzyl ester (2.084). (hrp4-108).  iPr2NEt (209 mg, 
282 µL, 1.62 mmol) and Cbz-Cl (184 mg, 154 µL, 1.08 mmol) were added to a stirred 
solution of 2.083 (233 mg, 1.08 mmol) in a mixture of THF and CH3CN (1:1, 10 mL 
total), and then the reaction was heated under reflux for 24 h. The mixture was cooled to 
rt, and EtOAc (10 mL) was added.  The mixture was washed with 1 M HCl sat. with 
NaCl (1 x 10 mL), and the aqueous layer was back extracted with EtOAc (2 x 10 mL).   
The combined organic layers were washed with sat. Na2CO3 (2 x 10 mL), and the 
aqueous layer was back extracted with EtOAc (2 x 10 mL).  The organic layers were 
combined and dried (Na2SO4).  The solvent was removed under reduced pressure, and 
the residue was purified by flash column chromatography eluting with CHCl3/MeOH 
(6:1) to give 236 mg (62%) of 2.084 as an clear oil; 1H NMR (500 MHz, DMSO-d6, 383 
K) δ 7.40-7.12 (comp, 5 H), 6.75 (br s, 4 H), 5.12 (d, , J = 12.8 Hz, 1 H), 5.05 (d, J = 
12.8 Hz, 1 H) , 4.58 (dd, J = 7.5, 6.2 Hz, 1 H), 3.80 (br s, 1 H), 3.57-3.52 (m, 1 H), 3.38-
3.33 (m, 1 H), 2.89 (dd, J = 15.8, 6.2 Hz, 1 H), 2.63 (dd, J = 15.8, 7.5 Hz, 1 H), 2.45 (dd, 
J = 7.8, 4.0 Hz, 1 H), 1.12-1.08 (m, 1 H), 1.04 (d, J = 5.9 Hz, 3 H), 0.94-0.90 (m, 1 H); 
13C NMR (125 MHz, DMSO-d6, 383K) δ 171.9, 171.6, 156.9, 136.8, 128.2, 127.6, 
127.5, 127.0, 126.8, 66.1, 58.9, 58.6, 41.2, 35.0, 29.8, 16.4, 16.2; IR 3480, 3408, 2960, 
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1690, 1590, 1400, 1309, 908 cm-1; mass spectrum (CI) m/z 350.1725 [C17H24N3O5 
(M+1) requires 350.1420], 169. 
NMR Assignments. 1H NMR (500 MHz, DMSO-d6, 383 K) δ 7.40-7.12 (comp, 
5 H, C13-H, C14-H & C15-H), 6.75 (br s, 4 H, N-H), 5.12 (d, , J = 12.8 Hz, 1 H, C11-H), 
5.05 (d, J = 12.8 Hz, 1 H, C11-H) , 4.58 (dd, J = 7.5, 6.2 Hz, 1 H, C6-H), 3.80 (br s, 1 H, 
O-H), 3.57-3.52 (m, 1 H, C5-H), 3.38-3.33 (m, 1 H, C5-H), 2.89 (dd, J = 15.8, 6.2 Hz, 1 
H, C7-H), 2.63 (dd, J = 15.8, 7.5 Hz, 1 H, C7-H), 2.45 (dd, J = 7.8, 4.0 Hz, 1 H, C2-H), 
1.12-1.08 (m, 1 H, C1-H), 1.04 (d, J = 5.9 Hz, 3 H, C4-H), 0.94-0.90 (m, 1 H, C3-H); 
13C NMR (125 MHz, DMSO-d6, 383K) δ 171.9 (C8 or C9), 171.6 (C8 or C9), 156.9 
(C10), 136.8 (C12), 128.2 (C13, C14 or C15), 127.6 (C13, C14 or C15), 127.5 (C13, C14 
or C15), 127.0 (C13, C14 or C15), 126.8 (C13, C14 or C15), 66.1 (C11), 58.9 (C5), 58.6 




























(1’’S, 2R, 3S, 1S)-2-[Benzyloxycarbonyl-(1,2-dicarbamoylethyl) amino]-3-
methylcyclopropanecarboxylic acid (2.085). (hrp4-112).  A mixture of NaHCO3 (375 
mg, 4.46 mmol), NaIO4 (808 mg, 3.78 mmol), RuCl3 (14 mg, 0.0675 mmol) and 2.084 
(236 mg, 0.675 mmol) in CH3CN/CCl4/H2O (1:1:2, 28 mL total) was stirred vigorously 
for 30 min at rt.  An additional 0.1 mole equivalent of RuCl3 was then added, and the 
reaction mixture was stirred vigorously for 1 h at rt.  The reaction mixture was diluted 
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with CH2Cl2 (30 mL), and the layers were separated.  The aqueous layer was washed 
with CH2Cl2 (2 x 30 mL).  The aqueous layer was acidified with 1 M HCl sat. with NaCl.  
The aqueous layer was then extracted with EtOAc (3 x 30 mL).  The organic layers were 
combined and dried (Na2SO4).  The solvent was removed under reduced pressure, and 
the residue was purified by flash column chromatography eluting with CH2Cl2/EtOH 
(4:1) containing 1% CH3CO2H to give 110 mg of the major diastereomer and 24 mg of 
the other diastereomers  of 22 (54%) as an clear oil:  1H NMR (500 MHz, DMSO-d6, 
383K) δ 7.38-7.28 (comp, 5 H), 5.16 (d, J =12.9 Hz, 1 H), 4.91 (d, J =12.9 Hz, 1 H), 
4.74 (dd, J =8.8, 5.4 Hz, 1 H), 3.00 (dd, J =16.2, 5.4 Hz, 1 H), 2.74 (t, J =6.0 Hz, 1 H), 
2.57 (dd, J =16.2, 8.8 Hz, 1 H), 1.76-1.72 (m, 2 H), 1.14 (d, J =5.6 Hz, 3 H); 13C NMR 
(125 MHz, DMSO-d6, 383K) δ172.4, 172.0, 171.4, 156.0, 136.0, 127.6, 127.0, 126.7, 
66.3, 57.9, 41.6, 34.0, 28.7, 22.0, 15.0; mass spectrum (CI) m/z 364.1449 [C17H22N3O6 
(M+1) requires 364.1509], 347. 
NMR Assignments.  1H NMR (500 MHz, DMSO-d6, 383K) δ 7.38-7.28 (comp, 
5 H, C13-H, C14-H & C15-H), 5.16 (d, J =12.9 Hz, 1 H, C11-H), 4.91 (d, J =12.9 Hz, 1 
H, C11-H), 4.74 (dd, J =8.8, 5.4 Hz, 1 H, C6-H), 3.00 (dd, J =16.2, 5.4 Hz, 1 H, C7-H), 
2.74 (t, J =6.0 Hz, 1 H, C2-H), 2.57 (dd, J =16.2, 8.8 Hz, 1 H, C7-H), 1.76-1.72 (m, 2 H, 
C1-H & C3-H), 1.14 (d, J =5.6 Hz, 3 H, C4-H); 13C NMR (125 MHz, DMSO-d6, 383K) 
δ 172.4 (C8 or C9), 172.0 (C8 or C9), 171.4 (C5), 156.0 (C10), 136.0 (C12), 127.6 (C13, 
C14 or C15), 127.0 (C13, C14 or C15)126.7 (C13, C14 or C15), 66.3 (C11), 57.9 (C6), 

































(1’’’S, 2’R, 3’S, 1S)-{2-[Benzyloxycarbonyl-(1,2-dicarbamoylethyl) amino]-3-
methylcyclopropyl} carbamic acid tert butyl ester (2.086). (hrp4-109).  Ethyl 
chloroformate (27 mg, 24 µL, 0.250 mmol) and Et3N (23 mg, 32 µL, 0.232 mmol) were 
added to a solution of 2.085 (70 mg, 0.193 mmol) in aqueous acetone (10:1, 2 mL total) 
at 0 oC, and the mixture was stirred at 0 oC for 30 min.  A solution of NaN3 (19 mg, 
0.290 mmol) dissolved in H2O (200 µL) was then added, and the mixture was stirred at 0 
oC for 30 min.  Cold H2O (2 mL) was added, and the mixture was extracted with CH2Cl2 
(3 x 5 mL).  The organic layers were combined, dried (Na2SO4) and concentrated to ca. 2 
mL under reduced pressure.  tert-Butyl alcohol (2 mL) was added, and the reaction was 
heated under reflux for 13 h.  The reaction was then concentrated under reduced pressure 
to yield 44 mg of 2.086 (59%) as a yellow oil; 1H NMR (500 MHz, DMSO-d6, 373K) δ 
7.38-7.28 (m, 5 H), 6.85 (br s, 4 H), 6.18 (br s, 1 H), 5.15 (d, J = 12.7 Hz, 1 H), 5.00 (d, J 
= 12.7 Hz, 1 H), 4.60 (dd, J = 7.8, 6.1, Hz, 1 H), 2.88 (dd, J = 15.8, 6.1 Hz, 1 H), 2.64 
(dd, J = 15.8, 7.8 Hz, 1 H) 2.61-2.59 (m, 1 H), 2.39-2.37, (m, 1 H), 1.38 (s, 9 H), 1.25-
1.18 (m, 1 H) 1.05 (d, J = 6.4 Hz, 1 H);13C NMR (125 MHz, DMSO-d6, 373K) δ 172.5, 
171.5, 156.2, 155.2, 136.2, 127.6, 127.0, 126.7, 77.4, 66.1, 57.9, 39.8, 36.7, 34.8, 27.7, 
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19.0, 14.7; IR 2624, 2253, 1794, 1689, 1462, 1382, 1096, 945, 902 cm-1; mass spectrum 
(CI) m/z 435.2248 [C21H30N4O6 (M+1) requires 435.2244], 421, 379, 162.   
NMR Assignments.  1H NMR (500 MHz, DMSO-d6, 373K) δ 7.38-7.28 (m, 5 H, 
C12-H, C13-H, C14-H), 6.85 (br s, 4 H, N-H), 6.18 (br s, 1 H, N-H), 5.15 (d, J = 12.7 
Hz, 1 H, C10-H), 5.00 (d, J = 12.7 Hz, 1 H, C10’-H), 4.60 (dd, J = 7.8, 6.1, Hz, 1 H, C5-
H), 2.88 (dd, J = 15.8, 6.1 Hz, 1 H, C6-H), 2.64 (dd, J = 15.8, 7.8 Hz, 1 H, C6-H) 2.61-
2.59 (m, 1 H, C1-H or C2-H), 2.39-2.37, (m, 1 H, C1-H or C2-H), 1.38 (s, 9 H, C17-H), 
1.25-1.18 (m, 1 H, C3-H) 1.05 (d, J = 6.4 Hz, 1 H, C4-H);13C NMR (125 MHz, DMSO-
d6, 373K) δ 172.5 (C7 or C8 or C9 or C15), 171.5 (C7 or C8 or C9 or C15), 156.2 (C7 or 
C8 or C9 or C15), 155.2 (C7 or C8 or C9 or C15), 136.2 (C11), 127.6 (C12 or C13 or 
C14), 127.0 (C12 or C13 or C14), 126.7 (C12 or C13 or C14), 77.4 (C16), 66.1 (C10), 



































(2’’S, 1’S, 3’S, 4’’S)-Phosphoric acid mono-(4-{2-acetylamino-2-[2-(1,2-
dicarbamoylethylamino)-3-methylcyclopropylcarbamoyl]ethyl}phenyl) ester (2.008). 
(hrp4-110, 111 and 119).  A solution of 2.087 (44 mg, 0.101 mmol) in neat TFA (0.2 
mL) was stirred for 90 min.  The reaction mixture was concentrated under reduced 
pressure, and the residue was triturated with Et2O (3 x 2 mL) to give an off white 
solid.(33 mg)  This crude amine was dissolved in DMF (1 mL) containing 2.030 (36 mg, 
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0.0737 mmol) at –10 °C, and 2,6-lutidine (24 mg, 26 µL, 0.221 mmol) and HATU (28 
mg, 0.0773 mmol) were added.  The mixture was stirred at –10 °C for 1 h and then at rt 
for 12 h.  EtOAc (10 mL) was added, and the organic layer was washed with sat. 
NaHCO3 (10 mL), 1 M HCl sat. with NaCl (10 mL) and brine (10 mL).  The organic 
layer was dried (Na2SO4) and concentrated under reduced pressure.  The crude residue 
was purified by flash chromatography, eluting with CH2Cl2/MeOH (9:1) to yield 22 mg 
of 2.087 (37%) as a yellow oil.  A solution of the product (4 mg, 0.006 mmol) in EtOH (2 
mL) containing 10 % Pd/C (10 mg) was stirred under H2 (1 atm) for 12 h.  The catalyst 
was removed by filtration through a pad of celite, and the filtrate was concentrated under 
reduced pressure to yield 3 mg of 2.008 (100%) as a white solid: mp oC; 1H NMR (500 
MHz, D2O) δ  7.22 (d, J = 8.3 Hz, 2 H), 7.14 (d, J = 8.3 Hz, 2 H), 4.74 (dd, J = 8.3, 6.5 
Hz, 1 H), 3.65 (br s, 1 H), 3.06 (dd, J = 13.9, 6.5 Hz, 1 H), 2.95 (dd, J = 13.9, 8.3 Hz, 1 
H), 2.67 (dd, J = 15.4, 5.8 Hz, 1 H), 2.58 (dd, J = 15.4, 8.0 Hz, 1 H), 2.46-2.43 (m, 1 H), 
2.16 (br s, 1 H), 1.95 (s, 3 H), 1.30-1.25 (m, 1 H), 1.05 (d, J = 6.4 Hz, 3 H); 13C NMR 
(125 MHz, D2O) δ 177.8, 177.6, 176.8, 176.8, 134.7, 133.0, 123.3, 58.0, 57.1, 42.4, 39.8, 
39.2, 33.2, 24.3, 17.2, 13.5; mass spectrum (FAB -) m/z 484.1600 [C19H28N5O9P (M-1) 
requires 484.1597]. 
NMR Assignments.  1H NMR (500 MHz, D2O) δ1H NMR (500 MHz, D2O) 
δ  7.22 (d, J = 8.3 Hz, 2 H, C13-H or C14-H), 7.14 (d, J = 8.3 Hz, 2 H, C13’-H or 
C14’H), 4.74 (dd, J = 8.3, 6.5 Hz, 1 H, C10-H), 3.65 (br s, 1 H, C6-H), 3.06 (dd, J = 
13.9, 6.5 Hz, 1 H, C11-H), 2.95 (dd, J = 13.9, 8.3 Hz, 1 H, C11’-H), 2.67 (dd, J = 15.4, 
5.8 Hz, 1 H, C7-H), 2.58 (dd, J = 15.4, 8.0 Hz, 1 H, C7’H), 2.46-2.43 (m, 1 H, C1-H or 
C2-H), 2.16 (br s, 1 H, C1-H or C2-H), 1.95 (s, 3 H, 17-H), 1.30-1.25 (m, 1 H, C3-H), 
1.05 (d, J = 6.4 Hz, 3 H, C4-H); 13C NMR (125 MHz, D2O) δ 177.8 (C5, C8, C9 or 
C16), 177.6 (C5, C8, C9 or C16), 176.8 (C5, C8, C9 or C16), 176.8 (C5, C8, C9 or C16), 
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134.7 (C12 & C15), 133.0 (C13 or C14), 123.3 (C13 or C14), 58.0 (C6), 57.1 (C10), 42.4 














(2S)-2-tert-Butoxycarbonylaminothiobutyric acid S-ethyl ester (2.089). (nn-
015).  DMAP (12 mg, 0.1 mmol) and EtSH (82 µL, 1.1 mmol) were added to 4-(tert-
butoxycarbonylamino) butyric acid (2.088) (203 mg, 1 mmol) in CH2Cl2 (10 mL).  DCC 
(227 mg, 1.1 mmol) was added to the mixture, and the reaction was stirred for 30 mins at 
rt.  The solution was filtered through cotton and concentrated under reduced pressure.  
The crude product was purified by column chromatography eluting with hexanes/EtOAc 
(6:1) to yield 245.2 mg (99%) of 2.089 as a colorless oil: 1H NMR (300 MHz, CDCl3) δ 
4.94 (br s, 1 H), 4.26 (br d, J = 5.0 Hz, 1 H), 2.85 (q, J = 7.4 Hz, 2 H), 1.90-1.85 (m, 1 
H), 1.65-1.55 (m, 1H), 1.43 (s, 9 H), 1.22 (t, J = 7.4 Hz, 3 H), 0.92 (t, J = 7.4 Hz, 3 H); 
13C NMR (75 MHz, CDCl3) δ 201.3, 155.2, 80.1, 61.6, 28.3, 26.1, 23.1, 14.5, 9.6; IR 
(CDCl3) 3439, 2972, 2932, 2252, 1714, 1494, 1368, 1163, 907, 730, 647 cm-1; mass 
spectrum (CI) m/z 248.1323 [C11H22NO3S requires 248.1320], 495, 248, 192 (base). 
NMR Assignments.  1H NMR (300 MHz, CDCl3) δ 4.94 (br s, 1 H, N-H), 4.26 
(br d, J = 5.0 Hz, 1 H, C1-H), 2.85 (q, J = 7.4 Hz, 2 H, C5-H), 1.90-1.85 (m, 1 H, C2-H), 
1.65-1.55 (m, 1H, C2’-H), 1.43 (s, 9 H, C9-H), 1.22 (t, J = 7.4 Hz, 3 H, C6-H), 0.92 (t, J 
= 7.4 Hz, 3 H, C3-H); 13C NMR (75 MHz, CDCl3) δ 201.3 (C7 or C4), 155.2 (C7 or C4), 


























(2S, 2S’)-2-(2-tert-Butoxycarbonylaminobutylamino)-succinic acid dimethyl 
ester (2.090). (hrp4-042).  Et3SiH (162 mg, 223 µL, 3.8 mmol) was added rapidly to a 
solution containing 2.089 (69 mg, 0.28 mmol) and 10% Pd/C (10 mg) in CH2Cl2 (2 mL) 
at 0 oC.  The reaction mixture was stirred for 90 min at 0 oC, and the catalyst was 
removed by filtrations.  DMF (1.0 mL) was added to the filtrate, and L-aspartic acid 
dimethyl ester hydrochloride (2.036) (57 mg, 0.288 mmol) was added at 0 oC.  A solution 
of Na(OAc)3BH (101 mg, 0.477 mmol) in DMF (0.5 mL) was then added, and the 
reaction mixture was stirred at 0 oC for 1 h and then at rt for 30 min.  The solvent was 
removed under reduced pressure, and the residue was purified by flash column 
chromatography eluting with EtOAc/hexanes (1:2 to 1:1) to give 77 mg (83%) of 2.090 
as an clear oil:  1H NMR (500 MHz, CDCl3) δ 4.58 (br s, 1 H), 3.72 (s, 3 H), 3.71-3.65 
(comp, 4 H), 3.52 (br s, 1 H), 2.79-2.76 (comp, 2 H), 2.67-2.62 (m, 1 H), 2.53 (br s, 1 H), 
1.57-1.47 (comp, 2 H), 1.42 (s, 9 H), 0.89 (t, J =7.4 Hz, 3 H); 13C NMR (125 MHz, 
CDCl3) δ 171.3, 79.1, 57.9, 52.3, 51.9, 50.9, 37.4, 28.4, 25.8, 10.2 ;IR (CDCl3) 3157, 
2254, 1794, 1736, 1707, 1466, 1380, 1167, 1095, 907 cm-1; mass spectrum (CI) m/z 
333.2024 [C15H29N2O6 requires 333.2026], 277 (base).  
NMR Assignments. 1H NMR (300 MHz, CDCl3) δ 4.58 (br s, 1 H, N-H), 3.72 
(s, 3 H, C10-H or C7-H), 3.71-3.65 (comp, 4 H, C10-H or C7-H, C5-H), 3.52 (br s, 1 H, 
C1-H), 2.79-2.76 (comp, 2 H, C4-H or C8-H), 2.67-2.62 (m, 1 H, C8-H), 2.53 (br s, 1 H, 
C4-H), 1.57-1.47 (comp, 2 H, C2-H), 1.42 (s, 9 H, C13-H), 0.89 (t, J =7.4 Hz, 3 H, C3-
H); 13C NMR (125 MHz, CDCl3) δ 171.3 (C6, C9, &C11), 79.1 (C12), 57.9 (C5), 52.3 
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({1-[(1,2-Dicarbamoylethylamino)methyl]propyl}carbamic acid tert-butyl 
ester (2.091). (hrp3-284).  Solid NaCN (6 mg, 0.128 mmol) was added to a solution of 
2.090 (332 mg, 1.28 mmol) in MeOH (13 mL) at room temperature.  The solution was 
saturated with ammonia gas for 30 min, and then heated at 55 oC for 3 d, during which 
time the mixture was resaturated with ammonia gas every 12 h.  The mixture was then 
concentrated under reduced pressure, and the residue was recrystallized from minimal 
amounts of hot CH3CN (10 mL total) to yield 328 mg of 2.091 (85%) as an off white 
solid: mp 177-180 oC; 1H NMR (500 MHz, CD3OD) δ 3.46 (br s, 1 H), 3.44 (dd, J =8.5, 
4.9 Hz, 1 H), 3.40 (dd, J =7.1, 3.0 Hz, 1 H), 2.62-2.51 (comp, 3 H), 2.44 (dd, J =15.4, 
8.7 Hz, 1 H), 1.58-1.49 (m, 1 H), 1.43 (s, 9 H), 1.40-1.30 (m, 1 H), 0.91 (t, J =7.4 Hz, 3 
H); 13C NMR (125 MHz, CD3OD) δ 178.7, 175.9, 158.6, 79.9, 60.4, 53.7, 52.6, 39.1, 
28.8, 27.0, 10.8; IR 2100, 1684, 1639, 1528, 1390, 1291, 1247, 1173 cm-1, mass 
spectrum (CI) m/z 303.2034 [C12H26N4O3 requires 303.2032], 286, 247.  
NMR Assignments. 1H NMR (500 MHz, CD3OD) δ 3.46 (br s, 1 H, N-H), 3.44 
(dd, J =8.5, 4.9 Hz, 1 H, C5-H), 3.40 (dd, J =7.1, 3.0 Hz, 1 H, C1-H), 2.62-2.51 (comp, 3 
H, C4-H & C6-H), 2.44 (dd, J =15.4, 8.7 Hz, 1 H, C6-H), 1.58-1.49 (m, 1 H, C2-H), 1.43 
(s, 9 H, C11-H), 1.40-1.30 (m, 1 H, C2’-H), 0.91 (t, J =7.4 Hz, 3 H, C3-H); 13C NMR 
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(125 MHz, CD3OD) δ 178.7 (C7, C8 or C9), 175.9 (C7, C8 or C9), 158.6 (C7, C8 or C9), 














































dicarbamoylethylamino)methyl]propylcarbamoyl}ethyl)phenyl ester diphenyl ester 
(2.092). (hrp3-290 & hrp3-291).  A solution of 2.091 (46 mg, 0.152 mmol) in TFA (0.4 
mL) was stirred for 2 h at room temperature. The solution was concentrated and triturated 
with Et2O (3 x 4 mL).  The residual solid was dissolved in DMF (0.6 mL), and 2.030 (79 
mg, 0.152 mmol) and 2,6-lutidine (49 mg, 53 µL, 0.456 mmol) were added.  The mixture 
was cooled to -10 oC and HATU (58 mg, 0.152 mmol) was added.  The mixture was then 
stirred at -10 ºC for 1 h and at rt for 14 h.  The solution was concentrated under reduced 
pressure, and the residue was purified by flash column chromatography eluting with 
CHCl3/MeOH (7:1) 68 mg (67%) of 2.092 as an yellow oil. 1H NMR (500 MHz) δ 7.34 
(br s, 1 H), 7.18-7.17 (comp, 11 H), 7.06 (d, J = 7.9 Hz, 1 H), 7.02 (d, J = 8.2 Hz, 2 H), 
6.95 (br s, 1 H), 6.89 (d, J =8.2 Hz, 2 H), 6.01 (br s, 1 H), 5.79 (br s, 1 H), 4.95 (d, J = 
5.3 Hz, 2 H), 4.93 (d, J = 3.5 Hz, 2 H), 4.51-4.48 (m, 1 H), 3.65 (br s, 1 H), 3.22 (br s, 1 
H), 2.92, (dd, J = 13.7, 6.4 Hz, 1 H), 2,77 (dd, J = 13.7, 7.5 Hz, 1 H), 2.51-2.42 (comp, 2 
H), 2.36-2.32 (comp, 2 H), 1.73 (s, 3 H), 1.36-1.24, (comp, 2 H), 1.10 (br s, 1 H), 0.70 (t, 
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J = 7.3 Hz, 3 H); 13C NMR (125 MHz, CD3OD) δ 173.3, 173.2, 170.9, 170.0, 148.8, 
135.0, 134.0, 130.3, 128.3, 128.2, 127.6, 119.3, 69.6, 69.5, 59.2, 54.2, 50.7, 50.5, 36.9, 
36.7, 25.0, 22.6, 10.0; mass spectrum (CI +) m/z 668.2868 [C33H43N5O8P (M+1) 
requires 668.2849. 
NMR Assignments. 1H NMR 1H NMR (500 MHz) δ 7.34 (br s, 1 H, N-H), 7.18-
7.17 (comp, 11 H, C20-H, C21-H, C22-H), 7.06 (d, J = 7.9 Hz, 1 H, N-H), 7.02 (d, J = 
8.2 Hz, 2 H, C15-H or C16-H), 6.95 (br 2, 1 H, N-H), 6.89 (d, J =8.2 Hz, 2 H, C15-H or 
C16-H), 6.01 (br s, 1 H, N-H), 5.79 (br s, 1 H, N-H), 4.95 (d, J = 5.3 Hz, 2 H, C18-H), 
4.93 (d, J = 3.5 Hz, 2 H, C18’-H), 4.51-4.48 (m, 1 H, C10-H), 3.65 (br s, 1 H, C1-H), 
3.22 (br s, 1 H, C5-H), 2.92, (dd, J = 13.7, 6.4 Hz, 1 H, C13-H), 2,77 (dd, J = 13.7, 7.5 
Hz, 1 H, C13’-H), 2.51-2.42 (comp, 2 H, C4-H and C6-H), 2.36-2.32 (comp, 2 H, C4’-H 
and C6’-H), 1.73 (s, 3 H, C12-H), 1.36-1.24, (comp, 2 H, C2-H), 1.10 (br s, 1 H, N-H), 
0.70 (t, J = 7.3 Hz, 3 H, C3-H); 13C NMR (125 MHz, CD3OD) δ 173.3 (C7 or C8 or C9 
or C11), 173.2 (C7 or C8 or C9 or C11), 170.9 (C7 or C8 or C9 or C11), 170.0 (C7 or C8 
or C9 or C11), 148.8 (C14 or C17 or C19), 135.0 (C14 or C17 or C19), 134.0 (C14 or 
C17 or C19), 130.3 (C15 or C16), 128.3 (C20 or C21 or C22), 128.2 (C20 or C21 or 
C22), 127.6 (C20 or C21 or C22), 119.3 (C15 or C16), 69.6 (C18), 69.5 (C18’), 59.2 







































(2S, 1S’, 1S’’) Phosphoric acid mono-(4-{acetylamino-[1-[(1,2-
dicarbamoylethylcarbamoyl)-2-methylpropylcarbamoyl]methyl}phenyl)ester 
(2.009). (hrp-038).  A mixture of 2.092 (20 mg, 0.030 mmol) and HCl (0.5 M, 0.12 mL, 
0.6 mmol) in EtOH and H2O (1:1, 1 mL total) containing 10% Pd/C (10 mg) was stirred 
under H2 (1 atm) for 13 h.  The catalyst was removed by filtration and the filtrate was 
concentrated under reduced pressure to yield 10 mg (100%) of 2.009 as a white solid:  
mp 195-197 oC dec;   1H NMR (500 MHz, D2O) δ 7.27 (d, J =8.1 Hz, 2 H), 7.16 (d, J 
=8.1 Hz, 2 H), 4.52 (t, J =7.8 Hz, 1 H), 4.27 (dd, J =7.3, 5.0 Hz, 1 H), 4.00-3.96 (m, 1 
H), 3.11-2.82 (comp, 6 H), 1.97 (s, 3 H), 1.67-1.62 (m, 1 H), 1.48-1.42 (m, 1 H), 0.87 (t, 
J = 7.3 Hz, 3 H); 13C NMR (125 MHz, CD3OD) δ 176.9, 176.8, 175.6, 172.3, 153.5, 
135.1, 133.2, 123.3, 59.8, 58.2, 52.5, 51.3, 38.8, 36.5, 27.1, 24.3, 12.0; mass spectrum 
(FAB +) m/z 488.1926 [C19H30N5O8P (M+1) requires 488.1910, 461, 369, 277 (base). 
NMR Assignments. 1H NMR (500 MHz, D2O) δ 7.27 (d, J = 8.1 Hz, 2 H, C15-
H or C16-H), 7.16 (d, J = 8.1 Hz, 2 H, C15-H or C16-H), 4.52 (t, J = 7.8 Hz, 1 H, C10-
H), 4.27 (dd, J = 7.3, 5.0 Hz, 1 H, C5-H), 4.00-3.96 (m, 1 H, C1-H), 3.11-2.82 (comp, 6 
H C4-H, C6-H & C13-H), 1.97 (s, 3 H, C12-H), 1.67-1.62 (m, 1 H, C2-H), 1.48-1.42 (m, 
1 H, C2’-H), 0.87 (t, J = 7.3 Hz, 3 H, C3-H); 13C NMR (125 MHz, CD3OD) δ 176.9 
(C7, C8, C9, or C11), 176.8 (C7, C8, C9, or C11), 175.6 (C7, C8, C9, or C11), 172.3 
(C7, C8, C9, or C11), 153.5 (C14  or C17), 135.1 (C14  or C17), 133.2 (C15  or C16), 
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123.3 (C15  or C16), 59.8 (C5), 58.2 (C10), 52.5 (C4), 51.3 (C1), 38.8 (C6 or C13), 36.5 











































methoxymethyltetrahydropyran) dimethyl silane (4.071). (hrp3-177). A solution of 
lithium diisopropylamide (LDA) in a THF (0.4 M, 2 mL, 0.782 mmol) was added to a 
solution of 4.070180,181 (263 mg, 0.391 mmol) in THF (4 mL) at -78 oC, and the mixture 
was stirred for 4 h at -78 oC.  Freshly distilled (bromomethyl)chlorodimethylsilane (107 
µL, 0.782 mmol) was added, and the reaction was stirred for 5 min at rt.  H2O (1 mL) 
was added, and the aqueous mixture was extracted with EtOAc (3 x 10 mL).  The 
combined organic layers were washed with brine (10 mL), dried (Na2SO4), and 
concentrated under reduced pressure.  The residue was purified by flash chromatography 
eluting with  EtOAc/hexanes (1:2) to give 11 mg recovered 4.070 and 265 mg of 4.071 
[82% (86% brsm)] as a colorless oil: The major diastereomer was isolated by careful 
flash chromatography and used for characterization: 1H NMR (500 MHz) δ 7.37-7.25 
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(comp, 13 H), 7.21-7.19 (comp, 2 H), 6.29 (s, 1 H), 4.92 (d, J = 10.8 Hz, 1 H), 4.70 (d, J 
= 11.6 Hz, 1 H), 4.64 (d, J = 11.6 Hz, 1 H), 4.61-4.55 (comp, 2 H), 4.49 (d, J = 12.1 Hz, 
1 H), 4.41 (d, J = 1.8 Hz, 1 H), 4.39 (d, J = 1.8 Hz, 1 H), 3.77-3.70 (comp, 3 H), 3.67 (dd, 
J = 10.6, 2.0 Hz, 1 H), 3.63-3.59 (comp, 2 H), 3.57 (s, 3 H), 3.52-3.49 (comp, 1 H), 3.47 
(s, 3 H), 3.42-3.37 (comp, 5 H), 3.16 (dd, J = 9.4, 9.0 Hz, 1 H), 2.72 (dd, J = 19.1, 12.8 
Hz, 2 H), 2.35 (ddd, J = 13.1, 5.0, 1.8 Hz, 1 H), 2.28 (ddd, J = 13.1, 5.0, 1.8 Hz, 1 H), 
1.78-1.67 (comp, 2 H), 0.41 (s, 3 H), 0.39 (s, 3 H); 13C NMR (125 MHz) δ 157.7, 152.1, 
138.5, 138.4, 138.1, 137.8, 128.4, 128.3, 127.9, 127.7, 127.6, 127.5, 106.5, 82.4, 80.9, 
79.8, 79.3, 79.2, 78.0, 75.1, 73.4, 71.8, 71.6, 71.5, 71.2, 69.3, 60.6, 59.3, 57.0, 38.1, 34.5, 
17.0, -3.7, -3.8; IR 3163, 2849, 2256, 1796, 1464, 1380, 1265, 1097, 908, 650, 461 cm-1; 
mass spectrum (CI) m/z 822.2798 [C43H55BrO9Si (M+1) requires 822.2799] 793, 791, 
763, 731, 715.  
NMR Assignments.  1H NMR (500 MHz) δ 7.37-7.25 (comp, 13 H, C24-H, C25-
H & C26-H), 7.21-7.19 (comp, 2 H, C24-H, C25-H & C26-H), 6.29 (s, 1 H, C4-H), 4.92 
(d, J = 10.8 Hz, 1 H, C20-H, C21-H or C22-H), 4.70 (d, J = 11.6 Hz, 1 H, C20-H, C21-H 
or C22-H), 4.64 (d, J = 11.6 Hz, 1 H, C20-H, C21-H or C22-H), 4.61-4.55 (comp, 2 H, 
C20-H, C21-H or C22-H), 4.49 (d, J = 12.1 Hz, 1 H, C20-H, C21-H or C22-H), 4.41 (d, J 
= 1.8 Hz, 1 H, C14-H or C5-H), 4.39 (d, J = 1.8 Hz, 1 H, C14-H or C5-H), 3.77-3.70 
(comp, 3 H, C16-H & C19-H), 3.67 (dd, J = 10.6, 2.0 Hz, 1 H, C10-H), 3.63-3.59 (comp, 
2 H, C10-H & C18-H), 3.57 (s, 3 H, C11-H, C12-H or C13-H), 3.52-3.49 (comp, 1 H, 
C17-H), 3.47 (s, 3 H, C11-H, C12-H or C13-H), 3.42-3.37 (comp, 5 H, C7-H, C9-H, 
C11-H, C12-H, C13-H), 3.16 (dd, J = 9.4, 9.0 Hz, 1 H, C8-H), 2.72 (dd, J = 19.1, 12.8 
Hz, 2 H, C29-H), 2.35 (ddd, J = 13.1, 5.0, 1.8 Hz, 1 H, C6-H), 2.28 (ddd, J = 13.1, 5.0, 
1.8 Hz, 1 H, C15-H), 1.78-1.67 (comp, 2 H, C6’-H & C15’-H), 0.41 (s, 3 H, C28-H), 
0.39 (s, 3 H, C28’-H); 13C NMR (125 MHz) δ 157.7 (C1, C2, C3 or C23), 152.1 (C1, C2, 
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C3 or C23), 138.5 (C1, C2, C3 or C23), 138.4 (C1, C2, C3 or C23), 138.1 (C1, C2, C3 or 
C23), 137.8 (C1, C2, C3 or C23), 128.4 (C24, C25 or C26), 128.3 (C24, C25 or C26), 
127.9 (C24, C25 or C26), 127.7 (C24, C25 or C26), 127.6 (C24, C25 or C26), 127.5 
(C24, C25 or C26), 106.5 (C4), 82.4(C7 & C9), 80.9 (C16 & C19), 79.8 (C8), 79.3 
(C17), 79.2 (C7 & C9), 78.0 (C18), 75.1 (C20, C21 or C22), 73.4 (C20, C21 or C22), 
71.8 (C10), 71.6 (C5 or C14), 71.5 (C5 or C14), 71.2 (C20, C21 or C22), 69.3 (C16 & 
C19), 60.6 (C11, C12 or C13), 59.3 (C11, C12 or C13), 57.0 (C11, C12 or C13), 38.1 

















































2(R)-methoxymethyltetrahydropyranbromomethyl dimethyl silane (4.072). (hrp 3-
179). A mixture of tetrabutylammonium iodide (TBAI) (18 mg, 0.048 mmol), K2CO3 (30 
mg, 0.218 mmol), 4.071 (36 mg, 0.0436 mmol), and 4.033 (12 mg, 0.057 mmol) in 
acetone (mL) was stirred for 4 d at rt.  H2O (5 mL) was added, and the aqueous mixture 
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was extracted with EtOAc (3 x 5 mL).  The combined organic layers were washed with 
brine (5 mL), dried (Na2SO4), and concentrated under reduced pressure.  The residue was 
purified by flash chromatography eluting with EtOAc/hexanes (1:2) to give 26 mg (88%) 
of 4.072 as a colorless oil:  1H NMR (500 MHz) δ 7.38-7.12 (comp, 15 H), 6.81 (s, 2 H), 
6.37 (s, 1 H), 4.94-4.90 (m, 1 H), 4.74-4.70 (m, 1 H), 4.66-4.55 (comp, 4 H), 4.51-4.48 
(m, 1 H), 4.47-4.43 (m, 1 H), 3.96-3.87 (comp, 2 H), 3.79-3.70 (comp, 6 H), 3.68-3.59 
(comp, 2 H), 3.63-3.59 (m, 1 H), 3.57-3.55 (comp, 3 H), 3.54-3.50 (comp, 2 H), 3.47-
3.45 (comp, 3 H), 3.43-3.38 (comp, 4 H), 3.21-3.15 (m, 1 H), 2.39-2.35 (m, 1 H), 2.30-
2.26 (m, 1 H), 1.79-1.71 (comp, 2 H), 0.49 (s, 1.5 H), 0.47 (s, 1.5 H), 0.49 (s, 3 H); 13C 
NMR (125 MHz) δ 157.1 155.4, 152.4, 148.0, 138.6, 138.5, 138.3, 137.8, 129.2, 128.4, 
128.3, 128.2, 128.0, 127.8, 127.7, 127.6, 127.4, 114.5, 106.5, 82.4, 81.0, 79.8, 79.3, 79.2, 
78.1, 75.0, 73.3, 71.8, 71.3, 71.1, 69.4, 66.8, 60.6, 59.3, 57.0, 55.9, 38.1, 34.5, -1.7, -4.1, -
4.4; IR (CHCl3) 3156, 2929, 2837, 2253, 1794, 1766, 1561, 1466, 1380, 1096, 908 cm-1; 
mass spectrum (CI) m/z 935.3350 [C50H60Cl2O11Si (M + H) requires 935.3360] 903, 
827, 763, 447, 433, 419 (base). 
NMR Assignments.  1H NMR (500 MHz) δ 7.38-7.12 (comp, 15 H, C24-H, C25-
H & C26-H), 6.81 (s, 2 H, C32-H), 6.37 (s, 1 H, C4-H), 4.94-4.90 (m, 1 H, C20-H, C21-
H or C22-H), 4.74-4.70 (m, 1 H, C20-H, C21-H or C22-H), 4.66-4.55 (comp, 4 H, C20-
H, C21-H or C22-H), 4.51-4.48 (m, 1 H, C14-H or C5-H), 4.47-4.43 (m, 1 H, C14-H or 
C5-H), 3.96-3.87 (comp, 2 H, C29-H), 3.79-3.70 (comp, 6 H, C10-H, C16-H & C34-H), 
3.68-3.59 (comp, 2 H, C19-H), 3.63-3.59 (m, 1 H, C9-H), 3.57-3.55 (comp, 3 H, C11-H, 
C12-H or C13-H), 3.54-3.50 (comp, 2 H, C17-H & C18-H), 3.47-3.45 (comp, 3 H, C11-
H, C12-H or C13-H), 3.43-3.38 (comp, 4 H, C7-H, C11-H, C12-H or C13-H), 3.21-3.15 
(m, 1 H, C8-H), 2.39-2.35 (m, 1 H, C6-H), 2.30-2.26 (m, 1 H, C15-H), 1.79-1.71 (comp, 
2 H, C6’-H & C15’-H), 0.49 (s, 1.5 H, C28-H), 0.47 (s, 1.5 H, C28-H), 0.49 (s, 3 H, 
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C28’-H); 13C NMR (125 MHz) δ 157.1 (C1, C2, C3, C23, C30, C31 or C33), 155.4 (C1, 
C2, C3, C23, C30, C31 or C33), 152.4 (C1, C2, C3, C23, C30, C31 or C33), 148.0 (C1, 
C2, C3, C23, C30, C31 or C33), 138.6 (C1, C2, C3, C23, C30, C31 or C33), 138.5 (C1, 
C2, C3, C23, C30, C31 or C33), 138.3 (C1, C2, C3, C23, C30, C31 or C33), 137.8 (C1, 
C2, C3, C23, C30, C31 or C33), 129.2 (C1, C2, C3, C23, C30, C31 or C33), 128.4 (C24, 
C25 or C26), 128.3 (C24, C25 or C26), 128.2 (C24, C25 or C26), 128.0 (C24, C25 or 
C26), 127.8 (C24, C25 or C26), 127.7 (C24, C25 or C26), 127.6 (C24, C25 or C26), 
127.4 (C24, C25 or C26), 114.5 (C32), 106.5 (C4), 82.4 (C7), 81.0 (C16), 79.8 (C8), 79.3 
(C17 or C18), 79.2 (C17 or C18), 78.1 (C9), 75.0 (C20, C21 or C22), 73.3 (C20, C21 or 
C22), 71.8 (C19), 71.3(C20, C21 or C22), 71.1 (C14), 69.4 C10), 66.8 (C29), 60.6 (C11, 
C12 or C13), 59.3 (C11, C12 or C13), 57.0 (C11, C12 or C13), 55.9 (C34), 38.1 (C15), 



















































Cycloadduct (4.073). (hrp3-182).  Furan 4.072 (171 mg, 0.183 mmol) was 
dissolved in THF (2 mL), and the solution was cooled to –95 °C with an Et2O/Liquid N2 
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bath. t-BuLi (235 µL of a 1.09 M solution in pentane, 0.256 mmol) was added dropwise, 
and the bath temperature was maintained below –90 °C for 15 min and then allowed to 
slowly warm to –10 °C for 30 min.  Saturated aqueous NH4Cl (2 mL) was added, and the 
mixture was extracted with EtOAc (3 x 2 mL). The combined extracts were dried 
(Na2SO4) and concentrated. The residue was purified by flash chromatography on silica 
gel eluting with hexanes/EtOAc (3:2) to afford 101 mg (61%) of cycloadduct 4.073 as a 
colorless oil. The mixture of two diastereomers was characterized:  1H NMR (500 MHz) 
δ 7.37-7.26 (comp, 13 H), 7.21-7.19 (comp, 2 H), 6.69 (d, J = 1.6 Hz, 1 H), 6.61 (s, 1 H), 
4.91 (d, J = 11.0 Hz, 1 H), 4.70-4.64 (comp, 1 H), 4.60-4.54 (comp, 1 H), 4.51 (d, J = 
11.6 Hz, 1 H), 4.43 (d, J = 11.6 Hz, 1 H), 4.09-3.97 (m, 1 H), 3.90-3.78 (comp, 2 H), 
3.75-3.72 (comp, 5 H), 3.71-3.69 (m, 1 H,), 3.67-3.60 (comp, 4 H), 3.59-3.54 (comp, 5 
H), 3.53-3.45 (m, 1 H), 3.44-3.32 (comp, 8 H), 3.03 (m, 1 H), 2.23 (ddd, J = 12.8, 5.0, 
1.9 Hz, 1 H), 2.20 (ddd, J = 12.8, 5.0, 1.6 Hz, 1 H), 1.82-1.75 (m, 1 H), 1.63-1.54 (m, 1 
H), 0.41 (s, 3 H), 0.12 (s, 3 H); 13C NMR (125 MHz) δ 171.1, 160.1, 153.7, 149.1, 148.4, 
147.3, 145.9, 143.6 , 138.7, 138.4, 138.3, 137.9, 136.7, 135.3, 128.4, 128.3, 128.3, 128.0, 
127.9, 127.9, 127.8, 127.7, 127.7, 127.6, 127.5, 127.4, 119.4, 113.1, 95.8, 83.2, 81.4, 
80.7, 80.4, 79.1, 77.8, 75.1, 73.4, 73.3, 73.2, 72.5, 71.3, 68.9, 61.3, 60.6, 59.3, 56.7, 56.2, 
36.2, 31.0, -4.6, -5.6; mass spectrum (CI) m/z 898.3502 [C50H59ClO11Si (M+H) requires 
898.3515]  867, 673, 641, 391. 
 NMR Assignments:  1H NMR (500 MHz) δ 7.37-7.26 (comp, 13 H, C24-
H, C25-H & C26-H), 7.21-7.19 (comp, 2 H, C24-H, C25-H & C26-H), 6.69 (d, J = 1.6 
Hz, 1 H, C4-H), 6.61 (s, 1 H, C32-H), 4.91 (d, J = 11.0 Hz, 1 H, C20-H, C21-H or C22-
H), 4.70-4.64 (comp, 1 H, C20-H, C21-H or C22-H), 4.60-4.54 (comp, 3 H, C5-H, C20-
H, C21-H & C22-H), 4.51 (d, J = 11.6 Hz, 1 H, C20-H, C21-H or C22-H), 4.43 (d, J = 
11.6 Hz, 1 H, C20-H, C21-H or C22-H), 4.09-3.97 (m, 1 H, C14-H), 3.90-3.78 (comp, 2 
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H, C29-H), 3.75-3.72 (comp, 5 H, C10-H, C19-H & C34-H), 3.71-3.69 (m, 1 H, C17-H), 
3.67-3.60 (comp, 4 H, C10’-H & C16-H), 3.59-3.54 (comp, 5 H, C11-H, C12-H or C13-
H & C19’-H), 3.53-3.45 (m, 1 H, C9-H), 3.44-3.32 (comp, 8 H, C7-H, C18-H, C11-H, 
C12-H & C13-H), 3.03 (m, 1 H, C8-H), 2.23 (ddd, J = 12.8, 5.0, 1.9 Hz, 1 H, C15-H), 
2.20 (ddd, J = 12.8, 5.0, 1.6 Hz, 1 H, C6-H), 1.82-1.75 (m, 1 H, C15’-H), 1.63-1.54 (m, 1 
H, C6’-H), 0.41 (s, 3 H, C28-H), 0.12 (s, 3 H, C28’-H); 13C NMR (125 MHz) δ 171.1 
(C1, C2, C3, C23, C30, C31, C33, C35 or C36), 160.1 (C1, C2, C3, C23, C30, C31, C33, 
C35 or C36), 153.7 (C1, C2, C3, C23, C30, C31, C33, C35 or C36), 149.1 (C1, C2, C3, 
C23, C30, C31, C33, C35 or C36), 148.4 (C1, C2, C3, C23, C30, C31, C33, C35 or C36), 
147.3 (C1, C2, C3, C23, C30, C31, C33, C35 or C36), 145.9 (C1, C2, C3, C23, C30, 
C31, C33, C35 or C36), 143.6 (C1, C2, C3, C23, C30, C31, C33, C35 or C36), 138.7 
(C1, C2, C3, C23, C30, C31, C33, C35 or C36), 138.4 (C1, C2, C3, C23, C30, C31, C33, 
C35 or C36), 138.3 (C1, C2, C3, C23, C30, C31, C33, C35 or C36), 137.9 (C1, C2, C3, 
C23, C30, C31, C33, C35 or C36), 136.7 (C4), 135.3(C1, C2, C3, C23, C30, C31, C33, 
C35 or C36), 128.4 (C24, C25 or C26), 128.3 (C24, C25 or C26), 128.3 (C24, C25 or 
C26), 128.0 (C24, C25 or C26), 127.9 (C24, C25 or C26), 127.9 (C24, C25 or C26), 
127.8 (C24, C25 or C26), 127.7 (C24, C25 or C26), 127.7 (C24, C25 or C26), 127.6 
(C24, C25 or C26), 127.5 (C24, C25 or C26), 127.4 (C24, C25 or C26), 119.4 (C1, C2, 
C3, C23, C30, C31, C33, C35 or C36), 113.1 (C32), 95.8 (C1, C2, C3, C23, C30, C31, 
C33, C35 or C36), 83.2 (C18), 81.4 (C17), 80.7 (C9), 80.4 (C8), 79.1 (C7), 77.8 (C16), 
75.1 (C20, C21 or C22), 73.4 (C5, C14, C20, C21 or C22), 73.3 (C5, C14, C20, C21 or 
C22), 73.2 (C5, C14, C20, C21 or C22), 72.5 (C10), 71.3 (C20, C21 or C22), 68.9 (C19), 
61.3 (29), 60.6 (C11, C12 or C13), 59.3 (C11, C12 or C13), 56.7 (C11, C12 or C13), 56.2 


















































oxatricyclo[6.2.1.0]undeca-2(7),3,5,9-tetraene (4.074). (hrp 3-184). A solution of 
tetrabutylammonium fluoride (TBAF) in THF (1.0 M, 87 µL, 0.0867 mmol) was added to 
a solution of 4.073 (26 mg, 0.0289 mmol) in DMF (0.3 mL) at rt, and the solution was 
stirred for 15 h at rt.  Saturated aqueous NaHCO3 (1 mL) and H2O (1 mL) were added, 
and the aqueous mixture was extracted with EtOAc (2 x 2 mL).  The combined organic 
layers were dried (Na2SO4) and concentrated under reduced pressure.  The residue was 
purified by flash chromatography eluting with EtOAc/hexanes (1:1) to give 18 mg of 
4.074 (72%) as mixture of diastereomers as a colorless oil:  1H NMR (500 MHz) δ 7.36-
7.25 (comp, 13 H), 7.24-7.21 (comp, 2 H), 6.72 (d, J = 1.8 Hz, 1 H), 6.65 (s, 1 H), 6.01 
(s, 1 H), 4.91 (d, J = 11.0 Hz, 1 H), 4.68 (d, J = 13.6 Hz, 1 H), 4.60-4.55 (comp, 4 H), 
4.50 (d, J = 12.1 Hz, 1 H), 4.07-4.05 (m, 1 H), 3.86 (s, 3 H), 3.76 (s, 3 H), 3.73-3.60 
(comp, 5 H), 3.56 (s, 3 H), 3.51-3.41 (comp, 4 H), 3.41 (s, 3 H), 3.40 (s, 3 H), 3.02 (dd, J 
= 9.5, 8.7 Hz, 1 H), 2.31 (ddd, J = 12.8, 5.0, 1.8 Hz, 1 H), 2.19 (ddd, J = 12.8, 5.0, 1.6 
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Hz, 1 H), 1.64-1.57 (comp, 2 H); 13C NMR (125 MHz) δ 156.7, 147.8, 144.2, 141.7, 
138.5, 138.3, 136.6, 135.2, 128.4, 128.3, 128.0, 127.8, 127.7, 127,7, 127.6, 127.5 124.7, 
112.8, 95.4, 83.0, 80.8, 80.5, 80.2, 80.1, 79.2, 78.2, 75.1, 73.5, 73.1, 72.6, 72.3, 71.3, 
69.6, 60.8, 60.6, 59.3, 56.3, 56.1, 34.9, 30.9; IR (CHCl3) 3003, 2938, 2865, 2837, 2253, 
1476, 1454, 1381, 1364, 1103, 908 cm-1; mass spectrum (CI) m/z 842.3424 
[C48H55ClO11 (M+H) requires 842.3433] 844, 812 (base).  
NMR Assignments:  1H NMR (500 MHz) δ 7.36-7.25 (comp, 13 H, C24-H, 
C25-H & C26-H), 7.24-7.21 (comp, 2 H, C24-H, C25-H & C26-H), 6.72 (d, J = 1.8 Hz, 
1 H, C4-H), 6.65 (s, 1 H, C30-H), 6.01 (s, 1 H, C2-H), 4.91 (d, J = 11.0 Hz, 1 H, C20-H, 
C21-H or C22-H), 4.68 (d, J = 13.6 Hz, 1 H, C20-H, C21-H or C22-H), 4.60-4.55 (comp, 
4 H, C5-H, C20-H, C21-H & C22-H), 4.50 (d, J = 12.1 Hz, 1 H, C20-H, C21-H or C22-
H), 4.07-4.05 (m, 1 H, 14-H), 3.86 (s, 3 H, C33-H), 3.76 (s, 3 H, C34-H), 3.73-3.60 
(comp, 5 H, C10-H, C16-H & C19-H), 3.56 (s, 3 H, C11-H, C12-H or C13-H), 3.51-3.41 
(comp, 4 H, C7-H, C9-H, C17-H & C18-H), 3.41 (s, 3 H, C11-H, C12-H or C13-H), 3.40 
(s, 3 H, C11-H, C12-H or C13-H), 3.02 (dd, J = 9.5, 8.7 Hz, 1 H, C8-H), 2.31 (ddd, J = 
12.8, 5.0, 1.8 Hz, 1 H, C15-H), 2.19 (ddd, J = 12.8, 5.0, 1.6 Hz, 1 H, C6-H), 1.64-1.57 
(comp, 2 H, C6’-H & C15’-H); 13C NMR (125 MHz) δ 156.7 (C1, C3, C23, C27, C28, 
C29, C31 or C32), 147.8 (C1, C3, C23, C27, C28, C29, C31 or C32), 144.2 (C1, C3, 
C23, C27, C28, C29, C31 or C32), 141.7 (C1, C3, C23, C27, C28, C29, C31 or C32), 
138.5 (C1, C3, C23, C27, C28, C29, C31 or C32), 138.3 (C1, C3, C23, C27, C28, C29, 
C31 or C32), 136.6 (C4), 135.2 (C1, C3, C23, C27, C28, C29, C31 or C32), 128.4 (C24, 
C25 or C26), 128.3 (C24, C25 or C26), 128.0 (C24, C25 or C26), 127.8 (C24, C25 or 
C26), 127.7 (C24, C25 or C26), 127.7 (C24, C25 or C26), 127.6 (C24, C25 or C26), 
127.5 (C24, C25 or C26), 124.7 (C1, C3, C23, C27, C28, C29, C31 or C32), 112.8 (C30), 
95.4 (C1, C3, C23, C27, C28, C29, C31 or C32), 83.0 (C17), 80.8 (C2), 80.5 (C16), 80.2 
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(C8), 80.1 (C9), 79.2 (C7), 78.2 (C18), 75.1 (C20, C21 or C22), 73.5 (C20, C21 or C22), 
73.1 (C5), 72.6 (C10), 72.3 (C14), 71.3 (C20, C21 or C22), 69.6 (C19), 60.8 (C33), 60.6 
(C10, C11, or C12), 59.3 (C10, C11, or C12), 56.3 (C10, C11, or C12), 56.1 (C34), 34.9 


















































dimethoxynaphthalen-1-ol (4.075). (hrp3-173).  Trifluoroacetic acid (TFA) (1 drop) 
was added to a solution of 4.074 (4 mg, 0.0019 mmol) in CH2Cl2 (0.25 mL) at 0 oC.  The 
reaction vessel was sealed with a glass stopper, warmed slowly to rt, and stirred for 24 h 
at rt.  The reaction mixture was diluted with CH2Cl2 (1 mL), and the solution was washed 
with saturated aqueous NaHCO3 (1 mL).  The organic layer was dried (Na2SO4) and 
concentrated under reduced pressure.  The residue was purified by flash chromatography 
eluting with EtOAc/hexanes (1:2) to give 4 mg of 4.075 (100%) as a single diastereomer 
as a colorless oil:  1H NMR (500 MHz) δ 10.07 (s, 1 H), 7.98 (s, 1 H), 7.41-7.23 (comp, 
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15 H), 6.73 (s, 1 H), 5.21 (d, J = 10.2 Hz, 1 H), 5.01 (dd, J = 11.2, 1.8 Hz, 1 H), 4.98 (d, 
J = 10.8 Hz, 1 H), 4.77-4.64 (comp, 5 H), 3.97 (s, 3 H), 3.91-3.89 (comp, 4 H), 3.84-3.83 
(m, 2 H), 3.67-3.66 (comp, 2 H), 3.62-3.61 (comp, 2 H), 3.57 (s, 3 H), 3.53-3.48 (comp, 2 
H), 3.43 (s, 3 H), 3.42 (s, 3 H), 3.11 (dd, J = 9.5, 8.7 Hz, 1 H), 2.52 (dd, J = 4.8, 1.6 Hz, 
1 H), 2.50 (dd, J = 4.8, 1.6 Hz, 1 H), 1.74-1.67 (m, 1 H), 1.52-1.45 (m, 1 H); 13C NMR 
(125 MHz) δ 154.0, 148.3, 145.5, 138.7, 129.7, 128.4, 128.3, 128.3, 128.1, 127.8, 127.7, 
127.6, 127.5, 127.4, 124.2, 123.8, 123.5, 121.3, 118.7, 107.2, 83.5, 81.4, 80.2, 79.9, 79.8, 
78.5, 75.5, 75.1, 73.5, 72.4, 71.8, 71.3, 69.5, 62.5, 60.6, 59.6, 56.5, 55.8, 39.0, 37.1; IR 
(CHCl3) 3320, 3002, 2935, 2862, 2253, 1711, 1598, 1466, 1454, 1359, 1300, 1115, 908 
cm-1; mass spectrum (CI) m/z 842.3444 [C48H55ClO11 (M+H) requires 842.3433] 811 
(base), 585.  
NMR Assignments.  1H NMR (500 MHz) δ 10.07 (s, 1 H, O-H), 7.98 (s, 1 H, 
C4-H), 7.41-7.23 (comp, 15 H, C24-H, C25-H & C26-H), 6.73 (s, 1 H, C30-H), 5.21 (d, J 
= 10.2 Hz, 1 H, C5-H), 5.01 (dd, J = 11.2, 1.8 Hz, 1 H, C14-H), 4.98 (d, J = 10.8 Hz, 1 
H, C20-H, C21-H or C22-H), 4.77-4.64 (comp, 5 H, C20-H, C21-H & C22-H), 3.97 (s, 3 
H, C33-H), 3.91-3.89 (comp, 4 H, C16-H & C34-H), 3.84-3.83 (m, 1 H, C19-H), 3.67-
3.66 (comp, 2 H, C17-H & C18-H), 3.62-3.61 (comp, 2 H, C10-H), 3.57 (s, 3 H, C11-H, 
C12-H or C13-H), 3.53-3.48 (comp, 2 H, C7-H & C9-H), 3.43 (s, 3 H, C11-H, C12-H or 
C13-H), 3.42 (s, 3 H, C11-H, C12-H or C13-H), 3.11 (dd, J = 9.5, 8.7 Hz, 1 H, C8-H), 
2.52 (dd, J = 4.8, 1.6 Hz, 1 H, C15-H or C6-H), 2.50 (dd, J = 4.8, 1.6 Hz, 1 H, C15-H or 
C6-H), 1.74-1.67 (m, 1 H, C15’-H), 1.52-1.45 (m, 1 H, C6’-H); 13C NMR (125 MHz) δ 
154.0 (C1, C2, C3, C23, C27, C28, C29, C31 or C32), 148.3 (C1, C2, C3, C23, C27, 
C28, C29, C31 or C32), 145.5 (C1, C2, C3, C23, C27, C28, C29, C31 or C32), 138.7 
(C1, C2, C3, C23, C27, C28, C29, C31 or C32), 129.7 (C1, C2, C3, C23, C27, C28, C29, 
C31 or C32), 128.4 (C24, C25 or C26), 128.3 (C24, C25 or C26), 128.3 (C24, C25 or 
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C26), 128.1 (C24, C25 or C26), 127.8 (C24, C25 or C26), 127.7 (C24, C25 or C26), 
127.6 (C24, C25 or C26), 127.5 (C24, C25 or C26), 127.4 (C24, C25 or C26), 124.2 
(C4), 123.8 (C1, C2, C3, C23, C27, C28, C29, C31 or C32), 123.5 (C1, C2, C3, C23, 
C27, C28, C29, C31 or C32), 121.3 (C1, C2, C3, C23, C27, C28, C29, C31 or C32), 
118.7 (C1, C2, C3, C23, C27, C28, C29, C31 or C32), 107.2 (C30), 83.5 (C9), 81.4 
(C16), 80.2 (C8), 79.9 (C17 or C18), 79.8 (C9), 78.5 (C17 or C18), 75.5 (C5), 75.1 (C20, 
C21 or C22), 73.5 (C20, C21 or C22), 72.4 (C10), 71.8 (C14), 71.3 (C20, C21 or C22), 
69.5 (C19), 62.5 (C33), 60.6 (C11, C12 or C13), 59.6 (C11, C12 or C13), 56.5 (C11, C12 











yl)carbamic acid benzyl ester (4.120). (hrp4-33 & hrp4-35).  A solution containing 
NaHCO3 (250 mg, 4.0 mmol) in H2O (3.0 mL) and Cbz-O-Suc (1.0 g, 3.0 mmol) were 
added to a solution of vancomycin (1.5 g, 1.0, mmol) in dioxane and H2O (1:1, 17 mL).  
The solution was stirred for 2.5 h at rt, and the solution was poured into acetone (200 
mL).  The mixture was sonicated for 30 min and then the solid was collected by filtration 
using a finely fritted (F) funnel.  The solid was dissolved in MeOH (10 mL) and 
azeotroped with toluene (3 x 10 mL).  The residue was dissolved in MeOH (30 mL), and 
HCl (4 M in dioxane, 2 mL, 8.0 mmol) was added.  The resultant pink solution was 
stirred for 2.5 h at room temperature (turned cloudy after 30 min), whereupon NaHCO3 
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(689 mg, 8.2 mmol) was added.  The mixture was concentrated under reduced pressure.  
The residue was suspended in acetone (100 mL) and sonicated for 30 min.  The solid was 
removed by filtration using a finely fritted funnel (F), and the filtrate was concentrated 
under reduced pressure.  The residue was suspended in EtOAc (40 mL) and sonicated for 
30 min.  The solid was removed by filtration using a finely fritted funnel (F) and the 
filtrate was concentrated under reduced pressure and purified by flash column 
chromatography eluting with hexanes/EtOAc (1:1) to provide 218 mg of 4.120 (71%) as 
an yellow oil and as a mixture of diastereomers (1:1.5);224  1H NMR (500 MHz) δ 7.35-
7.61 (comp m, 5 H), 5.48 (br s, 0.4 H), 5.38 (br s, 0.6 H), 5.07-5.00 (comp m, 2 H), 4.69 
(d, J = 4.7 Hz, 0.6 H), 4.39 (dd, J = 9.6, 2.2 Hz, 0.4 H), 4.07 (dd, J = 13.3, 6.6 Hz, 0.6 H), 
3.80 (dd, J = 13.3, 6.4 Hz, 0.4 H), 3.46 (s, 1.2 H), 3.28 (br s, 0.6 H), 3.29 (s, 1.8 H), 3.25 
(br s, 0.4 H), 2.22-2.13 (comp m, 2 H), 1.79 (dd, J = 14.2, 4.7 Hz, 0.4 H), 1.62-1.53 (m, 
0.6 H), 1.60 (s, 1.8 H), 1.50 (s, 1.2 H), 1.29 (d, J = 6.4 Hz, 0.4 H), 1.23 (d, J = 6.6 Hz, 0.6 
H); 13C NMR (125 MHz) δ 155.0, 136.6, 136.5, 128.5, 128.1, 128.0, 103.9, 100.2, 98.1, 
98.1, 88.8, 73.1, 72.6, 68.8, 66.2, 62.9, 56.4, 55.0, 54.9, 53.6, 37.4, 35.3, 23.3,21.6, 17.2, 
17.1; IR 3563, 3414, 2988, 2937, 1717, 1499, 1454, 1385, 1274, 1114, 1057 cm-1; mass 














































































































































































∆G (kcal mol-1) -7.753424
0.051567
Entropy (cal mol-1 K-1) 6.1635877
0.4719145  
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∆G (kcal mol-1) -7.784721
0.0781954
Entropy (cal mol-1 K-1) 4.3727007
0.452691  
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∆G (kcal mol-1) -7.442491
0.1492734
Entropy (cal mol-1 K-1) 8.089297
1.1758676  
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∆G (kcal mol-1) -5.861536
0.1414277
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